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General introduction
Anogenital intraepithelial neoplasia (AGIN), which includes cervical, vulvar, vaginal 
and anal intraepithelial neoplasia, is a collective term for a group of precancerous 
diseases of the female lower genital tract. Successful treatment of these neoplastic 
diseases can prevent the development of invasive cancer. Recently, it has become 
clear that human papillomavirus (HPV) is the infectious agent that is responsible for 
the development of these (pre)malignant disorders. 
The first observation that cervical cancer was related to sexual activity was made at 
the end of the nineteenth century, when the surgeon Rigoni-Stern reported that the 
appearance of cervical cancer was low in nuns, and high in prostitutes1. It was not 
until 1976 that Zur Hausen suggested that a virus might be involved in the develop-
ment of cervical cancer, when he made the important observation that the epidemio-
logic pattern of cervical cancer was the same as for human papillomavirus-induced 
condylomata acuminata2. In the little eighties HPV-DNA was extracted from cervical 
cancer specimens, and since then the research on HPV as a causal agent in the devel-
opment of genital cancers and their precursor lesions increased exponentially. Recent 
data have shown that in 99,7% of cervical cancers HPV is detectable3. Cervical cancer 
is the first cancer that is acknowledged by the World Health Organisation to be virally 
induced in essentially al cases4,5.  
Human papillomaviruses are small, double-stranded DNA viruses of approximately 
8000 base pairs. They are strictly epitheliotropic, which means that they only infect 
epithelial or mucosal surfaces. At the present, over 100 different HPV types have been 
described, of which about 40 can infect the anogenital tract6. Human papillomavi-
ruses are further divided in the low-risk or non-oncogenic types, which cause benign 
epithelial proliferations such as genital warts and condylomata acuminata, and the 
high-risk or oncogenic types, which can cause malignant transformation of infected 
cells. Human papillomavirus type 16 (HPV16) is found in 60% of cases of cervical 
cancer3,7. The HPV16 genome can be divided in the early (E) genes and the late (L) 
genes. The early genes encode proteins with regulatory functions engaged in genome 
persistence and DNA replication. The late genes encode structural proteins that form 
the capsid of HPV particles. HPVs probably infect the basal cells of the epithelia 
through breaks or tears in the epithelial layer. After infection, HPV expresses the viral 
early genes E1, E2, E5, E6 and E7 in the basal layers. Late viral proteins L1, L2 and 
E4 are made, viral DNA replication takes place, and virus particles are released only 
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at the superficial terminally differentiated layers (Figure 1). New virus particles may 
re-infect the host or be transmitted to new hosts by sexual transmission.
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HPV infection begins with binding of virions to the basal cells of the epithelium. In this layer the viral 
genome is amplified to several copies. In the suprabasal layers of the epithelium HPV early (E) proteins 
are expressed and the viral replication takes place. Only in the most superficial layers of the epithelium, 
E4 and the late (L) genes L1 and L2 are expressed, HPV DNA is encapsidated, and the virions are released 
at the epithelial surface. 
Anogenital HPV infection is believed to be the most common sexual transmitted viral 
infection, with an estimated 36-month cumulative incidence of more than 40% in 
young sexually active college women in the United States8, and an estimated lifetime 
risk for women of at least 75% for one or more genital HPV infections9-11. Fortunately, 
the vast majority of infections are transient and only a minor fraction of infected 
subjects develop persistent infections (often defined as infections that are detected 
more than once in an interval of 6 months or longer) with an oncogenic HPV type, 
especially HPV16 and 18, that may progress to premalignant lesions or cancer8,12-14. 
The immune system is likely to play an important role in this, because the incidence 
of HPV infections, HPV-associated warts, CIN lesions and cervical cancer is increased 
in immunocompromised subjects15.  
Figure 1. The HPV infectious cycle. 
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HPV-induced anogenital diseases
Cervical intraepithelial neoplasia (CIN) and cervical cancer
Cervical cancer is the second most common cancer in women worldwide, after breast 
cancer, accounting for over 200.000 deaths each year16. The interval between the 
acquisition of HPV infection and malignant progression usually takes at least 10 
years or longer17,18. Cervical cancer is therefore very uncommon in women under 25; 
the incidence rises progressively for women over 25 and is highest for women over 
40. In the Netherlands approximately 800 new cases of cervical cancer are reported 
annually, with an age-standardized incidence rate of 9,5 new cases per 100.000 
women. The precancerous stage of cervical cancer, known as cervical intraepithelial 
neoplasia (CIN), can be detected by cytological screening years before cervical cancer 
appears. CIN is histopathologically classified as mild (CIN 1), moderate (CIN 2), or 
severe (CIN 3), depending on the extent to which the epithelial layer is involved in 
the neoplastic changes. Although patients with CIN are at risk of developing cervi-
cal cancer, it is obvious that not all CIN lesions will progress to malignant disease. 
Studies examining rates of progression for CIN have found that the risk is related to 
the severity of dysplasia19,20. Approximately 57% of CIN 1 lesions may spontaneously 
regress, while 32% will persist as low-grade and 11% may progress to CIN 2 or 3. The 
corresponding figures for CIN 2 are 43%, 35% and 22%, respectively. Spontaneous 
regression, persistence, and progression of CIN 3 to invasive cancer occur in approxi-
mately 32%, 56% and 12%, respectively21. A model of cervical carcinogenesis in rela-
tion to infection with HPV is depicted in figure 2.
Figure 2. Model of cervical carcinogenesis. 
The major steps in cervical carcinogenesis are human papillomavirus (HPV) infection (balanced by viral 
clearance), progression to cervical intraepithelial neoplasia (CIN) (partly offset by regression of low-grade 
lesions), and invasion. The persistence of oncogenic or high-risk HPV types is necessary for progression and 
invasion. 
	 infection	 progression	 invasion
		regression
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Vulvar intraepithelial neoplasia (VIN) and vulvar cancer
Vulvar intraepithelial neoplasia (VIN) is an uncommon chronic skin disorder charac-
terized by histological abnormalities confined to the vulvar epithelium. The impor-
tance of VIN lies in its association with vulvar squamous cell carcinoma and impaired 
quality of life secondary to unpleasant symptoms and deforming treatments. The 
long-term risk of invasive cancer in women who have previously been treated for 
VIN 3 is 2,5-7%22-24, whereas the risk for untreated patients has been estimated up to 
80%23. High-grade VIN is in over 90% associated with HPV, HPV16 being the type 
most commonly involved25-27. In young women, vulvar cancer is associated with HPV 
in 60-90% of cases, whereas only the minority of cases in older women (less than 
10%) is positive for HPV28. 
Other HPV-associated anogenital disease
The available epidemiological studies indicate that cancers of the vagina and of the 
anus resemble cancer of the cervix with respect to the role of HPV. In both, HPV-
DNA is detected in the great majority of tumors and their precursor lesions. Between 
64 and 91% of vaginal cancers and 82 and 100% of cases of high-grade vaginal 
intraepithelial neoplasia (VAIN 3) lesions are HPV-DNA positive29-31. In anal cancers, 
HPV-DNA is detected in 88-94%32.  
Standard treatment for anogenital intraepithelial 
neoplasia and cervical cancer
Cervical intraepithelial neoplasia and cervical cancer 
The management of pre-invasive disease of the cervix is based on local control and 
prevention of progression to invasive cervical cancer. According to the Dutch guide-
lines women with histologically confirmed CIN 2 or CIN 3 should be treated to pre-
vent the development of cervical cancer33. Techniques that can be used to remove the 
transformation zone, which is the area of the cervix where most lesions are located, 
include surgical excision by large loop excision of the transformation zone (LLETZ) 
or cone biopsy, and ablation by laser evaporation or cryocoagulation (reviewed in34). 
In general a LLETZ is preferred, as it is a relatively simple and safe procedure that 
can be performed in an outpatient setting and it provides the availability of tissue 
for histological examination. Success rates for the different treatment modalities are 
comparable, exceeding 85-95%35-38. Eradication of HPV from the genital mucosa, 
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associated with over 90% of CIN lesions, is not possible with the currently available 
techniques. Therefore, cytological follow up is advised 6, 12 and 24 months after 
primary treatment to detect any residual or recurrent disease33.
The optimal treatment of cervical cancer depends on the stage at the time of diagno-
sis. Stage is determined clinically, on the basis mainly of the size of the tumor in the 
cervix or its extension into the pelvis39. Stage I disease is limited to the cervix; stage 
II disease extends beyond the cervix to the upper two thirds of the vagina or the para-
metrial tissue but not to the pelvic side wall; stage III tumors have spread to the pelvic 
side wall, the pelvic nodes, or the lowest third of the vagina; and stage IV tumors 
have invaded the mucosa of the bladder or rectum or have spread to distant sites of 
the body. Stage I tumors can be subdivided in stage IA that represents microscopic 
disease (stage IA1: invasion ≤ 3 mm, stage IA2: invasion 3-5 mm) and stage IB that 
represents clinically visible lesions confined to the cervix of less (stage IB1) or more 
(stage IB2) than 4 cm in size. Briefly, stage IA1 tumors can be treated by conization 
or by a simple hysterectomy. For stage IA2, IB or IIA tumors a radical hysterectomy 
with pelvic lymph node dissection or chemoradiation are the treatments of choice. 
Patients with stage IIB-IVA are usually treated by chemoradiation or radiation in 
combination with hyperthermia. The treatment for stage IVB cervical cancer and for 
recurrent disease has to be individualized and may be radiotherapy, extensive surgery 
or chemoradiation, or a combination of these therapies.
Clinical stage is a reliable prognostic indicator for patients with cervical cancer40,41. 
The 5-year survival approaches 100% for patients with stage IA tumors and averages 
70-85% for those with stage IB1 and smaller IIA lesions. For stage III and IV, these 
figures are 30-50% and 5-15%, respectively. After optimal primary treatment of early 
stage disease local recurrences are found in 15% of patients42. The most important 
prognostic factors in early stage cervical cancer are the presence of lymph node 
metastasis, tumor size, vaso-invasion, and infiltration depth43-45. 
Vulvar intraepithelial neoplasia 
The treatment for VIN 3 has classically been surgical local excision or, in case of 
multifocal VIN, vulvectomy. Because of the increasing incidence of the disease in 
younger women the past two decades24,46 and the major impact of surgical treatments, 
there has been a gradual trend towards more conservative treatment modalities in 
patients with VIN 3. Laser treatment as well as different types of medical therapies 
can be used, especially in younger patients to limit surgical mutilation47.
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New treatment modalities
New surgical techniques
New surgical modalities in the treatment of early-stage cervical cancer include trach-
electomy and nerve-sparing surgery. Radical vaginal trachelectomy (amputation of 
the cervix and surrounding parametrial tissue in combination with pelvic lymphad-
enectomy) is a fertility-sparing option for selected women with early-stage cervical 
cancer48-50. Recent studies have shown a low incidence of recurrences (0-7,3%) and 
acceptable cumulative conception rates. The operation is, however, associated with a 
significant incidence of second trimester miscarriage and premature labour50. 
Radical hysterectomy is associated with great morbidity in terms of serious bowel, 
bladder, and sexual dysfunction51-53. The pelvic autonomic nerves are responsible for 
the neurogenic control of rectal and bladder function. Nerve-sparing radical hysterec-
tomy, which includes the identification and subsequent preservation of these nerves, 
is currently under investigation as a new treatment option for early-stage cervical 
cancer54,55. The technique seems feasible and safe and might provide patients with an 
improved quality of life56. Future large clinical trials will have to decide whether it 
can be implemented as a standard treatment for cervical cancer patients.
Chemotherapy 
Chemotherapy for advanced or recurrent cervical cancer has been and continues to 
be considered palliative. Many agents have been investigated as single or combined 
regimens.  Cisplatin is considered the most active single agent in recurrent disease. 
As a single agent, cisplatin has been compared with the combination of cisplatin 
and paclitaxel in a randomized phase 3 study. The combined regimen was superior 
to single-agent cisplatin in terms of response rate and survival, at a cost of revers-
ible bone-marrow toxic effects57. The combination of cisplatin and topotecan was 
also shown to increase survival and response rates in patients with locally advanced 
cervical cancer in another phase 3 study58. Concomitant chemoradiation appears 
to improve overall survival and progression-free survival for patients with locally 
advanced cervical cancer (Cochrane Database Syst Rev 2005). Overall, response rates 
for chemotherapeutic regimens average 10-40%, with complete responses seen only 
rarely and for short duration. Therefore, there is need for new therapeutic approaches 
in the battle against cervical cancer. 
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Photodynamic therapy 
5-Aminolevulinic acid (ALA) photodynamic therapy (PDT) is a new technique that 
is based on the local or systemic application of the photosensitizer ALA, which is 
preferentially absorbed in neoplastic tissue. Activation of ALA by light leads to the 
release of highly reactive oxidants capable of producing local tissue destruction. PDT 
is a minimal invasive procedure that can be performed in an outpatient setting. Small 
trials using PDT in patients with CIN showed little efficacy59. Clinical responses to 
PDT in patients with VIN have been described60,61. In comparison to laser vaporization 
and surgery, PDT was shown to have little side effects but higher recurrence rates62. 
This may be explained by the fact that the therapy does not induce HPV-specific 
immunity aimed at long-term protection against HPV-infected cells but is just aimed 
at local destruction of tissue. 
Immunomodulators
Imiquimod is an immunomodulating agent that directly activates the innate immune 
system, resulting in cytokine release and costimulatory molecule expression, followed 
by T-cell activation. It has shown efficacy and safety in clinical trials for the treat-
ment of genital warts63-65. It is hypothesized that this topical treatment may be effec-
tive in stimulating HPV-specific T-cell immunity and the subsequent regression of 
HPV-related dysplastic lesions of the vulva. Recently, some trials reported on benefi-
cial effects of topical imiquimod application in the treatment of high-grade VIN66-69. 
A large randomized study on the use of Imiquimod in the treatment of patients with 
multifocal high grade VIN showed that Imiquimod was safe and highly effective in 
these patients (Van Seters, unpublished results). We have shown that the presence 
of IFNγ-associated T-cell immunity against HPV16 is significantly associated with 
a more favourable clinical response upon treatment with imiquimod in a group of 
patients with VIN 3 (chapter 6). 
HPV-specific immunotherapy
The important role of a viral agent in the pathogenesis of AGIN and cervical cancer 
offers the potential for the development of vaccination strategies. HPV-specific immu-
notherapy, aimed at prevention of HPV infection on the one hand and destruction of 
HPV-infected dysplastic cells on the other, is a promising new treatment regimen. For 
the design of effective immunotherapeutic strategies against HPV-induced disease, it 
is important to have detailed knowledge about the natural immune responses against 
HPV in healthy individuals and patients with HPV-induced disease. 
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Immune responses in anogenital neoplasia
The immune system can be divided in the non-specific immune system and the anti-
gen-specific immune system. The former functions as a first line of defense and 
involves the natural barriers (like skin and mucus), bactericidal enzymes, granulo-
cytes and macrophages, and the complement system. The latter consists of the cel-
lular and humoral immune system.  
Cell-mediated immunity can be divided in two categories: CD4+ T-cells, and CD8+ 
T-cells or cytotoxic T-lymphocytes (CTL). CD4+ T-cells can further be divided in T-
helper (Th) cells and regulatory T-cells (Treg). CD4+ T-helper cells play a central role 
in regulating immune responses and are essential in antitumor immunity70-72 (Figure 
3). Based on their pattern of cytokine production, CD4+ Th-cells can be divided into 
Th1 and Th2 subsets. Th1 cells produce type 1 cytokines like IL-2, IL-12, GM-CSF, 
TNF-α, and interferon gamma (IFNγ), and are primarily responsible for activating 
and regulating the development of CTL and innate effector cells. Th2 cells are char-
acterized by the production of type 2 cytokines IL-4, IL-5, IL-10, and TGF-β. Th2-
CD4+ T-helper (Th) cells play a central role in the protection against viral pathogens, by 1) stimulation of 
the production of antibodies (IgG/IgA) by B-cells, 2) activation and stimulation of innate effector cells, 
and 3) activation of CD8+ (cytotoxic) T-cells. Presentation of antigen by antigen presenting cells (APC) to 
Th-cells is necessary for the induction of an effective immune response.  
Figure 3. The central role of CD4+ T-helper cells in protective antiviral immunity. 
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type cytokines are immunoinhibitory for T-cell responses and predominantly induce 
humoral immune responses, i.e. the formation of antibodies.  Recently, it has been 
shown that regulatory T-cells play a major role in maintaining peripheral tolerance 
to tumors73,73. Based on their cytokine pattern Tregs can be divided in Tr1 cells that 
secrete IFNγ and IL-1074 and Tr3 cells that act predominantly via the secretion of 
TGF-β75. CD8+ T-cells play a pivotal role in the clearance of virally infected cells and 
killing of tumor cells.
The cytokine microenvironment in HPV-induced (pre)malignant lesions
Cytokines are secreted by macrophages, granulocytes, T-cells, normal epithelial 
cells, and tumor cells amongst others, and they regulate cell-mediated immune 
responses76-78. Some studies have indicated that CIN lesions are associated with a 
decreased expression of the proinflammatory type 1 cytokines IFNγ and TNF-α79-81 
and an increased production of the regulatory cytokine IL-1080,82. The local cytokine 
environment in HPV-infected lesions may determine the outcome of disease. The 
decreased expression of type 1 cytokines in tumor cells may contribute to a less 
effective local antitumor response, because these cytokines are involved in augment-
ing antigen presentation, maturation, and cytotoxicity of Langerhans cells. Indeed, 
the expression of IFNγ in cervical cancer has a better prognostic value83. In contrast, 
the presence of IL-10 was shown to be associated by more extensive disease in HPV-
induced CIN lesions84. Furthermore, cervical carcinoma cell lines continue to express 
TGF-β while the expression of the proinflammatory cytokines TNF-α and GM-CSF is 
strongly decreased85. The production and secretion of TGF-β by cervical cancer cells 
was associated with an increased amount of intratumoral stroma and a reduction in 
the number of infiltrating immune cells86. 
Recently, subsets of CD4+CD25+ regulatory T-cells have been described that suppress 
Th1 responses through the secretion of IL-10 and TGF-β87. A recent study showed 
that in high-grade CIN lesions the infiltrating CD4+CD25+ T-cells produced IFNγ as 
well as IL-10 and TGF-β, suggesting the presence of such regulatory T-cells in these 
lesions88. The production of another type 2 cytokine IL-4 by CD3+ T-cells in patients 
with cervical cancer was associated by increased infiltration of eosinophilic granulo-
cytes, which has been shown to correlate with a worse survival89,90. 
Taken together, these data indicate that an imbalance between type 1 and type 2 
cytokines in HPV-infected tissue may determine the efficacy of the local antitumor 
response. Modification of the local cytokine environment in the treatment of patients 
with HPV-induced AGIN may have strong effects on clinical outcome. 
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The infiltration of immune cells in HPV-infected (pre)malignant lesions
Infiltration of lymphocytes is correlated with regression of genital warts in both 
human and animal models91,92. Studies investigating the local immune environment 
in patients with HPV-induced anogenital disease have shown contradictionary results. 
Some studies reported on a localized immunodeficiency in cervical and vulvar dys-
plastic tissue in a qualitative or quantitative way. A depletion of intraepithelial CD4+ 
T-cells was shown in CIN lesions93,94 and infiltrating T-cells in cervical lesions dis-
played an immunosuppressed phenotype95. Other studies have shown that the num-
bers of infiltrating T-cells and Langerhans cells (LC) were significantly increased in 
cervical and vulvar neoplasia compared to healthy control tissue88,96-99. 
In several types of human invasive cancers the clinical significance of a local-
ized immune response has been inferred from the correlation of tumor-infiltrating 
CD8+ T-cells with outcomes100-103. The clinical significance of the local infiltration of 
immune cells in patients with HPV-induced disease has been suggested in a number 
of studies. In a group of vaccinated VIN patients clinical responsiveness to treat-
ment was shown to be dependent on the presence of lesion-associated CD4+, CD8+ 
and CD1a+ immune cells104. In another study, it was shown that an increase of CD8+ 
T-cell infiltration in the lesions of VIN patients was significantly associated with 
clinical responsiveness to treatment with photodynamic therapy (PDT)105. Decreased 
proportions of tumor-infiltrating CD4+ T-cells, which have been observed in cervical 
neoplasia93,94,98, were correlated with rapid tumor growth and lymph node metastasis 
in patients with cervical cancer106. We recently showed that an increased infiltration 
of intraepithelial CD8+ T-cells was significanty associated with the absence of lymph 
node metastases in patients with large early-stage cervical cancer (chapter 7). So far, 
the relationship between systemic antitumor immunity, tumor infiltration of T-cells, 
and clinical outcome in patients with HPV-induced cervical cancer has not yet been 
studied. 
HPV-specific immunity
Anogenital HPV infections are common sexually transmitted diseases. While most 
infections are transient, persistence is found in a small proportion of infected per-
sons and this may lead to the development of anogenital neoplasia and cancer. The 
enhanced prevalence of HPV infections and increased incidence of HPV-induced 
disease in immunocompromised subjects, such as HIV-infected subjects and organ 
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transplant patients15,107 suggests that the immune system plays a role in preventing 
the appearance and inducing the regression of anogenital lesions. Both the late and 
early viral proteins form a target for the HPV-specific immune response.
Humoral immunity to the structural protein L1
Mucosal IgG and IgA antibodies to HPV16 are present in a proportion of patients 
with HPV-induced lesions108-110 and may prevent re-infection of the epithelium by 
released viral particles. Unlike many other human viruses, human papillomaviruses 
do not naturally provoke a strong serological response. Although serum IgG antibod-
ies to HPV16 are found in 56-60% of subjects with incident HPV infections within 
8-18 months111-113, the titres of these antibodies are low111. Antibodies can persist for 
decades114, but in women without HPV-associated lesions they rapidly disappear115. 
Given the high frequency of serum IgG antibodies in patients with CIN76, VIN116,117, 
and cervical cancer118, these antibodies do not appear to correlate with the prevention 
or clearance of HPV-induced genital lesions but may serve as a marker for progres-
sive disease. Indeed, the presence of serum HPV antibodies seems to be correlated 
with the persistence of HPV and the development of premalignant lesions119,120. Serum 
HPV16-specific IgA was shown to be associated with an early appearance120 and a 
shorter duration compared to IgG121. Serum IgA seems to be a marker for an ungoing 
HPV infection whereas IgG is a marker for lifetime cumulative exposure to HPV16110. 
In contrast to the naturally occurring humoral response, vaccination with virus-like 
particles (VLPs) of papillomaviruses has shown to result in high titres of virus-specific 
serum IgG antibodies and protection against virus-induced (pre)malignant lesions in 
animals and in humans122-125.
CD4+ T-cell immunity against HPV16
Studies addressing T-cell immunity against HPV have focused on HPV16 because of 
the high prevalence in high-grade CIN lesions and in cervical cancers. So far, many 
studies addressing T-cell responses against the HPV16 early proteins E2, E6 and E7 
have been performed. Proliferative responses against HPV16 E6 were more frequent 
observed in sexually active women without disease than in women with current 
CIN126. Bontkes et al. showed that Th-cell responses against E2 were frequently seen at 
time of viral clearance in patients with CIN127. T-cell responses against HPV16 E6 and 
E7 were found to be associated with clearance of infection and regression of CIN128,129. 
We have detected frequent HPV16-specific Th immunity against E2 and E6 in the 
majority of healthy individuals, and also occasionally E7-specific T-cell responses130-
132, suggesting that in humans CD4+ T-cell immunity against the early antigens of 
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HPV16 protects against progressive disease. HPV-specific immunity in patients with 
AGIN may differ not so much in the quantitative aspects of the immune response but 
more in the quality of the response. We have recently found that although patients 
with cervical cancer display HPV16 E2 and/or E6-specific proliferation, this reactiv-
ity is not associated with the production of the type 1 cytokine IFNγ typical for the 
HPV16-specific response in healthy subjects (chapter 2). 
Animal models revealed that L1-specific immunity can protect against infection with 
the cottontail rabbit papilloma virus133 or the canine oral papilloma virus124,134,135. 
Previous work in humans has shown that patients diagnosed with HPV16+ CIN dis-
played proliferative responses against HPV16 L1136,137 and that there was no difference 
in such proliferative responses (measured by IL-2 production) between patients who 
cleared their lesions or in whom lesions persisted76. Large HPV16 L1-VLP vaccination 
trials in humans revealed that vaccine-induced immunity could prevent persistent 
infections and HPV-induced CIN123,125,138,139. Immunological evaluation of these tri-
als was predominantly focused on the role of neutralizing antibodies in preventing 
viral infection. HPV16 L1 vaccination in healthy subjects was shown to induce not 
only strong antibody responses, but also L1-specific T-cell responses140. These T-cell 
responses against L1 are not likely to protect against the progression of established 
HPV-induced disease. The large HPV VLP vaccination studies were not designed to 
evaluate the therapeutic effects of the vaccines on subjects with evidence of prior 
HPV infections. Recently, HPV VLP vaccination was shown not to speed viral clear-
ance in women with existing HPV infections141. We have shown that unlike E2 and 
E6, HPV-specific type 1 T-cell responses against L1 were present in the majority of 
patients with HPV16-induced CIN and cervical carcinoma, indicating that T-helper 
type 1 immunity against the structural protein is not correlated with health or disease 
(chapter 3).
Taken together, studies on HPV16-specific T-helper cell immunity in humans indi-
cate that HPV-specific CD4+ Th1 responses against the early antigens, but not the 
late antigen L1, are associated with protection against progression of HPV-induced 
disease. 
CD8+ T-cell immunity against HPV16
CD8+ T-cells or cytotoxic T-cells (CTL) play a vital role in the clearance of virally 
infected cells142. The role of naturally occurring CTL in mediating regression of HPV-
related disease has not been proven143, and limited data are available regarding the 
CTL responses to HPV16 in humans. Some studies have showed the presence of 
HPV16-specific CTL in the blood of patients with high-grade CIN, VIN and cervical 
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cancer. CTL responses to E6 and E7 were more commonly detected in HPV16-posi-
tive women without CIN than in HPV16-positive patients with CIN144,145, suggesting 
a protective effect of HPV-specific CTL in the development of AGIN. In other stud-
ies, patients with persistent infections or progressive disease occasionally displayed 
HPV16-specific CTL responses146-148. The impairment of CD4+ T-cell immunity, which 
is of pivotal importance for the induction and maintenance of CTL immunity149, may 
explain why the detection of HPV-specific CTL in all studies was rare, and of low 
frequency. 
Papillomavirus vaccination
Identification of a viral agent such as HPV as a cause of disease implies that suc-
cesfull intervention against the viral agent should prevent or cure the disease it 
causes. There are two types of immunological intervention strategies: prophylactic 
and therapeutic vaccination. 
Prophylactic HPV vaccination
Prophylactic vaccines aim at the induction of antibodies that are capable of pre-
venting viral infection. Efforts to develop a vaccine to prevent HPV infection have 
focused on eliciting humoral immune responses to the HPV capsid proteins using 
synthetic empty capsids, termed “virus-like particles” (VLPs)150. VLPs are morpho-
logically indistinguishable from the authentic virion, are non-infectious and lack 
any oncogenic DNA. In animal papillomavirus models, systemic vaccination with 
L1 VLPs was shown to be capable of inducing high titres of neutralizing antibod-
ies as well as protecting against viral infection after challenge with the homologous 
virus122,124. Early phase human trials have also indicated that L1 VLP vaccines are 
highly immunogenic in humans151-153. Recently, proof-of-principle trials of HPV16 
L1123,139, HPV16 and 18 L1138 or HPV6, 11,16 and 18 L1125 VLPs have shown that 
over 90% of vaccinated subjects were protected against persistent infection with the 
homologous HPV type, whereas the placebo group had persistent infections with 
HPV and subsequent HPV-associated cytological abnormalities. Although the results 
of these studies are highly encouraging, several things should be kept in mind. First, 
it has not been proven that these vaccines really protect against the development of 
cervical cancer. It will take several decades before this will become clear. Second, the 
studies mentioned indicated that protection was associated with the concentration 
of HPV-specific L1-antibodies. Although high anti-HPV16 titres were observed after 
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completion of the vaccination regimens, the titres waned over time125,139. It is impor-
tant to examine what titre of antibodies is necessary for optimal protection, and in 
what frequency booster vaccinations are needed for maintenance of this titre. Other 
unresolved issues include the most critical groups to vaccinate and if the costs of the 
vaccines are low enough for widespread implementation in the developing world, 
where 80% of cervical cancer occurs154,155. In conclusion, long-term studies address-
ing these issues are necessary before large-scale implementation of prophylactic HPV 
vaccines can take place. 
Therapeutic HPV vaccination
VLP vaccination leading to the circulation of antibodies to L1 will not elicit the cell-
mediated immune responses required for the therapeutic treatment of established 
HPV-induced (pre)malignant disease, in which a spectrum of early gene products is 
expressed and in which at later stages of disease the expression of the late antigen 
L1 is lost141,156,157. We showed that HPV16 L1-specific type 1 T-cell immunity is found 
in the majority of both healthy subjects and patients with HPV16-induced CIN and 
cervical cancer, suggesting that this type of immunity does not protect against the 
development of AGIN (chapter 3). Therapeutic vaccines are aimed at eradicating or 
reducing the number of HPV-infected cells. In many cases HPV-associated tumors 
only express the E6 and E7 oncoproteins, so it is not surprisingly that most candidate 
vaccines are aimed at inducing T-cell immunity against these proteins. However, 
animal studies suggest that targeting the early proteins E1 and E2 can contribute to 
therapeutic vaccine efficacy. In the cottontail rabbit papillomavirus (CRPV) model, 
which is a model for high-risk papillomavirus infections in humans, DNA vaccines 
encoding the early antigens E1, E2, E6 and E7 were shown to prevent persistent 
infections and associated dysplasia158,159. Immunization of rabbits with the E1 and 
E2 proteins induced a CD4+ T-cell response, fewer papillomas developed and they 
regressed more rapidly than in non-vaccinated animals160. Similarly, therapeutic vac-
cination with long E6 and E7 peptides was able to control wart growth in immunized 
rabbits and resolve latent infections161. In view of the strong immune responses to the 
E2, E6 and E7 early proteins that are readily detected in sexually active healthy indi-
viduals130,132, these animal models strengthen the notion that the same HPV proteins 
may form an important target for therapeutic vaccines.
At present, several vaccines have been tested in phase 1/2 clinical trials in humans 
(reviewed in162,163). A recombinant vaccinia virus expressing the HPV16 and HPV18 
E6 and E7 genes (TA-HPV) in patients with cervical cancer was shown to be safe, 
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well-tolerated164, and immunogenic in a proportion of the patients tested165. This 
vaccine was also tested in a group of patients with high-grade VIN. In the first 
series of 18 patients with VIN 3, there were T-cell responses against HPV16 in 13/18 
cases. Furthermore, a 50% decrease in lesion size was reported in 8/18 patients and 
a reduction or loss of viral load in 12/18 patients104. In a group of women with high-
grade VIN, the TA-HPV vaccine induced a systemic HPV-specific T-cell response in 
6/10 patients166. All these 6 patients showed a clinical response during treatment. 
Although there was no overt correlation between the clinical change and the T-cell 
responses, this was a remarkable observation. 
Peptide vaccines are attractive because peptides are relatively inexpensive and well 
tolerated in humans. In a phase 1 trial of 15 HPV16-positive patients with late-stage 
cervical cancer, vaccination with 2 HPV16 E7 CTL epitopes and a universal Th epi-
tope did not result in the induction of HPV16-specific CTL nor was there evidence 
of clinical benefit, although there were strong immune responses induced against 
the non-specific CD4+ component of the vaccine167. Vaccination with a similar E7 
vaccine resulted in E7-specific T-cell responses in a fraction of patients with high-
grade anogenital neoplasia168. In women with CIN an HPV16 E6E7 fusion protein 
in Isomatrix adjuvant resulted in cellular immune responses in a substantial part of 
vaccinated subjects169. Recently, a phase 1/ 2 trial involving vaccination with 32-
35 aminoacid long overlapping synthetic peptides spanning HPV16 E6 and E7 has 
shown that strong HPV16-specific IFNγ-associated CD4+ and CD8+ T-cell responses 
are induced, even in patients with advanced cervical cancer  (Kenter, van der Burg 
and Melief, unpublished observations).
In summary, potential therapeutic vaccine candidates are being tested in human clin-
ical trials. They have proven to be safe and well tolerated in patients and are immu-
nogenic in most cases. Although some encouraging clinical responses have been 
reported, the relation between the induction of systemic HPV-specific T-cell responses 
and clinical efficacy is not clear and needs to be examined in future studies. 
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Outline of this thesis
The aim of this study was to gain further insight into the natural HPV-specific T-cell 
responses in healthy individuals and in patients with HPV-induced disease of the 
female genital tract. Furthermore, the T-cell responses were studied in relation to 
clinical responses upon immunomodulatory treatment of anogenital intraepithelial 
neoplasia. 
In chapters 2 and 3 we describe the HPV-specific immune responses that spon-
taneously develop during viral infection and persistence. We found that systemic 
CD4+ T-cell responses against HPV16 E2 and E6 were frequently found in healthy 
subjects and were predominantly of a mixed Th1/Th2 character. HPV16-specific 
T-cell responses in patients with cervical cancer lacked the strong proinflammatory 
cytokine profiles generally associated with HPV16-specific responses in healthy indi-
viduals, suggesting immune failure in patients with HPV16+ cervical cancer. Unlike 
E2 and E6, type 1 T-cell immunity against the structural protein L1 was not correlated 
with health or disease, as we found HPV16-specific IFNγ-associated T-cell immunity 
to L1 in healthy individuals and in patients with HPV16- positive cervical neoplasia 
with similar magnitude. Chapter 4 reports on a pilot study of the use of a skin test 
as a safe and simple method to detect HPV16-specific T-cell responses in vivo. The 
skin test results and correlation with immunological responses in a group of eleven 
women with histories of cervical neoplasia and a group of nine healthy controls are 
evaluated. In chapters 5 and 6 we studied the immune responses against HPV16 dur-
ing immunomodulation in women with HPV16-associated anogenital intraepithelial 
neoplasia (AGIN). An HPV oncogene vaccination protocol was shown to be highly 
immunogenic in a group of patients with AGIN and in some cases these HPV-specific 
type 1 immune responses were associated with an objective regression of lesions. 
The presence of IFNγ-associated HPV16-specific T-cell responses was associated with 
a more favorable clinical response upon treatment with imiquimod in a group of 
patients with high-grade VIN. Chapter 7 describes the results of a detailed analysis 
of the systemic immune response and local tumor infiltration in a group of patients 
with HPV16- or 18- positive cervical cancer. Strong CD8+ T-cell tumor infiltration 
was found in patients without lymph node metastases and this may be associated 
with better prognosis.
A discussion of the overall results is presented in chapter 8, as well as directions for 
future research.
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Abstract
Cervical cancer is the possible outcome of genital infection with high-risk human 
papillomavirus (HPV) and is preceded by a phase of persistent HPV infection during 
which the host immune system fails to eliminate the virus. Fortunately, the major-
ity of genital HPV infections are cleared before the development of (pre)malignant 
lesions. Analysis of CD4+ T-helper (Th) immunity against the E2, E6 and E7 antigens 
of HPV type 16 (HPV16) in healthy women revealed strong proliferative E2- and E6-
specific responses associated with prominent IFNγ and IL-5 secretion. This indicates 
that the naturally arising virus-induced immune response displays a mixed Th1/Th2 
cytokine profile. Of all HPV16+ cervical cancer patients, approximately half failed to 
mount a detectable immune response against the HPV16-derived peptides. The other 
half of the patients showed impaired HPV16-specific proliferative responses, which 
generally lacked both IFNγ and IL-5. This indicates that the HPV16-specific CD4+ 
T-cell response in cervical cancer patients is either absent or severely impaired, 
despite a relatively good immune status of the patients, as indicated by intact 
responses against recall antigens. It is highly conceivable that proper CD4+ T-cell 
help is important for launching an effective immune attack against HPV because 
infection of cervical epithelia by this virus is, at least initially, not accompanied by 
gross disturbance of this tissue and/or strong proinflammatory stimuli. Therefore, our 
observations concerning the lack of functional HPV16-specific CD4+ T-cell immu-
nity in patients with cervical cancer offer a possible explanation for the development 
of this disease. 
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Introduction
Cervical encounter with human papillomavirus (HPV) generally results in a transient 
infection, with the majority of individuals showing clearance of the virus within 1 
year of detection1-4. Factors underlying the lag time between HPV infection and clear-
ance are related to the minimal disturbance of the epithelial layer initially caused by 
the virus, lack of HPV-induced Langerhans cell activation, and the capacity of viral 
proteins to evade innate immune recognition by physically inhibiting specific com-
ponents of the innate immune system, such as interference with the type I interferon 
pathway5-10. Once the process of regression of HPV-induced dysplasia is initiated, it is 
characterized by an influx of macrophages and T lymphocytes, resembling a delayed-
type hypersensitivity response11. Indirect evidence that the adaptive cellular immune 
system plays a major role in the protection against HPV-induced lesions is given by 
the high incidence of persistent HPV infections and subsequent HPV-related dyspla-
sia in both immunosuppressed transplant patients and HIV-infected individuals12,13. 
An underlying cause of the failing anti-HPV immune response in immunocompetent 
individuals with persistent infection was suggested to be a locally altered cytokine 
environment with an increase in IL-10 production and a decrease in proinflammatory 
cytokines14-16. Others have shown that a so-called T-helper (Th)2 type cytokine bias 
in the peripheral blood of CIN patients was associated with more extensive cervi-
cal disease17, but the implication of such altered cytokine balance on HPV-specific 
immunity has not been determined. 
Studies analyzing T-cell responses against viral antigens from the high-risk type 
HPV16 in the healthy population and several stages of disease do not present an 
unequivocal relationship between protection against HPV16-induced (pre)malignant 
lesions and virus-specific T-cell immunity18-21. We have previously described the 
presence of IFNγ-producing memory CD45RO+CD4+ Th cells specific for HPV16 E2 
and E6 proteins in the peripheral blood of the majority of healthy individuals22,23, 
suggesting a role for these Th cells in protection against HPV16-induced progres-
sive disease. In order to fully appreciate the importance of HPV16 E2- and E6-spe-
cific Th responses in managing infection and subsequent progressive (pre)malignant 
lesions, we have performed a detailed analysis with respect to the magnitude and 
cytokine polarization of this immunity and compared this between healthy subjects 
and HPV16+ patients. 
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Materials and methods
Healthy blood donors and patients
A selected group of twenty sexually active young females within the age of 19-31 
years (median 23 years) participated in this study after informed consent. It was 
expected that a large fraction of these individuals had experienced previous tran-
sient HPV infection because most anogenital HPV infections are acquired soon after 
sexual debut and are also cleared at an early age. Older individuals were excluded 
because women who are HPV DNA positive at ages 35 and above may represent fail-
ure of viral clearance24. A Pap smear was performed for cytological examination, and 
an additional cervical swab specimen was obtained for HPV DNA analysis. Women 
presenting with histologically proven cervical carcinoma or CIN at the department 
of gynecology of the Leiden University Medical Center (LUMC) were enrolled in this 
study after informed consent. Blood was drawn at day of treatment prior to surgery. 
Carcinoma subjects enrolled were staged FIGO IB/IIA and were treated by radical 
hysterectomy. The age of the cervical cancer patients (n=17) ranged from 34-72 years 
old (median 45 years), whereas the age of the CIN III patients (n=13) ranged from 29 
– 42 years (median 31 years) We preferred to use CIN III for analyses of cases in which 
the naturally occurring immune response has not been able to control the infection 
because there is a substantial heterogeneity in the microscopic diagnosis and biologic 
meaning of CIN II lesions in particular. In general, the majority of CIN III lesions are 
incipient precancers that are destined to persist2. PBMC and serum were obtained for 
the analysis of HPV16-specific T-cell reactivity and VLP L1-specific antibodies. 
The subjects were typed for HPV16 using HPV16-specific primers on DNA isolated 
from cervical swab specimens, paraffin-embedded sections of biopsies, or surgi-
cal resection specimens25. The study design was approved by the Medical Ethical 
Committee of the LUMC. Two of twenty healthy females were HPV positive (one type 
62 and the other type 31), but no HPV16 was detected. Of the CIN III and cervical 
carcinoma patients, only the HPV16 positive subjects were included in the immuno-
logical analyses. 
Antigens
A set of peptides spanning the whole HPV16 E2, E6, and E7 protein were used in 
pools of 2 peptides for the T-cell proliferation assays. The E2 peptides consisted of 
22 30-mer peptides with 15 amino acids overlap and the C-terminal peptide with a 
length of 35 amino acids. The length of the E6 and E7 peptides was 32 and 35 amino 
acids, respectively, with an overlap of 14 amino acids. The peptides were synthesized 
Impaired HPV16-specific immunity in cervical cancer 39
and dissolved as described previously26. The peptide pools are indicated by the first 
and last amino acid of the region in the protein covered by the two peptides (e.g. 
E21-45, residues 1-30 + 16-45). Memory Response Mix (MRM), consisting of a mixture 
of tetanus toxoid (0.75 LF/ml; National Institute of Public Health and Environment, 
Bilthoven, The Netherlands), Mycobacterium tuberculosis sonicate (2.5 µg/ml; gener-
ously donated by Dr.P. Klatser, Royal Tropical institute, Amsterdam, The Netherlands) 
and Candida albicans  (0.005%, HAL Allergenen Lab, Haarlem, The Netherlands), was 
used to confirm the capacity of PBMC to proliferate and produce cytokine in response 
to common recall antigens.
HPV16 VLP ELISA
For the detection of HPV16-specific antibodies in serum we used an ELISA method 
previously described by Kirnbauer et al.27. Each serum was tested for reactivity 
against HPV16 virus-like particles (VLP, baculovirus-expressed capsids comprising 
the L1 protein) and against bovine papillomavirus (BPV) capsids, the latter disrupted 
by treatment with 0.1M carbonate buffer to serve as a negative control. Both VLP 
and BPV were kindly provided by Prof. dr. J. Dillner (LUNDS University, Sweden). 
The patients (all proven HPV16-positive by PCR) were tested for HPV16-specific IgG 
only, whereas the healthy controls were tested for both IgG and IgA because it has 
been described that transient infections more frequently lead to specific serum IgA 
antibodies than IgG. Overall, HPV16-specific antibodies can only be detected in a 
small fraction of individuals experiencing a transient HPV16 infection and only for a 
limited time period after infection28. Therefore, only the presence, but not the absence 
of HPV16-specific antibodies allows conclusions as to whether or not an individual 
has experienced a transient infection in the past. 
Short-term T-cell proliferation assay
Freshly isolated PBMC were incubated with 12 pools of HPV16 E2-derived 30-mer 
peptides, 4 pools of E6 32-mer peptides, and 2 pools of E7 35-mer peptides (each 
pool containing two overlapping peptides). PBMC were seeded at a density of 1.5 x 
105 cells/well in a 96-well U-bottomed plate (Costar, Cambridge, MA) in 150 µl of 
ISCOVE’s medium (Bio-Whittaker) supplemented with 10% autologous serum. HPV16 
E2-, E6- and E7-derived peptides were added at a concentration of 10 µg/ml/peptide. 
Medium alone was taken along as a negative control, and MRM (dilution 1:50) served 
as a positive control. For each peptide pool, 8 parallel microcultures were incubated. 
50 µl of supernatant from the microcultures was taken at day 5 after incubation and 
stored at –20°C until cytokine analysis. Peptide-specific proliferation was measured 
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at day 7 by [3H]thymidine incorporation. Cultures were scored positive when the 
proliferation of ≥ 75% of the test wells exceeded the mean proliferation plus 3 x SD 
of the control wells containing medium only, and the stimulation index (SI), defined as 
the mean of all test wells divided by the mean of the control wells, was ≥ 3. Previously 
performed short-term proliferation assays with immunologically naïve cord blood cells 
(10 samples) revealed no specific proliferation against the E6 or E7 oncoprotein-derived 
peptides, indicating that the 7-day stimulation with peptides does not result in the in 
vitro induction of HPV16-specific proliferative responses.
CFSE labeling 
Freshly isolated PBMC were washed in cold PBS and incubated with 0.5 µM carboxy-
fluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene, OR) in PBS 
at 37°C for 30 min; 5% autologous serum was added, and the PBMC were washed 
twice in PBS. The CFSE-labeled PBMC were then resuspended in IMDM supplemented 
with 10% autologous serum and incubated with the HPV16-derived peptides as 
described for the short-term proliferation assays. 
Analysis of cytokines associated with HPV16-specific proliferative responses 
The detection of cytokines in the supernatants of the short-term proliferation assays 
was performed using the cytometric bead array (Becton Dickinson). Analysis of the 
cytokine kinetics revealed that at day 5, antigen-specific production of all cytokines 
could be detected. IL-2 and IL-4 can both be consumed by proliferating cells; there-
fore, levels of these cytokines in this assay may be underestimated. Supernatants 
from the individual microcultures harvested at day 5 were pooled per peptide pool 
and 50 µl of this supernatant was used for cytokine analysis. The cytometric bead 
array was performed according to manufacturer’s instruction. Cutoff values were 
based on the standard curves of the different cytokines (50 pg/ml for IFNγ and 10 pg/
ml for the remaining cytokines). Antigen-specific cytokine production was defined 
as a cytokine concentration above cutoff level and > 2x the concentration of the 
medium control29. 
Analysis of PHA-induced proliferation and cytokine production
Liquid nitrogen-stored PBMC were used for these assays, enabling the analysis of all 
the samples at the same time for optimal comparison. The cervical carcinoma and 
the healthy control group consisted of the same individuals as those analyzed in the 
short-term proliferation assays, minus those from whom an insufficient amount of 
PBMC was available (healthy subjects n=17, cervical carcinoma patients n=13). The 
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CIN group included additional samples, which had been collected previously and 
stored in liquid nitrogen (CIN patients n=13). PBMC were thawed and resuspended at 
a concentration of 106/ml in serum-free x-vivo15 medium (BioWhittaker). 100 µl of 
cell suspension was seeded per well of a 96-well round-bottom plate, in total 24 wells 
per subject. 50 µl of 1,5 µg/ml PHA (Murex Diagnostics, Dartford, UK) in x-vivo15 
was added to 12 wells, whereas 50 µl of plain x-vivo15 medium served as a negative 
control in the remaining 12 wells. After 48 hours 50 µl of supernatant per well was 
harvested, and the supernatants from the PHA-stimulated wells were pooled, as were 
the controls. Supernatants were stored at –20°C until cytokine analysis by ELISA. 
PHA-induced proliferation was measured by  [3H]thymidine incorporation 48 hours 
after stimulation. IFNγ was measured by ELISA as described previously26. IL-4 and 
IL-10 (CLB, Amsterdam) and IL-5 (Pharmingen) ELISA's were performed according to 
the instructions of the manufacturer. 
Statistical analysis
Statistical analysis of the HPV16-specific proliferative responses associated with 
cytokine production was performed using Fisher’s exact test. For the statistical analy-
sis of the mitogen-induced proliferation and the cytokine levels in response to recall 
antigens, an unpaired two-tailed t-test was applied, and an unpaired two-tailed t-test 
with Welch correction for the analysis of the mitogen-induced cytokine ratios. 
 
Results
HPV16 E2- and E6-specific CD4+ T-cell responses in healthy individuals are 
associated with Th1 and Th2 type cytokines
Previously, we have demonstrated the presence of HPV16 E2- and E6-specific mem-
ory CD4+ Th cells in the CD45RO+ fraction of peripheral blood of the majority of 
healthy individuals22,23. These memory Th cells produced IFNγ upon stimulation, indi-
cating that they are of a Th1 type. So far, it has not been determined whether the 
HPV16-specific responses in the healthy population consist solely of Th1 type cyto-
kines or whether other cytokines are also involved. We therefore analyzed the cyto-
kine profiles of the HPV16-specific T-cells in a cohort of 20 young, sexually active, 
healthy women. All women had a normal cytology and were proven HPV16 negative 
by PCR and VLP ELISA at the time of analysis, therefore, the presence of responses 
against the HPV16 antigens are expected to represent memory T-cells induced upon 
a transient HPV16 infection in the past. Short-term proliferation assays were per-
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formed against peptides derived from the HPV16 proteins E2, E6, and E7 as well as 
a mix of common recall antigens (Memory Response Mix, MRM). In accordance with 
our previous data22,23, half of the individuals showed proliferative responses against 
E2 (10/20), and an even larger fraction showed responses against the E6-derived 
peptides (13/20). E7-specific responses were detected in only a minority of subjects 
(2/20) (Figure 1a). CFSE labeling of PBMC demonstrated that exclusively CD4+ Th 
cells contributed to the HPV16-specific proliferation, as upon stimulation with E2 
and E6 peptides, cell division could only be detected in the CD4+ fraction of PBMC 
(Figure 2). This is in line with our previous notion that HPV16-specific IFNγ secretion 
was solely derived from CD4+ T-cells22,23 (and data not shown).
Analysis of the supernatants of these T-cell cultures for the presence of IFNγ, TNFα, 
IL-2, IL-4, IL-5, and IL-10 revealed the secretion of both Th1- and Th2-type cytokines 
in response to HPV16-derived peptides (Figure 1b). The most predominantly secreted 
cytokines were IFNγ and IL-5 (Figure 1b and Figure 3), often accompanied by IL-2 
and, to a lesser extent, by TNFα and IL-10. Antigen-specific secretion of IL-4 was 
rarely observed. In response to recall antigens (MRM), the majority of Th1- and Th2-
type cytokines for which we analyzed were detected. Taken together, the consistent 
HPV16-specific secretion of IFNγ and IL-5 in healthy individuals suggests that both 
Th1 and Th2 type immunity play a role in the effective control of HPV16 infection. 
Impaired HPV16-specific Th immunity in patients with HPV16+ (pre)malignant 
lesions 
Having characterized the HPV16-specific Th responses in healthy individuals, a frac-
tion of whom have apparently succeeded in clearing HPV16 infection, we questioned 
how these compare to patients who have evidently failed to establish an effective 
immune response against this virus. A group of HPV16-positive patients, consisting 
of 8 subjects diagnosed with CIN III and 17 subjects with cervical carcinoma (CxCa), 
was analyzed for E2, E6 and E7 reactivity by short-term proliferation assay. In only 1 
out of 8 CIN III patients HPV16-specific proliferation was observed (Figure 1c), which 
was associated with the production of both IFNγ and IL-5 (Figure 1d). The remaining 
7 patients with high-grade CIN did not show any proliferative reactivity against the 
E2, E6, or E7 antigens, whereas all 8 patients did respond to the recall antigens. In 
contrast to the near absence of HPV16-specific responses in high-grade CIN patients, 
cervical carcinoma patients showed a response frequency that resembled that of the 
healthy subjects (Figure 1c), with half of the patients showing proliferative responses 
against E2 (8/16; patient 9 was not tested against E2), and less frequent responses 
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Figure 1. 
a. Freshly isolated PBMC from 20 healthy female individuals (HD) were tested in short-term pro-
liferation assays using a complete set of HPV16 E2-, E6- and E7-derived peptide pools (indi-
cated by the first amino acid of the region in the protein covered by the peptides). Responses 
were scored positive when the proliferation (cpm) of  ≥ 6 of 8 test wells exceeded the mean 
proliferation + 3 x SD of the control (medium only) wells, and the mean stimulation index 
(SI) of all test wells over control wells was ≥ 3. Memory Response Mix (MRM), consisting of a 
mixture of recall antigens, was used as a positive control. Indicated are the stimulation indices 
(SI) of responses scored positive.
b. Supernatants of the positive proliferative responses indicated in (a) were analyzed for the pres-
ence of IFNγ, TNFα, IL-2, IL-4, IL-5, and IL-10 by Cytometric Bead Array. The indicated layout 
is used for the six measured cytokines; a filled square represents antigen-specific cytokine 
production. Cutoff values were based on the standard curves of the different cytokines (50 pg/
ml for IFNγ and 10 pg/ml for the remaining cytokines). Antigen-specific cytokine production 
was defined as a cytokine concentration above cutoff level and > 2 x the concentration of the 
medium control. 
c. 8 CIN III and 17 cervical cancer (CxCa) patients (all HPV16-positive) were tested in short-term 
proliferation assays as described in (a). 
d. Supernatants of the positive proliferative responses of the patient group were subjected to 
cytokine analysis as described in (b).  
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Figure 2. Detection of HPV16-specific T-cell 
proliferation in the CD4+ fraction of PBMC. 
Freshly isolated PBMC derived from 4 healthy 
subjects were labeled with CFSE and incubated 
with the most immunogenic pools of peptides 
derived from E2 and E6 (E231-75 and E637-86, 
respectively) and the mix of recall antigens 
(MRM). One representative example is shown. 
At day 6, the cells were counterstained with 
CD4 and CD8 antibodies, and the division in 
both T-cell subsets was determined by flow 
cytometric analysis.
against the E7 antigen (3/17). The number of cervical carcinoma patients showing a 
proliferative response against HPV16 E6 was lower (7/17) than of healthy individuals 
(13/20), but this difference was not statistically significant.
Despite this resemblance of the healthy female group in terms of frequency of pro-
liferative responses against HPV16 antigens, the corresponding cytokine production 
showed a completely different picture (Figure 1d). In the group of cervical carcinoma 
patients, only a minor fraction of the proliferative responses was associated with 
cytokine production. In fact, in most cases, none of the cytokines were detected, 
despite the occasional broad proliferative response against all three HPV16 antigens 
(Figure 1d and 4). In a large set of supernatants derived from microcultures lacking 
antigen-specific proliferation, we were not able to detect specific cytokine produc-
tion, indicating that selection of supernatant samples based on proliferation does 
not result in an underestimation of the cytokine responses. Overall, compared with 
the healthy subjects, the responses against both E2 and E6 in cervical carcinoma 
patients are characterized by lack of IFNγ and IL-5, as reflected by a significantly 
reduced fraction of total responses associated with either cytokine (IFNγ: p<0.05 
IL-5: p≤0.001, Fisher's exact test). The secretion of other cytokines besides IFNγ and 
IL-5 is also reduced in cervical carcinoma patients, but the antigen-specific secretion 
of IL-10 appears to be less affected. As a consequence, HPV16 responses associated 
solely with the immunoregulatory cytokine IL-10 can be observed. HPV16-specific 
IL-10 production was accompanied by IFNγ and /or IL-5 in 11 out of 12 responses in 
healthy individuals but in only 2 out of 6 responses in cervical carcinoma patients 
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Strong proliferative Th responses against the HPV16 E2- and E6-derived peptides were observed in healthy 
female-derived PBMC. One representative example (H7) displaying such proliferative responses is depicted 
in the upper panel. Each open circle represents the proliferation of an individual microculture; superna-
tants of the positive responses (arrows) were subjected to cytokine analysis. The corresponding cytokine 
levels are depicted in the lower panels, indicating the predominant secretion of IFNγ and IL-5. Antigen-
specific cytokine secretion, as defined in the legend of figure 1, is indicated with an asterisk (*).
Figure 3. HPV16-specific T-cell responses in healthy individuals are predominantly associated 
with IFNγ and IL-5. 
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Approximately half of the HPV16-positive cervical cancer patients revealed HPV16-specific proliferation. 
One representative example is shown (CxCa12, upper panel). HPV16-specific proliferative responses were 
generally not associated with detectable cytokine production (lower panels), whereas the recall response 
(MRM) was associated with high levels of IFNγ, TNFα, and IL-5.  For explanatory notes, see figure 3 legend. 
Figure 4. Absence of detectable cytokine levels despite HPV16-specific proliferation in 
cervical cancer patients.
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(p<0.05, Fisher's exact test). The low number of responses in CIN III patients and 
low number of E7 responses in all groups precluded these parameters from statisti-
cal analysis. Importantly, no significant differences in the magnitude and cytokine 
profiles of the recall antigen (MRM) responses were observed between cervical car-
cinoma patients and healthy individuals. The mean IFNγ and IL-5 levels in response 
to MRM were lower in cervical cancer patients than in healthy women; however, this 
difference was not significant (Figure 1. IFNγ: healthy subjects mean = 3110 pg/ml 
range 307-10500 pg/ml, CxCa patients mean = 2229 pg/ml range 150-8250 pg/ml. 
IL-5: healthy subjects mean = 466 pg/ml range 11-1091 pg/ml, CxCa patients 280 
pg/ml 10- 1276 pg/ml, two-tailed t-test). This indicates that the recall antigen-spe-
cific cytokine production was not significantly impaired in the patient population, 
which is in accordance with the fact that these patients had low-stage (mainly FIGO 
IB) disease. 
Even though the frequency at which HPV16 E2/E6-specific T-cell immunity was 
detected in patients and healthy females was roughly similar, it should be noted that 
all patients carried HPV16+ cervical lesions and therefore approximately half of the 
HPV16+ cervical carcinoma patients had failed to mount any detectable HPV16-spe-
cific Th response. Thus, failure of immune defense against cervical HPV16 infection 
can embody either HPV16 E2/E6-specific T-cell immunity with an impaired capacity 
to produce cytokines or a complete lack of such T-cell immunity. 
Patients with HPV16+ cervical disease display altered cytokine profile of 
peripheral T-cells 
The local cytokine environment in HPV-induced lesions differs from that observed 
in healthy tissue14,16, and it has been suggested that this can influence the overall 
polarization of peripheral T-cells toward a Th2 type cytokine profile in patients bear-
ing these lesions17,30,31. In our study, HPV16-specific CD4+ Th responses in patients 
with cervical cancer lack the clear Th1/Th2 cytokine profile that is exhibited by such 
responses in healthy subjects, whereas the cytokine profile of MRM-specific T-cell 
responses does not show significant differences between healthy and diseased indi-
viduals. We questioned whether the overall cytokine profiles of peripheral T-cells, as 
determined by mitogenic stimulation of PBMC, would reveal a difference between 
patients with HPV16-induced disease and healthy subjects. Supernatants from PHA-
stimulated PBMC were analyzed for the levels of IFNγ, IL-4, IL-5, and IL-10. Per indi-
vidual, the ratios of the different cytokines were calculated, which reflect the Th1/Th2 
polarization of the T-cell repertoire. Cervical carcinoma patients revealed relatively 
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higher levels of IL-10 and IL-4 as compared with IFNγ, suggesting the loss of Th1 
in favor of Th2 cytokines in the peripheral blood of the diseased population (Figure 
5a,b; p<0.01, unpaired two-tailed t-test with Welch correction). However, the IFNγ/
IL-5 ratios did not differ between the groups (data not shown), indicating that the 
cytokine profiles in cervical carcinoma patients do not represent a general Th2 bias. 
In line with this, the ratios of the Th2 type cytokines IL-5/IL-4 are also significantly 
lower in cancer patients (Figure 5c; p<0.05). The high-grade CIN patients revealed 
cytokine profiles similar to that observed in the cervical carcinoma patients, although 
the difference with the healthy subjects was less pronounced and was only significant 
for the IFNγ/IL-4 ratios (Figure 5a; p<0.05). Overall, the PHA-induced proliferation 
was slightly lower in both high-grade CIN and carcinoma patients compared with 
healthy individuals (Figure 5d). Taken together, the mitogen-induced cytokine pro-
files suggest the presence of an altered cytokine balance in HPV16-induced disease, 
which may have determined the lack in cytokine polarization of HPV16-specific 
Th responses found in patients and affected the proliferative capacity of these 
T-cells.
Thawed PBMC derived from healthy female individuals (n=17), CIN III patients (n=13), and cervical carci-
noma patients (n=13) were stimulated with PHA (0,5 µg/ml) for 48 hours after which the proliferation was 
measured by [3H]thymidine incorporation, and the supernatants were analyzed for the presence of IFNγ, 
IL-4, IL-5 and IL-10 by ELISA. The ranges of measured cytokines were 31-97 ng/ml, 5-109 pg/ml, 0-479 
pg/ml, and 50-1390 pg/ml, respectively. No significant differences in the absolute cytokine concentrations 
were observed between the groups. The cytokine ratios per subject were plotted because these reflect the 
overall polarization of the T-cell repertoire, independent of the absolute amounts of cytokine secreted. 
Significant differences between patients and healthy subjects are indicated with an asterisk (*) (p<0.05, 
two-tailed t-test with Welch correction). 
Figure 5. Patients with HPV16+ cervical disease display altered cytokine profile of peripheral 
T-cells.
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Discussion
Our analysis of CD4+ T-cell immunity against the HPV16 E2 and E6 antigens in 
healthy women and patients with HPV16+ cervical disease revealed that cervical 
cancer is associated with HPV16-specific immune failure. Of the HPV16+ carcinoma 
patients tested, approximately half lacked any detectable proliferative E2-, E6- and/
or E7-specific T-cell responses. The other half of the carcinoma patients did show 
systemic proliferative responses, but this immunity was, in general, not associated 
with a strong inflammatory cytokine profile. Because specific CD4+ T-cell help is of 
crucial importance for the development of humoral and cellular effector mechanisms 
against viral infections, these impaired responses against the viral antigens can be 
considered unfavorable in view of protection against progressive HPV-induced neo-
plasia. In contrast to cervical cancer patients, healthy women frequently displayed 
strong CD4+ T-cell responses against HPV16 E2 and E6, and these responses were 
generally associated with the secretion of inflammatory cytokines, most predomi-
nantly IFNγ and IL-5. Our observation that the HPV16-specific memory response in 
healthy subjects displays a mixed Th1/Th2 cytokine profile is in accordance with the 
notion that both humoral and cellular immunity are required to clear viral infection 
and provide subsequent protection against reinfection (Figure 6, left panel). Others 
have previously observed a lack of E6- and E7-specific IL-2 secretion in PBMC of 
cervical carcinoma patients and have, on the basis of this observation, suggested that 
this loss of IL-2, a cytokine indicative of a Th1 type response, might be accompanied 
by an increased Th2 type response20. Our data indicate that the HPV-specific cytokine 
secretion in the diseased population indeed lacks IL-2 but is not skewed toward Th2 
type. Instead, the HPV-specific T-cell response in patients features an overall defect 
in inflammatory cytokine production. 
Compared with the frequency at which HPV16-specific proliferative responses are 
detected in cervical carcinoma patients, the frequency of such immunity in patients 
with high-grade CIN lesions is surprisingly low, and this does not correspond with 
the idea of a gradual loss of HPV16-specific T-cell reactivity during disease progres-
sion. A similarly low frequency of HPV16-specific T-cell responses in CIN patients 
was also described by Nakagawa et al.32. On the basis of these accumulated data, 
we hypothesize that failure of the HPV-specific CD4+ T-cell response allows per-
sistent HPV infection and subsequent establishment of high-grade CIN (Figure 6, 
right panel). Indirect evidence supporting this hypothesis is given by reports showing 
that low CD4+ T-cell counts in HIV-infected individuals are associated with multiple 
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HPV infections, higher viral load, viral persistence, and cervical dysplasia12. Without 
surgical intervention, the majority of established high-grade CIN lesions will evolve 
toward cervical carcinoma. Our data suggest that in approximately half of the cervical 
carcinoma patients, the presence of the tumor will eventually trigger the induction of 
a CD4+ T-cell response. It is, however, conceivable that cervical cancers do not pro-
vide the appropriate proinflammatory environment for the induction of a potent and 
well-polarized T-cell response and that CD4+ T-cell priming at this stage of disease 
will most likely result in an ineffective HPV-specific antitumor immune response. 
The lack of responses in the remaining patients could reflect either a complete fail-
ure at the induction level or could be the result of silencing of preexisting impaired 
responses by tumor-induced or chronic infection-induced T-regulatory activity. We 
are currently performing longitudinal studies in cohorts of women to investigate the 
dynamics of the HPV16 E2/E6-specific CD4+ T-cell response in relation to clearance 
or persistence of HPV infection. 
Thick arrows represent the fate of the majority of HPV16-infected individuals; thin arrows represent the 
fate of the minority of HPV16-infected individuals. The dashed arrow indicates the option that persis-
tently infected individuals with low-grade dysplasia can show spontaneous regression, presumably via the 
induction of effective Th1/Th2 immunity. The dashed box represents the altered cytokine balance observed 
in high-grade CIN and cervical carcinoma (CxCa) patients.   
Figure 6. Proposed model for the association between HPV16-specific CD4+ T-cell immunity 
and the development of HPV16-induced disease. 
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We frequently detected E2-specific CD4+ T-cell immunity in cervical carcinoma 
patients, despite the fact that integration of viral DNA into the cellular genome often 
results in the loss of functional E2 gene expression. This may be explained by the 
finding that in addition to integrated copies, episomal HPV16 DNA capable of encod-
ing E2, can be found in cervical carcinoma33,34.
Comparison of the cytokine profiles of mitogen-induced T-cell responses in PBMC 
from cervical cancer patients versus healthy subjects showed the loss of the Th1 type 
cytokine IFNγ in favor of the Th2 type cytokines IL-4 and IL-10 in patients. Others 
have previously described a similar finding in patients with extensive CIN lesions 
compared with healthy controls17. Although cross-sectional analysis does not allow 
definite conclusions with respect to the order of events, it is likely that this altered 
systemic cytokine balance is a consequence of HPV-induced disease because the local 
cytokine environment in HPV-induced lesions is directly and indirectly (via anti-
gen-presenting cells, APC) capable of modifying cytokine profiles of T-cells15,16,30,31. 
Notably, we did not observe significant differences between patients and controls 
in the cytokine profile of recall (MRM)-specific T-cell responses. The discrepancy 
between the character of MRM-specific responses on one hand and mitogen-triggered 
and HPV-specific responses on the other can most readily be explained by the fact 
that MRM-specific T-cell memory was established and therefore properly polarized 
before the development of cervical neoplasia. These strongly polarized MRM-specific 
memory T-cells are, in contrast to naïve T-cells, relatively insensitive to modified 
APC function35,36, such as that expected to be found in cervical cancer patients37. 
Mitogen-induced cytokine secretion, on the other hand, reflects the cytokine produc-
tion of all peripheral T-cells, including that of naïve T-cells and those that have been 
primed against other pathogens during this period of HPV-induced disease. 
In conclusion, our data demonstrate an association between HPV16+ cervical disease 
and partial or complete failure of CD4+ T-cell function in E2- and E6-specific immu-
nity. The sophistically designed infection cycle of HPV16, which does not involve 
destruction of virus-infected keratinocytes and avoids proinflammatory signals that 
could stimulate recruitment and activation of APC, necessitates the role of CD4+ 
T-cell help in the process of anti-HPV immunity. In view of this consideration, our 
findings offer a possible explanation for the development of cervical disease. 
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Abstract 
Cervical cancer is the possible outcome of a genital infection with high-risk human 
papillomavirus type 16 (HPV16) and is preceded by a phase of persistent HPV infec-
tion during which the host immune system fails to eliminate the virus. Our previous 
work showed that failure is reflected by the absence of type 1 T-cell immunity against 
HPV16 early antigens E2 and E6 in patients with HPV16+ cervical lesions. We now 
show that a majority of both patients with cervical lesions and healthy subjects 
display HPV16 L1 peptide-specific type 1 T-cell responses with similar magnitude. 
The T-cell response in patients was directed at a broad range of peptides within L1, 
suggesting that during persistent or repeated exposure to HPV16 L1, the immune 
system maximizes its efforts to counter the viral challenge.  Unlike the type 1 T-cell 
responses against HPV16 early antigens E2 and E6, type 1 T-cell immunity against 
L1 does not correlate with health or disease. This argues that T-cell responses against 
early and late HPV16 antigens essentially differ in the manner in which they are 
induced and regulated, as well as in their impact on the subsequent stages of HPV16-
induced cervical disease.
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Introduction
Infection of both men and women with oncogenic human papillomavirus (HPV) 
types, such as HPV type 16 (HPV16), is quite common1-3 and leads to progressive 
disease in only a minor fraction of infected subjects4-6. The majority of the infec-
tions and HPV-induced epithelial lesions spontaneously resolve, most likely through 
intervention by the adaptive immune response7-9. In a majority of healthy subjects 
(approximately 60%) strong type 1 T-cell reactivity directed at the nonstructural 
proteins HPV16 E2 and E6 can be detected10-12, suggesting that these proteins are 
important target antigens for a protective immune response in humans, similar to 
what was found in animal models13-15. These animal models also revealed that L1-
specific immunity can protect against infection with the cottontail rabbit papilloma 
virus16 or the canine oral papilloma virus17-19. A large HPV16 L1-VLP vaccination trial 
in humans revealed that vaccine-induced immunity could prevent persistent HPV16 
infections20. Although the immunologic evaluation of this trial was focused on the 
role of neutralizing antibodies in preventing viral infection, VLP vaccination must 
also have affected the underlying CD4+ Th responses and possibly Th-dependent cell-
mediated effector functions.
Previous work has shown that patients diagnosed with HPV16+ CIN display pro-
liferative responses against HPV16 L121,22 and that there was no difference in such 
proliferative responses (measured by IL-2 production) between patients who cleared 
their lesions or in whom lesions persisted23. Immunity in such subjects may differ not 
so much in the quantitative aspects of the immune response but more in the qual-
ity of the response, as is indicated by our studies on immunity against the HVP16 
nonstructural antigens. Although we found patients with cervical cancer to display 
HPV16 E2 and/or E6-specific proliferation, this reactivity was not associated with 
the production of the type 1 cytokine IFNγ typical for the HPV16-specific response 
in healthy subjects11. To gain a better understanding of the role of HPV16 L1-specific 
T-cell response, we analyzed the L1 peptide-specific type 1 T-cell immunity in adult 
healthy subjects, patients with HPV16+ CIN II/III and patients with HPV16+ cervi-
cal cancer by IFNγ ELISPOT. In addition, we studied the HPV16 L1-specific T-cell 
response in 10-15-year-old females who have had no previous experience of penetra-
tive sex, hence referred to as virgin female subjects. This sample group participated 
in an L1-VLP vaccination study, a setting that provided us with a unique opportunity 
to analyse L1-specific T-cell cross-reactivity between common HPV types (skin and 
low-risk) and HPV16, as well as to compare vaccine-induced T-cell reactivity with 
that induced upon infection. 
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Material and methods
Subjects
PBMCs were isolated from buffy coats of anonymous healthy blood bank donors after 
informed consent. Because these donors were anonymous, no data on medical history 
were available. There was no serum available to determine the HPV infection status 
by serological analysis. However, donors with a known recent history of infection, 
including abnormal pap smear were, as part of normal regulations, discouraged to 
donate blood.
Subjects with histologically proven cervical carcinoma or CIN were nested in the 
CIRCLE study, which investigates cellular immunity against HPV16- positive cervi-
cal lesions. The study design was approved by the Medical Ethical Committee of the 
Leiden University Medical Center. Blood samples were collected on the day of treat-
ment before surgery, and peripheral blood mononuclear cells (PBMC) were isolated by 
density centrifugation on the same day. Cells were cryopreserved in liquid nitrogen 
until further use. Carcinoma subjects were staged FIGO IB-IIB and were treated by 
radical hysterectomy or chemoradiation. The patients with CIN were treated by loop 
electrosurgical excision procedure (LEEP) or by conization. The subjects were typed 
for HPV16 using HPV16-specific primers on DNA isolated from paraffin-embedded 
sections of biopsies or surgical resection specimens24. For the ELISPOT-analyses, only 
HPV16-positive subjects were included. The age of the cervical cancer patients (n=10) 
ranged from 27-57 years old (median 37 years), and the age of the CIN II/III patients 
(n=10) ranged from 25-70 years (median 36 years). For the clinical characteristics of 
the patients, see Table 1.
In addition, PBMC and serum samples from 15 healthy virgin female subjects (aged 
10-15 years, median 12 years) were collected to determine vaccine-induced immu-
nologic responses against HPV16 L1. These subjects participated in a phase III trial 
to examine the safety and immunogenicity of 3 injections of different doses of a 
L1-VLP vaccine consisting of HPV6, 11, 16 and 18 VLPs mixed with alumn adjuvant 
(Merck Research Laboratories, West Point, PA, USA). These subjects were enrolled at 
the Groningen University Medical Center (The Netherlands), and the protocol for this 
study was approved by the Central and Local Medical Ethical Committees. Subjects 
received vaccinations, injected i.m. into the deltoid muscle, at 0, 2 and 6 months. 
Blood specimens were collected for immunologic assays before the initial vaccination 
(i.e. at month 0) and at months 3 and 7 (1 month after the second and 1 month after 
the last vaccination, respectively) and PBMC and serum samples were stored in liquid 
nitrogen until further use. 
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Antigens 
A set of peptides spanning the whole HPV16 L1, E2 and E6 protein were used for 
the ELISPOT assays. The L1 peptides consisted of 33 30-mer peptides with 15 amino 
acids overlap and the C-terminal peptide with 20 amino acids overlap. The length 
of the E2 and E6 peptides was 30 and 22 amino acids, respectively, with an overlap 
of 15 and 12 amino acids. The peptides were synthesized and dissolved as described 
previously25.
Analysis of HPV16 L1, E2 and E6-specific T-cell reactivity by IFNγ ELISPOT
Interferon-γ (IFNγ) producing HPV-specific T-cells (CD4+ and/or CD8+) were quanti-
fied using ELISPOT that was performed as described previously26,27. Briefly, PBMC 
were thawed, washed and seeded at a density of 1-2 x 106 cells per well of a 24-well 
plate (Costar, Cambridge, MA) in 1 ml of IMDM (Bio Whittaker, Verviers, Belgium) 
Table 1. Patient characteristics
patient no age (yrs) diagnosis grade/stage treatment 
 1 35 CIN II LEEP
 2 34 CIN  II LEEP
 3 33 CIN  II LEEP
 4 41 CIN  III conization
 5 25 CIN  II LEEP
 6 28 CIN  II LEEP
 7 29 CIN  III LEEP
 8 30 CIN III conization
 9 70 CIN  III hysterectomy1
10 31 CIN  III conization
11 46 SCC IB1 radical hysterectomy
12 32 SCC    IB1 radical hysterectomy
13 44 SCC    IB1 radical hysterectomy
14 43 AC IB1 radical hysterectomy
15 45 SCC    IIB chemoradiation
16 27 SCC    IB1 radical hysterectomy
17 36 SCC    IIB chemoradiation
18 40 SCC    IB1 radical hysterectomy
19 45 SCC    IB1 radical hysterectomy
20 57 SCC    IB1 radical hysterectomy
 
CIN, cervical intraepithelial neoplasia; LEEP, loop electrosurgical excision procedure; SCC, squamous 
cell carcinoma; AC, adenocarcinoma. 1 hysterectomy performed because of patient’s age and suspected 
malignancy.
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enriched with 10% human AB serum, in the presence or absence of indicated HPV 
16 L1, E2, E6 and E7 peptide pools. As a positive control, PBMC were cultured in the 
presence of a memory recall mix (MRM), consisting of a mixture of tetanus toxoid 
(0.75 limus flocculentius/ml final concentration; National Institute of Public Health 
and Environment, Bilthoven, The Netherlands), Mycobacterium tuberculosis sonicate 
(2.5 µg/ml; generously donated by Dr. P. Klatser, Royal Tropical Institute, Amsterdam, 
The Netherlands) and Candida albicans (0.005%, HAL Allergenen Lab, Haarlem, The 
Netherlands). HPV16 peptides were used in pools of 4-5 peptides at a concentration 
of 5 µg/ml/peptide. The peptides, as indicated by their first and last amino acid in the 
protein, were used in the following pools: E2-I: 1-30, 16-45, 31-60, 46-75; E2-II: 61-
90, 76-105, 91-120, 106-135; E2-III: 121-150, 136-165, 151-180, 166-195; E2-IV: 
181-210, 196-225, 211-240, 226-255; E2-V: 241-270, 256-285, 271-300, 286-315; 
E2-VI: 286-315, 301-330, 316-345, 331-365; E6-I: 1-22, 11-32, 21-42, 31-52; E6-II: 
41-62, 51-72, 61-82, 71-92; E6-III: 81-102, 91-112, 101-122, 111-132; E6-IV: 111-
132, 121-142, 131-152, 137-158. For our first analysis of HPV16 L1-specific immu-
nity in healthy donors, we used 17 pools of 2 peptides per pool. The peptide pools 
are indicated by the first and last amino acid of the region in the protein covered by 
the 2 peptides (e.g., L11-45, residues 1-30 + 16-45). For our analysis in healthy donors 
compared to HPV16-positive patients, we used 7 pools of 4 peptides, and the last 
pool consisted of 5 peptides. In addition, for analysis of the PBMC of the vaccinated 
virgin female subjects, 3 pools of 11 peptides covering the L1 protein were used to 
decrease the required number of cells. After 4 days of incubation at 37ºC, PBMC were 
harvested, washed, and seeded in 4 replicate wells at a density of 105 cells per well in 
100 µl IMDM enriched with 10% FCS in a Multiscreen 96-well plate (Millipore, Etten-
Leur, The Netherlands) coated with an IFNγ-catching antibody (Mabtech AB, Nacha, 
Sweden). Further antibody incubations and development of the ELISPOT were per-
formed according to the manufacturer’s instructions (Mabtech). Spots were counted 
with a fully automated computer-assisted video-imaging analysis system (Bio Sys). 
Specific spots were calculated by subtracting the mean number of spots + 2 x SD 
of the medium-only control from the mean number of spots in experimental wells. 
Based on our previous reports, antigen-specific T-cell frequencies were considered 
to be increased compared to non-responders when specific T-cell frequencies were ≥ 
1/10,00027,28. 
HPV16 VLP ELISA
For the detection of HPV16-specific antibodies in serum, we used an ELISA method 
previously described by Kirnbauer et al29. Each serum sample was diluted 30 times and 
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tested for reactivity against HPV16 virus-like particles (VLP, baculovirus-expressed 
capsids comprising the L1 protein) and against bovine papillomavirus (BPV) capsids, 
the latter disrupted by treatment with 0.1 M carbonate buffer to serve as a nega-
tive control. Both VLP and BPV were kindly provided by Prof. Dr. J. Dillner (LUNDS 
University, Sweden). The patients (all proven HPV16-positive by PCR) and vaccinated 
virgin female subjects were tested for both HPV16-specific IgG and IgA. 
The induction of HPV16 L1-VLP-specific antibodies was analysed by ELISA in the 
sera of all 15 vaccinated virgin female subjects prevaccination and after all vaccina-
tions. In addition, a set of sera of healthy children (n=8, mean age 7.3 years, range 
4.3-14.1 years) was tested to determine background reactivity.  All sera were diluted 
30 times. For HPV16 L1-VLP IgG-type responses a cutoff OD value of 0.230 was used 
(mean OD=0.060; range –0.056 to 0.150; mean + 2 x standard deviation =0.230). For 
IgA-type responses, a cutoff of OD=0.178 was used (mean OD=0.043; range –0.062 
to 0.128). 
Homology search in protein database
The search for sequence homology of the overlapping HPV16 L1 peptides with other 
HPV types was performed in a protein database (SwissProt) using standard Basic 
Local Alignment Tool (BLAST)30. Included were those HPV types that are most preva-
lent in healthy women without HPV-associated cervical disease according to 2 large 
cohort studies31,32 (high- risk types 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 
59, 66, 68, 73, and 82, and low-risk types 6, 11, 40, 42, 43, 44, 54, 55, 57, 61, 70, 72, 
81, and 83) as well as the common wart types (2, 3, 4, 7, 10, 27, 28, 29). To identify 
the major regions that could give rise to cross-reactivity, only reported matches with 
>70% amino acid homology with HPV16 L1 peptides were included. 
Statistics
The strength of spontaneous and vaccine-induced L1-specific T-cell response was 
compared by entering all of the positive L1 responses found in healthy donors (Table 
3) versus the responses found in CIN and cervical cancer patients (Table 3).  The 
spread of the T-cell response in the healthy individuals versus the HPV16+ patients 
was calculated using the 2-sided Fisher’s exact test. Statistical analyses were per-
formed using Graphpad Instat Software.
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Results
HPV16 L1-specific T-cell responses in healthy donors
So far, the HPV16 L1-specific T-cell response has been analysed by measuring the 
proliferative capacity of PBMC in the presence of either L1-VLP or limited sets of 
synthetic L1-derived peptides21-23,33,34. To obtain more detailed information about the 
magnitude, specificity and functionality of T-cell responses against HPV16 L1, we 
incubated PBMC isolated from the blood of a group of 20 healthy donors with an 
overlapping set of 30-mer peptides covering the entire HPV16 L1 sequence and tested 
T-cell reactivity by IFNγ ELISPOT assay.  In addition, PBMC were incubated with 
HPV16 E6 peptides to relate the reactivity against L1 with our previous findings for 
early antigens.  In a first group of 10 healthy individuals, HPV16 L1 peptide-specific 
T-cell responses against one or more of the HPV16 L1 peptides were detected in 7 of 
10 healthy donors (Table 2). These data suggested that in healthy subjects T-cell reac-
tivity against HPV16 L1 was observed even more commonly than reactivity against 
HPV16 E6 (4 of 10 subjects in this case). Interestingly, in 6 of 7 cases, a reaction was 
found to one particular region of HPV16 L1 (Table 2), indicating that these peptides 
must harbour one ore more particularly immunogenic epitopes.
We then analysed HPV16-specific T-cell immunity in a second group of 10 healthy 
individuals and compared the L1-peptide specific response with immunity against 
both HPV16 E2 and E6.  To allow a full comparison with the reactivity found in the 
blood of patients with HPV16-associated cervical neoplasia, of which the number 
of isolated PBMC is limited, we used L1-peptide pools consisting of 4 peptides per 
pool. This analysis confirmed our results, in that again 7 of the 10 donors responded 
to one or more of the L1-peptide pools and 4 of 10 against E2 and/or E6 (Table 3). 
Taken together, T-cell reactivity against HPV16 L1 was detected in about 70% (14 of 
20) of all healthy subjects. The most frequently recognized region of L1 was located 
between amino acids 301 and 435. The frequency of healthy subjects responding to 
E2 and/or E6 (8 of 20, Tables 2 and 3), which is comparable to what we have found in 
our previous studies10-12, is somewhat lower than that against HPV16 L1, suggesting 
that not only E2 and E6 but also HPV16 L1 forms a  target for the immune system 
during a transient infection. 
HPV16 L1-specific T-cell immunity in patients with HPV16-positive cervical lesions
Our previous analyses of HPV16 E2- and E6-specific T-cell immunity in cervical cancer 
patients showed that, although antigen-specific proliferation could still be detected, the 
capacity of such T-cells to produce type 1 cytokines (IFNγ) was generally lost11. Others 
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Table 3. HPV16-specific T-cell responses in healthy individuals and HPV16+ patients
Donora
E2 peptides E6 peptides L1 peptides
MRM VLPb1
75
61
135
121
195
181
255
241
315
286
365
1
52
41
92
81
132
111
158
1
75
61
135
121
195
181
255
241
315
301
375
361
435
421
505
11 - - 16 - 1 13 2 21 3 6 6 5 9 1 68 11 12 5 182
12 - 8 13 - - - - 12 2 - 7 - - - - 29 - - 57
13 - - - - - - - - - - 62 - - - - 6 58 - 32
14 - - - - - 4 6 4 6 - - - 4 4 4 4 7 - 185
15 - - 17 - - - 4 7 10 - - - - - - 5 - - 91
16 4 - 5 - 2 - 2 - 1 - - 4 15 9 2 18 11 - 148
17 69 47 - - - 2 - - - - - - - - 4 - 28 - 85
18 - - 1 - - 3 - 2 - - - - - - - 18 - - 43
19 - - - 4 - - - - - - - - - - - - - - 156
20 - 4 - - - 3 3 - - - - - 13 - 3 2 - - 34
Total 1 1 3 - - 1 - 2 1 - 1 - 2 - 1 4 4 - 10
Patient                                                                                                                                       
CIN 1 - - - - - - - - - - - - - - 8 - - - 89 -
CIN 2 - - - - 4 - - - - - - 17 54 17 - - 2 - 231 -
CIN 3 6 7 - - 2 6 - - 51 20 - 3 - 14 - 5 21 35 156 +
CIN 4 - 10 9 1 26 19 34 - 3 - 8 10 10 1 5 4 3 9 5 +
CIN 5 - 1 2 - - - - - 2 - - 9 - - - - 1 - 42 +
CIN 6 3 2 - - 1 5 - 8 - - 55 57 76 17 20 45 108 9 144 +
CIN 7 - - - - - - 6 19 3 - - 4 3 - - - 48 - 186 +
CIN 8 - - - - - 6 2 3 - - - - - 1 1 29 - - 51 +
CIN 9 2 - - - - 2 - 14 2 21 - 42 23 59 59 33 1 61 237 -
CIN 10 - - 2 - - - - - 4 7 - - - - - - - - 32 -
Ca 11 - - - - 4 - - - - - - 2 - 8 159 14 1 - 33 +
Ca 12 - 1 2 - 3 5 - 1 - 5 1 2 - 7 - 26 5 3 114 -
Ca 13 - - - - 21 28 4 - 5 3 - 6 12 2 13 29 5 10 202 +
Ca 14 - - - - 1 11 - - 2 - 3 4 - 2 10 - 26 18 207 -
Ca 15 - - - - - - - - - - - - - - - 6 - - 90 -
Ca 16 - - - - - - - - - - - - - 12 - - - - 28 -
Ca 17 - - - - - - - - - - - 1 23 10 17 15 38 2 10
Ca 18 7 - 2 - 7 7 - - - - 2 13 8 2 15 24 17 5 67 +
Ca 19 - - - - - - 4 - - - - 1 - 2 - 7 28 1 61 -
Ca 20 - 1 1 - - - - - 6 - 1 - - - 10 11 - 3 29 -
Total - 1 - - 2 3 1 2 1 2 1 5 6 6 8 9 7 4 19
a For explanatory notes, see Table 2
b  Sera of the HPV16+ patients were tested for the presence of HPV16 L1-VLP-specific IgG antibodies. Indicated is 
  the presence (+) or absence (-) of antibodies. An empty box means not tested.
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Table 3. HPV16-specific T-cell responses in healthy individuals and HPV16+ patients
Donora
E2 peptides E6 peptides L1 peptides
MRM VLPb1
75
61
135
121
195
181
255
241
315
286
365
1
52
41
92
81
132
111
158
1
75
61
135
121
195
181
255
241
315
301
375
361
435
421
505
11 - - 16 - 1 13 2 21 3 6 6 5 9 1 68 11 12 5 182
12 - 8 13 - - - - 12 2 - 7 - - - - 29 - - 57
13 - - - - - - - - - - 62 - - - - 6 58 - 32
14 - - - - - 4 6 4 6 - - - 4 4 4 4 7 - 185
15 - - 17 - - - 4 7 10 - - - - - - 5 - - 91
16 4 - 5 - 2 - 2 - 1 - - 4 15 9 2 18 11 - 148
17 69 47 - - - 2 - - - - - - - - 4 - 28 - 85
18 - - 1 - - 3 - 2 - - - - - - - 18 - - 43
19 - - - 4 - - - - - - - - - - - - - - 156
20 - 4 - - - 3 3 - - - - - 13 - 3 2 - - 34
Total 1 1 3 - - 1 - 2 1 - 1 - 2 - 1 4 4 - 10
Patient                                                                                                                                       
CIN 1 - - - - - - - - - - - - - - 8 - - - 89 -
CIN 2 - - - - 4 - - - - - - 17 54 17 - - 2 - 231 -
CIN 3 6 7 - - 2 6 - - 51 20 - 3 - 14 - 5 21 35 156 +
CIN 4 - 10 9 1 26 19 34 - 3 - 8 10 10 1 5 4 3 9 5 +
CIN 5 - 1 2 - - - - - 2 - - 9 - - - - 1 - 42 +
CIN 6 3 2 - - 1 5 - 8 - - 55 57 76 17 20 45 108 9 144 +
CIN 7 - - - - - - 6 19 3 - - 4 3 - - - 48 - 186 +
CIN 8 - - - - - 6 2 3 - - - - - 1 1 29 - - 51 +
CIN 9 2 - - - - 2 - 14 2 21 - 42 23 59 59 33 1 61 237 -
CIN 10 - - 2 - - - - - 4 7 - - - - - - - - 32 -
Ca 11 - - - - 4 - - - - - - 2 - 8 159 14 1 - 33 +
Ca 12 - 1 2 - 3 5 - 1 - 5 1 2 - 7 - 26 5 3 114 -
Ca 13 - - - - 21 28 4 - 5 3 - 6 12 2 13 29 5 10 202 +
Ca 14 - - - - 1 11 - - 2 - 3 4 - 2 10 - 26 18 207 -
Ca 15 - - - - - - - - - - - - - - - 6 - - 90 -
Ca 16 - - - - - - - - - - - - - 12 - - - - 28 -
Ca 17 - - - - - - - - - - - 1 23 10 17 15 38 2 10
Ca 18 7 - 2 - 7 7 - - - - 2 13 8 2 15 24 17 5 67 +
Ca 19 - - - - - - 4 - - - - 1 - 2 - 7 28 1 61 -
Ca 20 - 1 1 - - - - - 6 - 1 - - - 10 11 - 3 29 -
Total - 1 - - 2 3 1 2 1 2 1 5 6 6 8 9 7 4 19
a For explanatory notes, see Table 2
b  Sera of the HPV16+ patients were tested for the presence of HPV16 L1-VLP-specific IgG antibodies. Indicated is 
  the presence (+) or absence (-) of antibodies. An empty box means not tested.
C
ha
pt
er
 3
66
have reported that the majority of patients with high-grade CIN lesions displayed 
HPV16 L1-specific proliferative responses22,23, but it is unclear whether these responses 
were associated with the production of IFNγ.  We, thus, examined the type 1 (IFNγ)-
associated HPV16 L1 peptide-specific T-cell response in HPV16 DNA-positive CIN III 
and cervical cancer patients and compared these responses with those found in healthy 
subjects. A group of 10 subjects with HPV16+ CIN II/III and 10 subjects diagnosed with 
HPV16+ cervical carcinoma (see Table 1 for patient characteristics) was analysed for 
reactivity against HPV16 L1, E2 and E6 by IFNγ ELISPOT assays. In accordance with 
our earlier studies, HPV16 E6-specific T-cell immunity associated with IFNγ produc-
tion was absent in patients with HPV16+ cervical carcinoma, whereas only 2 patients 
exhibited a detectable HPV16 E2-specific IFNγ response (Table 3). In patients with 
high-grade CIN, HPV16 E2 and E6-specific IFNγ responses were found in, respectively, 
1 and 4 of the 10 subjects, which was similar to what we found in the healthy control 
group. In contrast to the low number of IFNγ responders found against these non-
structural antigens (6 of 20), HPV16 L1 peptide-specific IFNγ-producing T-cells were 
detected in the vast majority (16 of 20) of the patients diagnosed with HPV16+ cervical 
carcinoma (9 of 10) or CIN II/III (6 of 10) (Table 3; p<0.004, Fisher’s exact test). In 9 of 
these 20 patients, an IFNγ-associated T-cell response was detected against the region 
HPV16 L1300-375, corroborating previous results on L1 peptide-specific T-cell reactivity 
by proliferation22,23. In contrast to the healthy subjects, in which the T-cell reactivity 
was primarily focused on the region HPV16 L1300-435, HPV16+ patients diagnosed with 
high-grade CIN or cervical carcinoma exhibited a significantly broader T-cell response 
against HPV16 L1. In 46 of the 160 different cultures, an L1 peptide-specific T-cell 
response could be detected, as compared to 12 of 80 L1-cultures in healthy donors 
(Table 3; p=0.02; 2-sided Fisher’s exact test), suggesting that a broad T-cell repertoire 
is activated during a persistent HPV16 infection or repeated exposure to antigen by de 
novo infections. 
CD4+ T-helper responses participate in the generation and maintenance of protective 
B-cell responses, and HPV16 L1 is a known target for antibodies35. We, therefore, 
analysed the sera of the CIN II/III and cervical carcinoma patients for the presence of 
HPV16 L1-VLP-specific antibodies. Compared to cervical carcinoma patients, more 
subjects with high-grade CIN had detectable IgG antibodies against HPV16 L1 (6 of 
10 and 3 of 9, respectively, Table 3), which is in accordance with the fact that pro-
gression of cervical neoplasia is associated with a shutdown of L1 expression, while 
maintenance of high levels of antibodies benefit from sustained virus production. No 
circulating IgA antibodies against HPV16 L1 were found in these groups of HPV16+ 
subjects (data not shown). As expected, patients with detectable HPV16 L1 IgG levels 
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(8 of 9) generally displayed a concurrent HPV16 L1 peptide-specific T-cell response. 
Nevertheless, in only half of the patients (8 of 16), L1-specific T-cell reactivity was 
accompanied by detection of L1-specific IgG, indicating that in half of the patients 
the presence of antigen-specific T-cell immunity does not suffice to induce and/or 
sustain systemic HPV16 L1-specific IgG levels.
Spontaneous HPV16 L1 peptide-specific type 1 T-cell immunity is not detected 
in virgins
Due to the common nature of HPV infections, a majority of the human population is 
likely to encounter multiple HPV types2,36. It is therefore possible that at least a frac-
tion of the T-cell repertoire induced by a previous encounter with HPV types other 
than HPV16 could cross-react with the HPV16 L1 peptides (Table 4). We had the 
unique opportunity to analyse the HPV16 L1-specific T-cell response in the PBMC 
isolated from the blood of virgin female subjects aged 10-15 years who were recruited 
for a phase III VLP vaccination study. Most (50-70%) of the preadolescents at this age 
will have been infected with the skin types of HPV37,38, and a considerable number 
of them will have encountered common (approximately 40%) and low-risk (approxi-
mately 20%) HPV types38-43. The small amounts of blood available from these children 
necessitated the use of 3 large pools of HPV16 L1 peptides, covering amino acids 1-
180, 166-345 and 331-505. The use of pools of 11 peptides will result in some loss of 
specificity with respect to the exact sequences recognized. However, the sensitivity of 
the assay will be increased because the number of detected spots is the result of mul-
tiple L1 peptide-specific T-cells responses. In none of these preadolescents, HPV16 
L1 peptide-specific type 1 T-cell reactivity was detected before vaccination by IFNγ 
ELISPOT (Table 5; T=0), suggesting that T-cell priming against the common and skin 
types of HPV is not likely to result in a T-cell response with strong cross-reactivity to 
HPV16.  This also suggests that in healthy subjects, detected HPV16 L1301-435-specific 
T-cell responses, a region which shows only limited homology with the skin and low-
risk HPV types (Table 4), are not likely to represent T-cell immunity against these skin 
and low-risk HPV types but are more likely to be specific for HPV16 and/or closely 
related types.   
In addition, the HPV16 L1 peptide-specific T-cell type 1 response was measured in 
the peripheral blood of these preadolescents following 1 month after the second 
vaccination (T=3) and 1 month after the last vaccination (T=7) (3 injections; prime-
boost-boost). Although in some cases not enough material was available at all time 
points, all 14 female subjects displayed HPV16 L1 peptide- specific T-cell immunity 
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Table 4. HPV16 L1 30-mer peptides sharing >70% homology with those of several other HPV
types that are prevalent ≥0.1% in women with normal cytological Pap smears1
L1 peptides common/flat warts low-risk anogenital HPV typesa high-risk anogenital HPV types
2 3 4 7 10 27 28 29 6 11 40 42 43 54 70 72 18 31 33 34 35 39 45 51 52 58 59 66
1b 83 93 83 93 93 83c 82 93 96 83 86 96
16 93 93 93 93 93 93 100 93 96
31 85 86 90 86 86 86 86 93
46 83 83 76 83 80 90 75
61 82 96 96 93 96 96 82
76 100 100 89 86 100 100 89 89 96
91 100 100 100
106 93 86 93 93 93 90
121 73 76 80 78 80
136 88 88 86 96 93 90
151 83 90 96 86 100 96
166 76 83 90 90
181 92 96 100 96 100 96 90
196 93 93 96 93 93 100 93
211 93 96 83 89 100 96
226 90 93 93 100 93 96 96
241 89 96 96 96 100 96 96
256 93 93 93 85
271 90 93 86 80 81
286 93 96 93 96 96
301 100 100 96 100
316 100 100 100
331 80 96 86 96 83
346 96 96 95
361 93 93 93 100 90 100 100
376 96 93 96 93
391 90 90
406 82
421 83
436 90 96
451 90 96 92 96 96 96 96
466 83 76 80 76 76
476
1The prevalence of mucosotropic HPV types were calculated in healthy subjects using 2 published large cohort 
studies in which HPV was typed on a cytologic normal Pap smear taken from control women in the Netherlands31; 
n=3305 and from control women in Africa, South America, Asia and Spain32; n=1928.
The amino acid sequences of the HPV16 L1 peptides were aligned with the sequences of all HPV types that 
displayed a prevalence ≥0.1% in at least one of the two studies.
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Table 4. HPV16 L1 30-mer peptides sharing >70% homology with those of several other HPV
types that are prevalent ≥0.1% in women with normal cytological Pap smears1
L1 peptides common/flat warts low-risk anogenital HPV typesa high-risk anogenital HPV types
2 3 4 7 10 27 28 29 6 11 40 42 43 54 70 72 18 31 33 34 35 39 45 51 52 58 59 66
1b 83 93 83 93 93 83c 82 93 96 83 86 96
16 93 93 93 93 93 93 100 93 96
31 85 86 90 86 86 86 86 93
46 83 83 76 83 80 90 75
61 82 96 96 93 96 96 82
76 100 100 89 86 100 100 89 89 96
91 100 100 100
106 93 86 93 93 93 90
121 73 76 80 78 80
136 88 88 86 96 93 90
151 83 90 96 86 100 96
166 76 83 90 90
181 92 96 100 96 100 96 90
196 93 93 96 93 93 100 93
211 93 96 83 89 100 96
226 90 93 93 100 93 96 96
241 89 96 96 96 100 96 96
256 93 93 93 85
271 90 93 86 80 81
286 93 96 93 96 96
301 100 100 96 100
316 100 100 100
331 80 96 86 96 83
346 96 96 95
361 93 93 93 100 90 100 100
376 96 93 96 93
391 90 90
406 82
421 83
436 90 96
451 90 96 92 96 96 96 96
466 83 76 80 76 76
476
a. Low-risk and high-risk HPV types that are prevalent in ≥0.1% of women with normal cytological Pap 
smears31,32 
b. Indicated is the first amino acid of the 30-mer peptide of the HPV16 L1 protein,
c. Percentage of the HPV16 L1 peptides sharing >70% homology with indicated HPV types. The HPV16 L1301-435 
region (in border) is most frequently recognized in healthy subjects (Tables 2 and 3).
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after vaccination. In 10 cases, we could establish that these responses were vaccine-
induced  (B, C, D, G, H, I, J, M, N, and O, Table 5). It is likely that the HPV16 L1 
peptide-specific T-cell responses detected in the other 4 subjects (A, E, F, P) were also 
vaccine-induced, but the absence of prevaccination samples in these cases precludes 
a definite conclusion.  Except for one case, all subjects responded to at least 2 of the 
3 L1-peptide pools and half of the subjects tested responded to all 3 L1-peptide pools. 
This shows that a repeated exposure to sufficient quantities of virus-like particles 
results in a strong and broad HPV16 L1 peptide-specific T-cell response, a feature 
reminiscent of that found for L1-specific immunity in HPV16+ patients (Table 3). In 
7 of 9 subjects from whom both postvaccination samples were available, systemic 
immunity against HPV16 L1 peaked after completion of all vaccinations (T=7) rather 
than after 2 vaccinations (T=3) (Table 5). In the 2 other subjects, the induced L1-spe-
cific type 1 immune response was apparently transient since L1-peptide specific IFNγ 
production could only be detected after 2 vaccinations.
In all cases, vaccination resulted in induction of clear-cut anti-HPV16 L1 VLP IgG 
levels in the serum (Figure 1). A low preexisting HPV16 L1-VLP-specific IgG response 
was observed in 1 subject (D), all the other subjects were negative. The serologic 
responses remained stable over at least the study period  (Figure 1). No serum HPV16 
L1-VLP-specific IgA was detected (data not shown).
HPV16 L1 IgG antibodies in serum from 15 vaccinated female subjects prior to vaccination (T=0) and at 
months 3 and 7 (T=3 and T=7, 1 month after the second and 1 month after the last vaccination, respec-
tively). Serum antibody responses were measured by ELISA. Depicted are the OD values at 415 nm of 30x 
diluted sera. The cutoff point for the antibody levels (solid line) was based on the OD values from 8 healthy 
children aged 4-14 years and was calculated as the mean of the OD values + 2 x SD.
Figure 1. Strong serologic responses after vaccination with VLP vaccine.
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Discussion
We have analysed the HPV16 L1 peptide-specific type 1 (IFNγ) T-cell responses in 
healthy individuals, in patients with HPV16+ cervical neoplasia as well as in a unique 
group of virgin female subjects (10-15 years) before and after vaccination with a 
combined L1-virus-like particle (L1-VLP) vaccine of types 6, 11, 16 and 18. The 
response rate against HPV16 L1 was compared to immunity against 2 other fre-
quently recognized antigens HPV16 E2 and E6. Our data show that HPV16 L1 pep-
tide-specific T-cell immunity occurs in a high frequency in healthy individuals but 
is absent in virgin female subjects before vaccination, indicating that the observed 
immunity in healthy control subjects has resulted from exposure to HPV16 or closely 
related types, most likely through sexual transmission. Accordingly, strong HPV16 
L1 peptide-specific T-cell responses were observed in all subjects after VLP vaccina-
tion. Analysis of HPV16 L1 peptide-specific immunity in patients with HPV16+ CIN 
II/III also revealed that the vast majority of these subjects displayed strong type 1 
T-cell immunity against this antigen, corroborating the data of others21-23,34. In addi-
tion, this study shows that strong HPV16 L1 peptide-specific type 1 T-cell immunity 
is also present in the majority of patients with an HPV16+ cervical carcinoma. These 
responses were covering a broad range of peptides within L1, suggesting that dur-
ing persistent or repeated exposure to HPV16 L1, the immune system maximizes its 
efforts to counter the viral challenge. This broad T-cell reactivity is reminiscent of 
what we observed for the influenza virus matrix 1-specific T-cell response12,27.  
The frequent detection of type 1 anti-L1 responses in patients contrasts with our 
previous observation that such patients generally lack such IFNγ-associated T-cell 
immunity against the HPV16 early antigens E2 and E6 (11, this study). Thus, although 
failure of the immune defense does extend to the L1 peptide-specific response in a 
minority of the patients tested, the presence and character of these IFNγ-associated 
L1 peptide-specific responses is not a good indicator for efficient protection against 
HPV16-induced cervical infection. A lack of protective capacity of such L1 peptide-
specific T-cell responses at the stage of CIN and cervical carcinoma may very well 
be attributed to a loss in the active production of L1 in these lesions44. Nevertheless, 
the question remains why the majority of cancer patients have been able to mount 
a systemic type 1 T-cell response against L1 (7 of 10, Table 3), but failing to do so 
against the early antigens E2 and E6 (2 of 10, Table 3 and 11). A possible explana-
tion for this disparity may lie in the fact that the APC required for cross priming of 
HPV-specific T-cells acquire the early and late HPV antigens from distinct sources. 
During the productive phase of cervical HPV16 infection, the L1 protein is primarily 
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contained within the progeny virus particles that are released from the apical lay-
ers of keratinocytes. In contrast, E2 and E6 are primarily found in the keratinocytes 
positioned in the lower half of the epithelium. HPV infection, at least in the begin-
ning, is a subtle process that does not induce keratinocyte death and that does not 
result in major proinflammatory signals. Consequently, one could envision that this 
setting does not trigger efficient transfer of antigen from HPV-infected keratinocytes 
to the APC, leaving free viral particles as the only truly accessible antigen source at 
this stage. Early antigens, such as E2 and E6, will only become available for cross-
presentation at later stages in infection. This scenario implies that presentation of L1 
takes place in a setting that is more favorable to induction of systemic type 1 T-cell 
immunity. This notion is supported by data suggesting that the uptake of HPV16 
L1-VLP directly activates dendritic cells45-47. Conversely, cross-presentation of the 
early antigens lack such activation signals and may under the wrong circumstances 
result in an improperly primed T-cell response48. Taken together, our data argue that 
systemic T-cell responses against HPV16 early (E2, E6) and late (L1) antigens essen-
tially differ in the manner in which they are induced and regulated, as well as in their 
impact on the subsequent stages of HPV16-induced cervical disease. Furthermore, the 
presence of L1-specific type 1 immune responses suggests that patients diagnosed 
with HPV-induced cervical lesions are not profoundly predisposed to an overall type 
2 immune response.
A recent analysis of HPV type 11 L1-specific T-cell immunity suggested that a signif-
icant fraction of HPV16 L1-specific T-cell responses as detected in our study may be 
caused by cross-reactivity between skin and anogenital types of HPV, in that T-cell 
cultures stimulated with HPV11 L1 peptides simultaneously responded to correspond-
ing peptides of HPV 1-4 and HPV1649. The cross-reactive peptides are predominantly 
located at the N-terminal side of HPV16 L1, which indeed shows homology with 
several low-risk anogenital types (Table 4) as well as skin types (data not shown). 
Interestingly, the most immunodominant region of HPV16 L1 that is recognized by 
healthy subjects in our study is located outside this area and shows predominantly 
homology with HPV types that are members of the HPV-clade A9 (types 16, 31, 33, 
35, 52, 58; Table 4) . The total absence of detectable HPV16 L1 peptide-specific T-cell 
immunity in the group of young virgin female subjects 10-15 years of age, who will 
have encountered most of the low-risk and skin types of HPV37-43, further indicates 
that cross-reactivity at the T-cell level does not readily occur between these common 
HPV types and the high-risk HPV types. The high conservation of HPV16 L1 within 
the HPV types of clade A9 suggests that L1-specific T-cell cross-reactivity against 
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these group members could occur.
Vaccination of young virgin female subjects (10-15 years of age) with a vaccine 
containing HPV16 L1-VLP resulted in the induction of a strong L1 peptide-specific 
IFNγ-associated T-cell response and a concomitant B-cell response producing L1-
VLP-specific IgG type antibodies. A similar T-cell response was detected in adult 
female volunteers 18-25 years of age of whom PBMC were stimulated in vitro with 
L1-VLP50. Studies should be conducted to understand whether the presence of these 
preexistent vaccine-induced L1-specific T-cells may assist in establishing a condu-
cive environment that allows a rapid induction and deployment of strong type 1 T-
cell responses against the other HPV16 antigens at the time that the vaccinated virgin 
female subjects become sexually active and encounter a genuine HPV16 infection. 
In conclusion, HPV16 L1 peptide-specific type 1 T-cell immunity is induced in human 
subjects by either natural exposure to transient HPV16 infections, the persistence of 
this virus in low- or high-grade cervical lesions44 or by L1-VLP vaccination. Although 
the presence of L1-specific type 1 T-cell responses may assist in protective immunity, 
the detection of these T-cells, unlike that of type 1 T-cell immunity against E2 and/or 
E6, is not indicative of successful control of this virus. 
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Abstract
Purpose:  To validate the use of skin tests as a safe and simple method to detect 
HPV16 E2, E6 and E7-specific type 1 T-cell responses in humans.
Experimental design: A group of eleven women with cervical neoplasia and 9 healthy 
individuals were challenged with intracutaneous injections of 8 different pools of 
HPV16 E2, E6 and E7 peptides. In addition, peripheral blood was isolated to determine 
the number of circulating HPV16-specific type 1 T-cells by IFNγ ELISPOT analysis. 
Results: In our study population, only two classical (<72 hours) delayed-type 
hypersensitivity (DTH) reactions were detected. However, we found positive skin 
reactions in the majority of healthy subjects and in a part of the patients 1 to 3 weeks 
after injection. In healthy subjects, early skin reactions (within 11 days) developed to 
peptides of which the T-cell frequency exceeded 1/20,000 in our IFNγ ELISPOT analy-
sis while late skin reactions developed in response to peptides for which we were not 
able to detect Th1 immunity (p=0.001). In vitro expansion of the T-cells present in 
the positive skin test sites revealed that this population comprised  HPV16-specific 
CD4+ and CD8+ T-cells and that both IFNγ and IL-10 were produced. This suggests 
that both Th1 and Th2 cells infiltrated the skin test site. In the patients, positive skin 
reactions were not associated with systemic type 1 T-cell reactivity, suggesting that 
HPV16-specific T-cells producing cytokines other than IFNγ infiltrated the skin.
Conclusions:  Our pilot study did not unequivocally show that HPV16 peptide-induced 
skin reactions were associated with an HPV16-specific type 1 T-cell response. Further 
analyses of the type and character of T-cells infiltrating the skin of patients with 
cervical cancer are needed before larger field trials are initiated. 
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Introduction
Genital infection with human papillomavirus (HPV) is one of the most common sexu-
ally transmitted diseases1-4. Persistent infections with one of the high-risk types of 
HPV, in particular type 16 (HPV16), promote the development of cervical cancer5. 
This is the second leading cause of death in women worldwide, and the most common 
malignancy among women in developing countries6,7.
Immunocompromised subjects, such as renal transplant patients and HIV-infected 
subjects display an increased incidence of HPV infections and cervical carcinoma8,9 
and this reveals the important role of the immune system in controlling HPV infec-
tions.  In accordance, strong T-cell responses against the early antigens of the high 
risk HPV type 16 are detected in the peripheral blood of most healthy women10-17. 
However, in a minority of immunocompetent individuals the immune system fails to 
mount an effective HPV16-specific immune response and this results in viral persis-
tence and the development of malignancies. 
Our recent studies suggested an important role for the HPV16 E2, E6 and E7 early 
antigen-specific type 1 T-cell response in the control of HPV16-induced progressive 
disease13,16. Based on these results we hypothesized that subjects who live in HPV 
endemic geographic regions and who failed to mount such an HPV16-specific type 
1 response may be at risk for developing HPV16-induced malignancies and would 
directly benefit from therapeutic vaccination. In general, these endemic regions 
are located in the developing countries, which by definition have low resources. 
Therefore, an immunological screening strategy to identify individuals at risk should 
be simple.  
Intracutaneous antigen challenges (skin tests) have been used to monitor the 
development of delayed type IV hypersensitivity reactions, detected as flat red 
papules that arise 24-72 hours after injections. These skin reactions are the result of 
circulating antigen-experienced CD4+ Th1 and/or Th2 cells, which upon recognition 
of their cognate antigen migrate to the antigen site to attract macrophages or 
eosinophils, respectively18,19. The use of a skin test to detect HPV16-specific type 1 T-
cell immunity would have the advantage that there is no need for laboratory facilities 
and highly skilled persons. The first demonstration of a skin test to detect HPV16 
L1-specific T-cell mediated immunity was in individuals with HPV16-associated 
CIN who exhibited a delayed type hypersensitivity (DTH) reaction to a subcutaneous 
challenge with HPV16 capsid protein L120. Subsequently, it was shown that an HPV16 
E7-specific DTH response could be detected in subjects with spontaneously regressing 
CIN lesions21. 
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The aim of the current pilot study was to validate the use of skin tests as a safe 
and simple method to detect HPV16 E2, E6 and E7-specific type 1 T-cell responses. 
We, therefore, injected different pools of overlapping clinical grade E2, E6 and E7 
peptides in both healthy subjects and patients with HPV-associated cervical cancer 
and in parallel determined the presence of circulating HPV16-specific type 1 T-cells 
in the peripheral blood by IFNγ ELISPOT. 
Materials and Methods
Subjects
Eleven non-pregnant women (age 29-72 years, median 49 years) with histories of cer-
vical intraepithelial neoplasia (CIN) (n=3) or cervical carcinoma (n=8) were recruited 
for this study at the Department of Gynecology of the Leiden University Medical 
Center, The Netherlands, from October to December 2004. The clinical characteris-
tics of the patients are summarized in Table 1. A group of nine healthy subjects (4 
males, 5 females) within the age of 29-51 years (median 38 years) participated in this 
study after informed consent. Blood samples for the analysis of HPV16-specific T-cell 
reactivity were obtained from all subjects immediately before skin testing. The study 
design was approved by the Medical Ethical Committee of the LUMC and all subjects 
gave written informed consent.
Table 1. Patient characteristics
patient age diagnosis grade/ treatment time  HPV
 (yrs)  stage  (months)a
1 72 CxCa IAb radical hysterectomy 9 16
2 57 CxCa IA radical hysterectomy 18 16
3 57 CxCa IB radical hysterectomy 36 ?
4 50 CxCa IB radical hysterectomy 6 16
5 44 CxCa IA hysterectomy 36 16
6 53 CxCa IIB chemoradiation 36 16neg
7 34 CxCa IA radical hysterectomy 48 ?
8 44 CxCa IB radical hysterectomy 7 16
9	 29	 CIN	 III	 LEEPc	 2	 ?
10	 42	 CIN	 II	 LEEP	 3	 ?
11 49 CIN III LEEP 60 18
a Time of treatment before skin tests were performed b cervical cancer stage according to FIGO c Loop 
electrosurgical excision procedure
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Antigens 
A set of peptides spanning the whole HPV16 E6 and E7 protein, and the most immu-
nogenic regions of the E2 30-mer peptides12,16 were used for the IFNγ ELISPOT assays 
and skin tests. For the skin tests, 8 pools of 2 or 3 long synthetic peptides were used 
(Table 2). The peptides were produced under GMP conditions in our own production 
facility (Interdivisional GMP Facility LUMC, IGFL) and were synthesized and dis-
solved as decribed previously22. The peptide pools are indicated by the first and last 
amino acid of the region in the protein covered by the two peptides (e.g., E231-75, resi-
dues 31-60 and 46-75). IFNγ ELISPOT assays were performed with the same peptide 
pools, only peptide pools 4 and 5 differed slightly from the peptides used for the skin 
tests (peptide pool 4 used for IFNγ ELISPOT: E637-68, E655-86, and E673-104; peptide pool 
5: E691-122 and E673-104) (Table 2). Memory response mix (MRM), consisting of a mixture 
of tetanus toxoid (0.75 limus flocculentius/ml final concentration; National Institute of 
Public Health and Environment, Bilthoven, The Netherlands), Mycobacterium tubercu-
losis sonicate (2.5 µg/ml; generously donated by Dr. P. Klatser, Royal Tropical Institute, 
Amsterdam, The Netherlands) and Candida albicans (0.005%, HAL Allergenen Lab, 
Haarlem, The Netherlands), was used as a positive control in the ELISPOT assays.
Table 2. HPV16 peptide pools used for skin tests and ELISPOT assays
pool antigen amino acid sequence
1 E2 31-60 DYWKHMRLECAIYYKAREMGFKHINHQVVP
 E2 46-75 AREMGFKHINHQVVPTLAVSKNKALQAIEL  
2 E2 301-330 LRYRFKKHCTLYTAVSSTWHWTGHNVKHKS 
 E2 316-345 SSTWHWTGHNVKHKSAIVTLTYDSEWQRDQ  
3 E6 1-32 MHQKRTAMFQDPQERPRKLPQLCTELQTTIHD 
 E6 19-50 LPQLCTELQTTIHDIILECVYCKQQLLRREVY  
4a E6 41-65 KQQLLRREVYDFAFRDLCIVYRDGN 
 E6 55-80 RDLCIVYRDGNPYAVCDKCLKFYSKI 
 E6 71-95 DKCLKFYSKISEYRHYCYSLYGTTL  
5b E6 85-109 HYCYSLYGTTLEQQYNKPLCDLLIR 
 E6 91-122 LYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEK  
6 E6 109-140 RCINCQKPLCPEEKQRHLDKKQRFHNIRGRWT 
 E6 127-158 DKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL  
7 E7 1-35 MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEE 
 E7 22-56 LYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVT  
8 E7 43-77 GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR 
 E7 64-98 TLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP
a For the IFNγ ELISPOT assays pool 4 consisted of HPV16 E637-68, E655-86, and E673-104 peptides
b For the IFNγ ELISPOT assays pool 5 consisted of HPV16 E691-122 and E673-104 peptides
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Skin tests
Skin tests, using HPV16 E2, E6 and E7 antigens, were performed similar to previous 
studies20,21. The skin test preparations consisted of 0.2 mg/ml peptides in 16% DMSO 
in 20 mM isotonic phosphate buffer. Skin tests included intracutaneous injection of 
0.05 ml (10 µg/peptide) of the 8 peptide pools and the negative control (dissolvent 
only), at individual skin test sites of the upper arm. Skin test sites were inspected 
minimally two times, at 3 and 10 days after injection of the peptides, and after 
contact by telephone in case of positive skin reactions that appeared after this time. 
Reactions were considered positive when papules greater than 2 mm in diameter 
arose no less than 2 days after testing. All positive skin reactions were documented 
by photography.
Analysis of HPV16-specific T-cell reactivity by IFNγ ELISPOT
The HPV-specific T-cell reactivity in vitro was analyzed using ELISPOT that was per-
formed as described previously15,23. Briefly, fresh PBMC were washed and seeded at 
a density of 2 x 106 cells per well of a 24-well plate (Costar, Cambridge, MA) in 1ml 
of IMDM (Bio Whittaker, Verviers, Belgium) enriched with 10% human AB serum, in 
the presence or absence of indicated HPV 16 E2, E6 and E7 peptide pools. Peptides 
were used at a concentration of 5 µg/ml/peptide. Following 4 days of incubation at 
37ºC, PBMC were harvested, washed, and seeded in four replicate wells at a density 
of 105 cells per well in 100 µl IMDM enriched with 10% FCS in a Multiscreen 96-well 
plate (Millipore, Etten-Leur, The Netherlands) coated with an IFNγ catching antibody 
(Mabtech AB, Nacha, Sweden). Further antibody incubations and development of the 
ELISPOT were performed according to the manufacturer’s instructions (Mabtech). 
Spots were counted with a fully automated computer-assisted video-imaging analy-
sis system (Bio Sys). Specific spots were calculated by subtracting the mean number 
of spots + 2 x SD of the medium control from the mean number of spots in experi-
mental wells15. 
Statistics
Statistical analysis of the number of positive skin reactions in healthy subjects versus 
patients with cervical neoplasia and the association between the time of development 
of positive skin reactions in healthy subjects and the number of specific spots in the 
ELISPOT analyses was performed using 2-tailed Fisher’s exact test. Statistical ana-
lyzes were performed using Graphpad Instat Software (version 3.0).
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Results
Skin reactions to intracutaneous injection with HPV16 E2, E6 and E7 peptides
Skin tests are used as a simple assay to test the presence and type of immunity 
against recently encountered pathogens. In general, red papules that arise within 
24-72 hours after an intracutaneous challenge with antigen are the result of the 
influx of mononuclear cells indicating the presence of a Th1 and/or Th2 response. 
This type of response is known as the classical delayed-type hypersensitivity (DTH) 
reaction18. We have studied skin reactions in both healthy subjects and patients with 
HPV-induced high-grade disease after an intracutaneous injection with HPV16 E2, 
E6- and E7 peptides. In our study population, positive skin reactions appeared as flat 
reddish papules of 2-20 mm in diameter arising within 2 to 25 days after skin testing. 
In total, 35 out of 72 skin tests were found positive in the healthy controls, whereas 
in the patient group a significantly lower number of skin reactions were detected 
(17 out of 88; p<0.0001, 2-sided Fisher’s exact test). The time for skin reactions to 
appear differed considerably between healthy controls and patients. A classical DTH 
reaction could be detected only in 1 female healthy control and in one of the patients 
(Figure 1). However, the majority of reactions in the patient group developed around 
7 days (range 2-14 days). In the healthy controls, the number of skin reactions peaked 
around 13 days and again 20 days after skin testing, revealing a bi-phasic response 
pattern (Figure 2A and 2B). This late reactivity suggests that the frequency of the 
responding HPV16 peptide-specific T-cells capable of migrating to the antigen depot 
in the skin is lower in the healthy population than in patients with HPV16-associated 
cervical neoplasia. 
In alignment with our previous work13,16, we found frequent skin reactions against the 
E231-75 (6/9 subjects) and E2301-345 region (4/9 subjects), and E6 protein (7/9 subjects) in 
a substantial part of the healthy subjects. Furthermore, we detected positive skin reac-
tions against the E7 protein (5/9 subjects), most of which appeared after day 13 (Figure 
1). A similar reaction pattern was found in the patient group. The mean size of the skin 
reactions did not differ between patients and healthy subjects (data not shown). 
A positive skin test is associated with the infiltration of HPV16-specific CD4+ and 
CD8+ T-cells 
In order to confirm that positive skin test sites were infiltrated with HPV16-specific 
T-cells a small biopsy from one E6-peptide positive skin test site as well as a negative 
control site at the other arm were taken from one healthy subject (HD2) at day 21 
after antigen injection (Figure 3). After 25 days of culture in medium supplemented 
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An overview of the number, day of appearance and injected antigen that induced a positive skin reaction 
in the group of 9 healthy subjects (HD) and 11 patients (P) with history of cervical neoplasia.
Eight pools of peptides spanning the whole HPV16 E6 and E7 protein and the most immunogenic regions 
of the HPV16 E2 protein were injected separately at individual skin test sites of the upper arm. As a nega-
tive control the dissolvent only was used. Skin reactions were considered positive when papules greater 
than 2 mm in diameter arose no less than 2 days after testing. The indicated layout is used for the 8 peptide 
pools; a filled square represents a new developed, positive skin reaction to the indicated peptide pool.
Figure 1. Skin reactions to intracutaneous injection with HPV16 E2, E6 and E7 peptides in 
healthy individuals and in patients with cervical neoplasia
with TCGF, IL-15, and FCS, the infiltrating immune cells were expanded to suffi-
cient numbers for further analysis. The expanded infiltrating T-cells recognized their 
cognate epitope on monocytes pulsed with either peptide or protein when tested in 
a standard short-term proliferation assay (Figure 3). Analysis of the supernatants 
of these cultures revealed a predominant production of the Th1 cytokine IFNγ but 
also low amounts of the Th2 cytokine IL-10  (Figure 3). Flowcytometric analyses of 
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Figure 2. The number of 
skin reactions to HPV16 
E2, E6 and E7 peptides 
in relation to the time of 
appearance in healthy 
individuals and in patients 
with HPV-induced cervi-
cal disease (A,B). The total 
number of skin reactions 
are depicted. The major-
ity of skin reactions in the 
patient group developed 
around day 7 (A), whereas 
in the healthy controls the 
number of skin reactions 
showed two peaks at day 
13 and day 20. 
antigen-specific cytokine production by the IFNγ and IL-10 capture assay17 revealed 
that the expanded T-cell population comprised both HPV16-specific CD4+ and CD8+ 
T-cells  (data not shown). These preliminary results suggest that the skin-infiltrating 
immune cells after an intradermal challenge with HPV16 peptides comprises HPV16-
specific Th1, Th2, and CD8+ T-cells. We are currently addressing this in a larger 
patient group.  
Early skin reactions are associated with higher frequencies of HPV16-specific T-cells 
in the peripheral blood
In order to examine how the results of the skin test correspond to the detection 
of HPV16-specific Th1 immunity by IFNγ ELISPOT, PBMC were collected from 8/9 
healthy subjects and all patients immediately before the intracutaneous injection of 
the HPV16 peptide antigens. 
In 4 of 8 healthy subjects we were able to detect HPV16-specific IFNγ ELISPOT reac-
tivity. When we compared the number of HPV16 peptide-specific spots detected by 
ELISPOT to the day that a skin reaction to this particular peptide appeared we found 
A
B
day 1-7 day 8-14 day 15-25
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that ELISPOT response of  ≥ 5 spots per 100,000 PBMC was associated with the presence 
of an early skin reaction (within 11 days) to that particular peptide (p=0.001, two-tailed 
Fisher’s exact test) (Figure 4). Late skin reactions were found to peptides for which we 
were not able to detect a response by ELISPOT, suggesting that the frequency of circu-
lating antigen-specific cells determines the delay time for skin reactions to appear. 
We were able to isolate blood from 5 healthy subjects at the time that skin reac-
tions were present. In these subjects, 28 skin reactions were found and in 22 cases a 
positive (≥ 5 spots/100,000 PBMC) Th1 response was detected by IFNγ ELISPOT (data 
not shown) indicating that the frequency of HPV16-specific T-cells in the blood of 
healthy subjects was higher at the time a skin reaction was present. These data sug-
gest that the intracutaneous injection of peptide antigens enhances the number of 
HPV16-specific T-cells in the blood of healthy individuals. 
In contrast to the healthy subjects, an occasional positive IFNγ ELISPOT response 
was found in the HPV16-positive patients and within this small group the appear-
ance of early skin reactions was not associated with HPV16-specific Th1 immunity 
in the peripheral blood, suggesting that other types of HPV16-specific cells migrate 
into the skin.    
Figure 3. T-cell cultures of 
healthy donor 2 derived from 
a E6-peptide positive skin test 
site that recognize HPV16 E6-
specific peptide pools.  
A. The responses are shown of 
a standard short-term prolif-
eration assay, indicating that 
skin-site T-cells of healthy 
donor 2 recognized E6109-140 
and E6127-158 peptides corre-
sponding to the E6 peptides 
injected at the skin test site. 
B. Supernatants were tested 
for IFNγ and IL-10 production 
in a standard ELISA. 
A
B
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Discussion
In this pilot study we have analyzed the HPV16-specific T-cell immunity in vivo in 
a group of nine healthy subjects and eleven patients with HPV16-associated cervical 
neoplasia by a peptide-based skin test using HPV16 E2, E6 and E7 peptides. One main 
observation of the present study is that the time for skin reactions to appear is cor-
related with the number of circulating HPV16-specific CD4+ T-cells in the peripheral 
blood. In healthy subjects, early skin reactions (within 11 days) developed to peptides 
of which the T-cell frequency exceeded 1/20,000 in our IFNγ ELISPOT analysis while 
late skin reactions developed in response to peptides for which we were not able to 
detect Th1 immunity (p=0.001). In line with this is the observation that early HPV16 
E7 peptide-specific skin reactions (2-6 days after skin testing) can be detected in 
patients with immune driven regression of CIN lesions21. These patients who suc-
Figure 4. Early skin reactions are associated with higher frequencies of circulating HPV16-
specific T-cells in healthy individuals
Immediately before injection of the HPV16 peptide antigens, PBMC of 8 healthy subjects were tested with 
IFNγ ELISPOT. Detection of HPV16-specific T-cells by INFγ ELISPOT in the prechallenge blood sample of 
healthy subjects is significantly correlated with the appearance of an early (<11 days) positive skin reaction 
to the recognized peptide pool (p=0.001, two-tailed Fisher’s exact test). Specific responses were calculated 
by subtracting the mean number of spots +2 x SD of the medium control from the mean number of spots 
in experimental wells. The number of specific spots per 100.000 PBMC is given. Responses were considered 
positive if peptide pool-specific T-cell frequencies were ≥ 5 in 100.000 PBMC.
HPV16-specific spots before skin test
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cessfully fight an active HPV infection have high numbers of HPV16-specific T-cells 
in their blood (van der Burg & Hopfl, unpublished data). It is highly likely that the 
HPV16-specific T-cell frequencies gradually decline in individuals who have success-
fully dealt with an HPV16 infection, such as will be the case with our healthy subject 
group. Similarly, a decline in responsiveness was observed in individuals vaccinated 
with BCG24. Upon intracutaenous challenge with HPV16 peptide-antigen such spe-
cific T-cells will be reactivated, start to divide and migrate to site of antigen. Indeed, 
at the time that skin reactions appeared, strong HPV16-specific Th1 cells were also 
detected in the peripheral blood of these healthy subjects by IFNγ ELISPOT.
Similar to the earlier observations21, we found in the group of patients that the major-
ity of the skin reactions appeared in about a week. These skin reactions were not 
associated with circulating HPV16-specific Th1 cells as measured by IFNγ ELISPOT, 
suggesting that HPV16-specific T-cells producing cytokines other than IFNγ infil-
trated the skin. Although delayed-type skin reactions to soluble antigens are usually 
regarded as type 1 T-helper cell responses, Th2 cells can also infiltrate DTH sites for 
instance in chronic asthma25-27. We recently showed that HPV16-specific IFNγ-associ-
ated T-cell responses were lacking in the great majority of cervical cancer patients, 
whereas the secretion of the Th2 cytokine IL-10 was less affected13. Therefore, the 
skin reactions in cancer patients could well be the result of infiltrating HPV16-spe-
cific Th2 cells. Indeed, recent data of our group have shown that skin biopsies of 
positive DTH sites of healthy volunteers contain both Th1 and Th2 cells (van den 
Hende, unpublished results). 
Unexpectedly, we observed a bi-phasic pattern in the number of skin reactions in 
healthy subjects. Skin reactions peaked 2 weeks and again 3 weeks after intracutane-
ous injection of peptide (Figure 2A). Low numbers of memory T-cells that circulate 
and that need to be activated and divide before they migrate to the antigen site can 
explain the first peak. It is, however, more difficult to explain the second peak in a 
similar way. If to some of the peptides even lower numbers of memory T-cells were 
present, one would expect a more evenly distributed pattern of skin reactions from 
day 13 to day 25. It may well be that the very late skin reactions (~day 20) are the 
result of T-cell priming, in which the T-cell response develops more slowly. Skin-test 
induced priming of T-cells has also been noted in 29% of patients whom underwent 
a 2-step tuberculin skin testing protocol28. Interestingly, in cancer patients, who are 
known to respond weakly to HPV16 antigens, we did not observe such very late skin 
reactions.
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The main objective of this pilot study was to examine if an HPV16 peptide-based skin 
test could be used as a tools for measuring HPV-specific T-cell immunity in vivo. It is 
clear that at least two items need to be clarified before larger field tests are initiated. 
First, we need to know the Th1/Th2 character of the HPV-specific T-cells present in 
skin test sites of patients with HPV16-induced high-grade neoplasia. Secondly, we 
should firmly establish the maximal timeframe in which memory T-cell mediated 
skin reactions appear. 
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Abstract
Purpose: To study the immunogenicity of heterologous prime-boost human papil-
lomavirus (HPV) oncogene vaccination in patients with anogenital intraepithelial 
neoplasia (AGIN). 
Experimental Design: Twenty-nine women with high-grade AGIN received three i.m. 
doses of TA-CIN (HPV16 L2/E6/E7 protein) at four weekly intervals followed by a 
single dermal scarification of vaccinia HPV16/18 E6/E7 and were followed up for 
12 weeks. Immunity to HPV16 was assessed by lymphoproliferation, IFNγ enzyme-
linked immunospot (ELISPOT), and ELISA. 
Results: The patient group significantly responded to TA-CIN and not to the control 
antigen HPV6 L2/E7 at all postvaccination time points when compared with baseline 
responses (p ≤ 0.05). Ten of the patients showed at least a 3-fold increase in TA-
CIN-specific proliferation at one or more time points after vaccination. Comparison 
of stimulation with HPV16 E6- or E7-GST fusion proteins showed that proliferative 
responses were biased to HPV16 E6. This bias was also seen by IFNγ ELISPOT using 
overlapping peptides, with HPV16 E6- or E7- specific T-cells being detected in 9 and 2 
patients, respectively. In addition, vaccination resulted in the induction of antibodies 
against the HPV16 oncoproteins. Of the 6 clinical responders, 2 patients showed both 
a proliferative TA-CIN-specific response and an E6-specific IFNγ response, whereas 
3 other patients displayed E6-specific reactivity only. Stable disease was recorded in 
19 patients, 8 of whom showed a concomitant TA-CIN-specific proliferative and/or 
E6-specific T-cell response. Of the 4 progressors, 2 failed to make a T-cell response 
and 2 responded by either proliferation or E6 ELISPOT alone.
Conclusions: The prime-boost regimen is immunogenic in AGIN patients (humoral 
and cellular immunity), but there is no simple relationship between induction of sys-
temic HPV16-specific immunity and clinical outcome. Other factors that may play a 
role in the eradication of long-term established AGIN lesions need to be determined 
to identify the patient group that would benefit from immunotherapy with the vac-
cines used in this study.
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Introduction
Human papillomavirus (HPV) oncogenes E6 and E7 are expressed throughout the 
spectrum of HPV-associated anogenital intraepithelial neoplasia (AGIN) and therefore 
are potential targets for immunotherapy1. A number of vaccine strategies are being 
evaluated in clinical trials2. In the pioneering studies, vaccinia HPV16/18 E6/E7 (TA-
HPV), a live recombinant vaccinia virus encoding modified versions of HPV16 and 
18 E6 and E7, was used in patients with advanced cervical carcinoma3 and subse-
quently in early-stage cervical carcinoma patients 4. These studies established safety 
and immunogenicity in that modest T-cell and antibody responses were induced. 
These studies in cancer patients, however, did not allow the evaluation of any clini-
cal effects in the short term. Two recent studies5,6 have tested a single dose of TA-
HPV in patients with high-grade vulval intraepithelial neoplasia (VIN), a chronic, 
premalignant, frequently symptomatic disease. In the first study6, a single dose of 
TA-HPV was shown to be immunogenic in 13 of 18 women as demonstrated by 
lymphocyte proliferation, enzyme-linked immunospot (ELISPOT), and/or antibody 
responses. Eight patients demonstrated a reduction in lesion diameter of at least 
50%, and an additional 4 patients showed significant symptom relief. The lesions 
that shrank showed significantly higher levels of infiltrating CD4+, CD8+, and CD1a+ 
immune cells before vaccination as demonstrated by immunohistochemistry. In a 
second study in VIN patients5, 6 of 10 women demonstrated vaccine-induced HPV16-
specific T-cells by IFNγ ELISPOT, 5 with a concomitant significant reduction in lesion 
diameters. Delivery of cure in patients with this and other HPV-associated lesions 
may depend on viral clearance or at least sustained anti-HPV immunity, and a single 
vaccination may, therefore, not be enough. 
A second vaccine formulation that has been tested in humans consists of a HPV16 
L2E6E7 fusion protein (TA-CIN). It was well tolerated when administered to healthy 
volunteers and induced antibody and proliferative responses against TA-CIN, as well 
as IFNγ ELISPOT responses to the HPV16 oncoproteins7. A small study of VIN patients 
who received three booster vaccinations with TA-CIN between 7 and 15 months after 
the TA-HPV vaccination demonstrated HPV16-specific proliferative T-cell and/or 
serological activity, but there was no direct correlation between immunological and 
clinical responses8. 
In preclinical studies, a heterologous prime-boost immunization strategy using a 
HPV16 L2E6E7 fusion protein (TA-CIN), in combination with TA-HPV, showed 
enhanced immunogenicity compared with the use of either agent alone9. The proto-
col of TA-CIN followed by TA-HPV was superior to the reciprocal as defined by the 
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induction of T-cell reactivity against the oncoproteins. This may be related to the 
fact that TA-HPV comprises a multitude of vaccinia-specific T-cell epitopes, which 
can efficiently compete with the two HPV16 oncogenes for the attention of the T-
cell-mediated immune response. In the case that the immune response is naïve to 
either of these epitopes, immunity may very well be skewed toward vaccinia-derived 
epitopes. Immunization with TA-CIN is thus likely to focus the immune response to 
the oncoproteins, whereas boosting with TA-HPV will increase the magnitude of this 
oncoprotein-specific T-cell response. Here, we describe the immunogenicity of a sim-
ilar heterologous prime-boost strategy of three monthly immunizations with TA-CIN, 
followed by a single boost with TA-HPV in patients with HPV16-associated AGIN.
Patients and methods
The United Kingdom Medicines Control Agency, the Gene Advisory Committee, and 
the appropriate Local Ethics Committees approved the study, and all patients gave 
written informed consent. Twenty-nine women with stable, noncervical AGIN (27 
VIN 3 and 2 VAIN 3) were recruited in three centers: St Mary’s Hospital (Manchester, 
United Kingdom); University Hospital of Wales, Llandough Hospital (Cardiff, United 
Kingdom); and Addenbrooke’s Hospital (Cambridge, United Kingdom). Three prime 
vaccinations of TA-CIN (533 µg) were given i.m. at four weekly intervals, followed 4 
weeks later by a boost vaccination comprising a single dose (2.5 x 105 plaque-form-
ing units) of TA-HPV by dermal scarification. Women were followed up for 12 weeks 
after completion of the vaccination schedule. Blood was taken before vaccination 
(week 0) and at 12, 16, 20, and 24 weeks for assessment of cell-mediated and humoral 
immunity. Prevaccination samples were limited for 2 patients (404 and 405), and 
patient 416 baseline sample was taken at week 4. Biopsies were taken at weeks 12 
and 24 for histology and HPV status as described previously6. At entry, 26 patients 
had lesions with HPV16, 1 had HPV33 and HPV58, 1 was HPV high-risk but could 
not be typed, and 1 was HPV negative. Clinical responses were defined as partial if 
lesion area was reduced by ≥ 50% and a complete response by complete reduction of 
the lesion with no evidence of disease in the biopsy. Progression was defined as an 
increase in lesion area by ≥ 50%. The clinical findings will be reported elsewhere*. 
*Kitchener H, Tristram A, Davidson EJ, Tomlinson A, Dobson J, Baldwin P, Sterling J, and Fiander A. 
The clinical effects of a multicentre trial of a prime boost vaccination strategy in women with high grade 
anogenital intraepithelial neoplasia.  Manuscript submitted.
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Analysis of HPV16-specific T-cell proliferation 
Blood samples were collected in monovettes containing citrate and peripheral blood 
mononuclear cells (PBMC) were isolated by density centrifugation. Cells were cryo-
preserved in liquid nitrogen until additional use. PBMC from all time points for each 
patient were assessed in a slightly modified assay previously described6 and as follows. 
Briefly, cells were thawed and placed into 24-well suspension cell plates (Sarstedt) 
for a recovery period of 2 h before being seeded in triplicate wells of a 96-well round 
bottomed microtitre plate (Alpha Laboratories Ltd.) at 2 x 105 cells/well in RPMI 1640 
supplemented with 10% human AB serum (Quest Biomedical), 100 µg/ml streptomycin, 
and 100 IU/ml penicillin (Life Technologies, Inc.). PBMC alone (medium control) or 
PBMC with 50 µg/ml recombinant HPV16 L2E6E7 protein (TA-CIN; Xenova Research 
Ltd.), 50 µg/ml recombinant HPV6 L2E7 protein (TA-GW, Xenova Research Ltd.), 25 
µg/ml HPV16 GST-E6, 25 µg/ml HPV16 GST-E7, 25 µg/ml glutathione S-transferase 
(GST) tag protein alone (all proteins purified on glutathione-Sepharose; ref.10), or 7000 
units/ml tuberculin purified protein derivative (PPD, Evans Vaccines Ltd., Liverpool, 
United Kingdom) were incubated for 6 days at 37oC. During the final 18 h of culture, 
1 µCi/well of [3H]thymidine (NEN Life Science Products) was added. The cells were 
harvested using a Packard 96-well vacuum cell harvester onto Unifilter plates (Packard 
BioSciences), left to dry overnight, and 30 µl/well of Microscint 20 scintillation fluid 
(Packard) added. [3H]Thymidine incorporation was measured using a Topcount scintil-
lation counter (Packard). Replicates were within 10%. Results are presented as stimula-
tion index (SI) = the mean number of counts incorporated by antigen-stimulated PBMC 
divided by the mean number of counts for PBMC in medium alone (negative control); 
SIs for GST-E6 and GST-E7 were calculated using the response to GST as control. A 
preexisting proliferative T-cell response to HPV16 L2E6E7 was defined as SI ≥ 2. A 
postvaccination proliferative T-cell response to HPV16 L2E6E7 was defined as a 3-fold 
increase in the SI compared with the prevaccination value. Paired Wilcoxon’s signed 
ranks tests were used to test for population differences in the responsiveness to each 
antigen before and after vaccination with p ≤ 0.05 considered statistically significant. 
The response to TA-HPV boost vaccination (week 12 versus week 16 and so on) was 
also compared by Wilcoxon’s signed rank tests.
Analysis of HPV16 E6- and E7-specific T-cell reactivity by IFNγ ELISPOT
IFNγ-producing HPV-specific T-cells were quantified using ELISPOT that was per-
formed as described previously7,11. Briefly, PBMC were thawed, washed, and seeded at 
a density of 2 x 106 cells/well of a 24-well plate (Costar, Cambridge, MA) in 1 ml of 
Iscove’s modified Dulbecco’s medium (BioWhittaker, Verviers, Belgium) enriched with 
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10% human AB serum in the presence or absence of indicated HPV16 and HPV18 E6 
and E7 peptide pools. As a positive control, PBMC were cultured in the presence of a 
memory recall mix, consisting of a mixture of tetanus toxoid (0.75 limus floccolentius/
ml final concentration; National Institute of Public Health and Environment, Bilthoven, 
The Netherlands), Mycobacterium tuberculosis sonicate (2.5 µg/ml; generously donated 
by Dr. Paul Klatser, Royal Tropical Institute, Amsterdam, The Netherlands) and Candida 
albicans (0.005%, HAL Allergenen Laboratory, Haarlem, The Netherlands). The peptides 
used spanned the HPV16 and HPV18 E6 and E7 protein and consisted of 15 E6 and 9 
E7 overlapping 22-mer peptides. Peptides were used in pools of 4-5 peptides at a con-
centration of 5 µg/ml/peptide. The peptides, as indicated by their first and last amino 
acid in the protein, were used in the following pools: E6-I: 1-22, 11-32, 21-42, 31-52; 
E6-II: 41-62, 51-72, 61-82, 71-92; E6-III: 81-102, 91-112, 101-122, 111-132; E6-IV: 
111-132, 121-142, 131-152, 137-158; E7-I: 1-22, 11-32, 21-42, 31-52; E7-II: 41-62, 
51-72, 61-82, 71-92, 77-98 (HPV18: last peptide 81-105). After 4 days of incubation at 
37ºC, PBMC were harvested, washed, and seeded in four replicate wells at a density of 
105 cells/well in 100 µl Iscove’s modified Dulbecco’s medium enriched with 10% FCS 
in a Multiscreen 96-well plate (Millipore, Etten-Leur, The Netherlands) coated with an 
IFNγ catching antibody (Mabtech AB, Nacka, Sweden). Additional antibody incuba-
tions and development of the ELISPOT were performed according to the manufacturer’s 
instructions (Mabtech). Spots were counted with a fully automated computer-assisted 
video imaging analysis system (Bio Sys). Specific spots were calculated by subtracting 
the mean number of spots + 2 x SD of the medium only control from the mean number 
of spots in experimental wells. Antigen-specific T-cell frequencies were considered to 
be increased compared with nonresponders when specific T-cell frequencies were ≥ 
1/10,00011. T-cell frequencies were considered to be boosted by the vaccine when they 
were at least 3-fold higher than before vaccination7. 
 
Analysis of HPV-specific IgG antibodies by ELISA
HPV16/18 E6/E7 and HPV16 L1 IgG levels were measured by ELISA using recombi-
nant proteins fused to GST; GST without HPV protein sequences was used as speci-
ficity control, and any background response to the latter was subtracted to give the 
HPV-specific absorbance as described previously10,12. Antibody levels were measured 
in sera from a group of normal blood donors (n=15). Cutoff values for sera positivity 
were HPV16 E6, 119; HPV16 E7, 31; HPV18 E6, 356; HPV18 E7, 500; and HPV16 
L1 101. In addition to a 3-fold increase over week 0 baseline absorbance values, the 
mean specific absorbance + 3 x SD of this group of normals for each assay was used 
as the cutoff value to define seropositivity in the AGIN patients. The normal and 
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baseline AGIN patient serological responses were compared using Mann-Whitney 
U (nonparametric) tests. Pre- and postvaccination AGIN patient group serological 
responses were compared by paired Wilcoxon’s signed rank tests with p ≤ 0.05 con-
sidered statistically significant. 
Results
HPV16-specific proliferative T-cell responses 
The capacity of the heterologous prime-boost protocol to induce HPV16-specific 
proliferative T-cell responses was examined by analysis of HPV-specific immunity 
before vaccination, after 3 vaccinations with TA-CIN (week 12), and after booster 
vaccination with TA-HPV (weeks 16, 20 and 24). Figure 1A shows an example of 
such proliferative responses detected in an individual patient. A 3-4-fold increase in 
TA-CIN-specific proliferation was detected after the three prime vaccinations with 
TA-CIN. This is not boosted by TA-HPV at week 16 but continues above baseline 
over the course of the study. The group responses to the HPV antigens are shown as 
box whisker plots in Figure 1B. The patient group as a whole showed significantly 
increased TA-CIN-specific responses after the three TA-CIN vaccinations, which was 
sustained on weeks 16-24. There was no significant change in response to the control 
antigen HPV6 L2/E7 at any time point (Table 1).
When examining individual patient responses, 10 of 27 patients tested had evidence 
of a preexisting proliferative T-cell response to TA-CIN, and 7 of these also showed 
Table 1. P-values from Wilcoxon’s signed rank tests showing statistical evaluation of patient 
group proliferative responses to human papillomavirus (HPV)16 L2/E6/E7 protein (TA-CIN), 
HPV6 L2/E7 (TA-GW), HPV16 GST-E6, and HPV16 GST-E7a.
Antigen Week 12 Week 16 Week 20 Week 24
 Wk 12 
     vs Wk 16
TA-CIN	 0.0001	 0.0003	 0.0002	 0.0017	 0.1613
TA-GW 0.2135 0.1979 0.205 0.2505 0.273
HPV16 E6 0.1681 0.0452 0.1146 0.0537 0.0453
HPV16 E7 0.533 0.6043 0.2902 0.6265 0.8758
a Vaccine-induced proliferation (stimulation index) was compared at time 0 versus postvaccination time 
points in a Wilcoxon’s signed rank test. Data were considered significant when p ≤ 0.05. Group responses 
to TA-CIN, TA-GW, HPV16 GST-E6, and HPV16 GST-E7 were compared after vaccinations with TA-CIN 
(week 12), after boosting with HPV16/18 E6/E7 (week 16) and in the follow-up. Specific booster activity of 
HPV16/18 E6/E7 was tested by comparison of group responses in week 12 versus week 16.
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Figure 1A. PBMC proliferative responses of an individual patient to TA-CIN, TA-GW, GST-E6 and GST-E7 at weeks 
0, 12, 16, 20 and 24. Stimulation index (SI) was calculated by dividing the mean number of counts for the antigen-
stimulated PBMC by the mean number of counts for the medium only (for TA-CIN, TA-GW and PPD). GST-E6 and E7 
counts were normalized to the mean number of counts to GST protein. A preexisting proliferative T-cell response to 
TA-CIN and HPV16 E6/E7 was defined as a SI of >2. A vaccine-specific proliferative T-cell response to TA-CIN was 
defined as a 3-fold increase in the stimulation index postvaccination compared with the prevaccination value. 
Figure 1B. Box-whisker plot representing PBMC proliferative responses (SI) of the patient group at weeks 0, 12, 16, 
20 and 24 to GST proteins E6 and E7, TA-CIN and TA-GW. Boxes represent upper and lower quartiles, center point 
is the median, and whiskers are the upper and lower range values.
Figure 1C. Ratio of SI change over time; HPV16 E6 SI values were divided by HPV16 E7 SI values to demonstrate 
the bias of vaccine-specific lymphoproliferative responses to HPV16 E6 over time. Error bars represent the SE.
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Individual patient (301) lympho-proliferative response reflecting vaccine 
immunogenicity.
S
tim
ul
at
io
n 
in
de
x
Prime-boost HPV oncogene vaccination in AGIN patients 103
baseline responses to HPV6 L2/E7. Of all patients, 17 showed evidence of a TA-CIN-
specific response (at least a 2-fold increase) at some point after prime or prime-boost 
vaccination. Ten of these 17 patients showed a definite vaccine induced response 
(>3-fold increase in SI), with only 2 from those displayed a preexisting response 
to TA-CIN. No similar individual responses were seen to the control antigen HPV6 
L2/E7. Patients with preexisting responses had an average increase in postvaccina-
tion proliferation of 1.49 +/-0.13 SE, whereas patients without preexisting immunity 
gave 2.16 +/-0.15 SE. It seems there are higher and more consistent responses in the 
patients with lower preexisting proliferative responses. 
Examination of the proliferative responses against the two oncoproteins using recom-
binant HPV16 GST-E6 or GST-E7 proteins in the proliferation assay showed that 
group responses were significantly increased only for GST-E6 at weeks 16 (Table 1). 
The ratio of E6 to E7 responses over the trial period supports this bias for E6-specific 
T-cell proliferation (Figure 1C). The overall magnitude of response, reflected by the SI 
range and median values, is greater for TA-CIN than E6-GST (Figure 1), implying that 
the magnitude of the T-cell response reactive with non-E6 or E7-encoded T-cell epi-
topes is higher. A comparison of proliferative responses at weeks 12 (before TA-HPV) 
and 16 showed evidence for a booster effect of the TA-HPV vaccination for E6-GST 
reactivity (p=0.045) but not for TA-CIN (p=0.16). All patient lymphocytes showed a 
proliferative response to tuberculin purified protein derivative, indicating that there 
was no overt immune suppression in these patients as well as that the samples tested 
were of good quality. 
Vaccine-induced IFNγ-producing T-cell reactivity to HPV16/18 E6 and E7
IFNγ ELISPOT assays were performed with PBMC provided from 25 patients, taken 
before vaccination (week 0) and following all vaccinations (week 16 and/or week 
20/24). HPV16-specific T-cell responses were detected in 11 of 25 patients (Table 2). 
Preexisting HPV16-specific immunity was detected in 3 patients (201, 301, and 412), 
all of whom showed reactivity to HPV16 E6 peptides. None of the patients showed 
HPV16 E7-specific T-cells before vaccination. Vaccine-induced HPV16 E6-specific T-
cells were found in 9 of 25 patients after all vaccinations (Table 2). All of the patients 
who displayed at least a 3-fold increase in E6-specific reactivity in the proliferation 
assays (201, 301, 304, 310 and 311) responded to one or more pools of E6 peptides 
in the ELISPOT assay. In two patients (301 and 405), HPV16 E7-specific T-cells were 
enhanced after all vaccinations (Table 2 and Figure 2). 
HPV18 E6 and E7 ELISPOT assays were performed with 10 of 25 patient lymphocytes 
pre- and postvaccination (201, 304, 305, 307, 311, 403, 407, 409, 411, and 413). One 
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Table 2. HPV16/18 E6- and E7-specific immune responses pre- and postvaccination determined by IFNγ 
enzyme-linked immunospot.
Patient
HPV16 HPV18
Timea
(weeks)
E6
pool 1
E6
pool 2
E6
pool 3
E6
pool 4
E7
pool 1
E7
pool 2 MRM
E6
pool 1
E6
pool 2
E6
pool 3
E6
pool 4
E7
pool 1
E7
pool 2 MRM
201
0
16
20
-b
-
-
39 
54 
22 
-
-
-
-
-
-
-
-
-
-
-
-
339
353
293
14
-
-
29
-
-
22
-
-
-
-
-
-
1
-
4
-
-
339
350
282
301
0
16
24
19
187
109
-
45
61
-
2
72
164
128
117
-
-
-
7
39
119
391
305
309
304
0
16
24
-
-
NA
-
20
NA
-
-
NA
-
-
NA
-
-
NA
-
-
NA
117
137
NA
-
-
7
-
-
-
-
-
-
-
-
-
113
94
305
0
16
20
-
-
-
2
10
4
-
2
-
1
-
-
-
-
-
-
-
2
56
50
74
-
2
-
-
2
-
-
1
1
-
-
1
-
-
-
-
1
2
44
51
62
307
0
16
20
-
-
3
-
-
-
-
6
22
-
2
15
-
1
-
-
2
4
75
58
103
311
0
16
24
-
-
2
-
-
6
-
-
11
-
-
-
-
-
-
-
-
-
98
255
259
-
-
3
4
-
7
-
-
-
-
-
-
104
147
403
0
16
20
-
-
-
1
-
7
2
-
-
1
-
-
4
-
-
-
-
5
282
35
354
404
0
16
24
-
-
-
-
-
-
-
-
-
-
-
14
-
-
-
-
-
-
26
34
91
405
0
16
24
-
79
56
1
87
59
-
-
-
-
-
-
-
36
22
-
5
29
43
60
135
407
0
16
20
-
-
-
-
-
-
-
-
-
-
-
12
-
-
-
-
-
-
46
45
164
409
0
16
24
-
-
-
-
3
6
-
19
5
-
-
-
-
-
-
-
-
-
127
87
129
4
-
-
-
-
-
-
-
-
-
-
-
147
182
411
0
16
24
-
12
7
-
4
9
-
-
-
-
-
-
-
-
-
-
-
-
129
132
170
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
29
75
100
412
0
16
24
-
-
5
-
-
-
10
-
-
-
-
-
-
-
2
-
-
5
200
247
217
413
0
16
20
-
-
-
-
24
1
-
9
8
-
-
-
-
-
-
-
-
-
86
239
214
-
-
-
-
-
-
-
-
-
-
-
25
-
-
-
-
-
-
86
197
199
a Patient lymphocytes were assayed for IFNγ production on weeks 0, 16, and weeks 20 or 24. The 11 patients in 
whom no responses were detected against either HPV16 or HPV18 are not shown in this table. b Specific responses 
shown were calculated by subtracting the mean number of spots + 2 x SD of the medium control from the mean 
number of spots of experimental wells. The number of specific spots/ 100.000 PBMC is given. Peptide pool-specific 
T-cell frequencies ≥ 1/10.000 PBMC and at least 3-fold the prevaccination response were considered to be vaccine 
enhanced (new or enhanced responses indicated in bold). NA, not available for analysis; (-), no specific response to 
E6 or E7; MRM, memory recall mix was used as a positive control.
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T-cell responses are shown at week 0 (prevaccination), week 16 (8 weeks after vaccination with HPV16 
L2/E6/E7 protein, 4 weeks after vaccination with HPV16/18 E6/E7) and week 24. The prime-boost regimen 
induces HPV16 E6 and E7-specific IFNγ responses. The mean number of spots and SE bars/ 100,000 PBMC 
induced by the medium control or the peptides present in the E6 and E7 peptide pools are depicted. As 
positive control, a memory recall antigen mix was used.
Figure 2. Vaccine-enhanced HPV16-specific IFNγ-producing T-cell responses in 2 clinical 
responding patients (405 and 409). 
Figure 2 
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Figure 3. Antibody responses of the patient group to HPV16 E6 and E7 throughout the prime-
boost vaccination trial period.
 - 1 - 
Figure 3
Antibody responses of the patient group to HPV16 and 18 E6/7 throughout the prime boost 
vaccination trial period. 
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Table 3. P-values from Wilcoxon’s signed rank tests showing statistical evaluation of patient 
group antibody responses to HPV16/18 E6 and E7a.
HPV type Week 12 Week 16 Week 20 Week 24 Week 12 versus Week 16
     (boost effect)
16 E6 0.001	 <0.001	 0.006	 <0.001 0.158
16 E7 <0.001	 <0.001	 <0.001	 <0.001 0.998
16 L1 0.46 0.89 0.99 0.19 0.42
18 E6 0.23 0.55 0.70 0.94 0.78
18 E7 0.51 0.43 0.44 0.63 0.10
a HPV16/18 E6/E7- and HPV16 L1-specific IgG levels at time 0 were compared with postvaccination 
HPV16 L2/E6/E7 (week 12), after boosting with HPV16/18 E6/E7 (week 16) and in the follow-up in a 
Wilcoxon’s signed ranks test where p ≤ 0.05 was considered significant. Comparisons were also made by 
the same method between weeks 12 and 16 to assess a HPV16/18 E6/E7 boost effect. 
Box-whisker plot representing serum antibody levels of the patient group before vaccination (week 0), after 
three prime vaccinations of HPV16 L2/E6/E7 protein (week12), after boost vaccination of HPV16/18 E6/E7 
(week 16), and during clinical follow up (weeks 20 and 24).
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patient (201) had preexisting T-cells to several HPV18 E6 peptide pools and 3 others 
(307, 407, and 413) showed enhanced HPV18 E6-specific T-cell activity postvaccina-
tion at week 20. No preexisting or vaccine-induced HPV18 E7 reactivity was detected 
in this group of patients. Importantly, no indications were found for cross-reactiv-
ity between HPV16 and 18 peptides because patients responded to either HPV16 or 
HPV18 peptides or to different peptide pools of these two virus types. In summary, 
using IFNγ ELISPOT assays for the detection of HPV16- and HPV18 E6- and E7-spe-
cific T-cells, we found that 11 of 25 patients responded to vaccination. 
Induction of HPV16 E6- and E7-specific antibodies
Compared with normal control subjects, the patients before vaccination had evidence 
of significantly higher levels of antibodies to HPV16 E7 (p = 0.0001), HPV18 E7 (p = 
0.036), and HPV16 L1 (p =0.0001) in a nonpaired non-parametric Mann-Whitney U 
test. Thirteen patients had HPV16 L1-specific antibodies at baseline greater than the 
arbitrary cutoff generated from the normal blood donors; these L1 antibody levels 
remained stable over the course of the study. Figure 3 shows box-whisker plots of 
group serological responses to HPV16 E6 and E7 after vaccination and statistical 
analysis. Table 3 shows significant group responses at all time points compared with 
baseline for both HPV16 E6 and E7 but not L1. No significant changes were seen in 
serological responses to HPV18 E6 or E7 after vaccination. As defined by a 3-fold 
increase from baseline and being above the normal cutoff level, 14 of 24 patients 
tested were categorized as showing positive IgG responses to HPV16 E7, 1 of whom 
also had positive responses to HPV16 E6 (Table 4). The responses to HPV16 E6 or E7 
were transient, with levels peaking at week 16 and declining by weeks 20 and 24, 
consistent with the single booster vaccination with E6 and E7 encoding TA-HPV at 
week 12. 
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Table 4. Summary of patient immunological responses to vaccinationa
Summary of immunological responses to HPV16 
Patient SI TA-CIN ELISPOT  Antibodies to HPV16 Clinical
  no. >3x increase >3x increase E6 E7 responses
201 + - + + Progressor
301 + + + - Stable
302 - NT - + Stable
303 + - - + Stable
304 + + - - Stable
305 - + - - Progressor
306 - NT - - Progressor
307 - - - - Stable
308 - - - + Stable
309 - - - + Progressor
310 + - - - Stable
311 - + - + Responder
401 - - - + Responder
402 - NT - + Stable
403 - - - - Stable
404 D0 NT  + - + Responder
405 D0 NT 
 (x3 to boost)b + - + Responder
406 - - - + Responder
407 + - - - Stable
408 - - - + Stable
409 + + - - C. Responder
410 - - - + Stable
411 + + - + Stable
412 + - NT NT Stable
413 - + - - Stable
414 - NT NT NT Stable
415	 -	 -	 NT	 NT	 Stable
416	 -	 -	 NT	 NT	 Stable
417 - - NT NT Stable
         
a A vaccine-induced 3-fold increase in immunity at any postvaccination timepoint as measured by prolif-
eration, enzyme-linked immunospot (ELISPOT), or ELISA is denoted by (+). (-) is < 3-fold and NT is not 
tested. 
b Patient 404 and 405 samples were limited at time 0 for lymphoproliferation analysis; however, patient 
405 did show a 3-fold SI increase at week 16 compared with week 12. Clinical responses are categorized: 
progressor, stable, responder, and complete (C.) responder.
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Discussion
We have analyzed the immunogenicity of a combination of TA-CIN and TA-HPV can-
didate therapeutic vaccines for the treatment of HPV16-positive, high-grade AGIN 
in a Phase II clinical study. Our previous preclinical mouse model study had shown 
that the E7-specific T-cell antitumor activity was optimally boosted by a heterolo-
gous prime-boost protocol in which mice were primed by TA-CIN and boosted by 
TA-HPV9. In this study, there is clear evidence that the prime-boost vaccinations 
are immunogenic in AGIN patients, and the response appears to be biased to HPV16 
E6. Evidence of a booster effect of the TA-HPV immunization is seen with HPV16 
E6-specific proliferative responses, which were shown to be significantly higher at 
week 16, after the administration of TA-HPV. The HPV16 E6 bias in T-cell reactivity 
is also detected in the ELISPOT analysis of PBMC samples that were isolated after all 
vaccinations. De novo HPV18 E6 ELISPOT responses were found in 4 of 10 patients, 
consistent with the effectiveness of a single TA-HPV vaccination5,6 and supporting 
immunogenicity of this component of the prime/boost regimen. 
Strong proliferative TA-CIN-specific responses were found in the AGIN patients after 
the vaccinations with TA-CIN, and these are of similar magnitude as those found in 
TA-CIN vaccinated healthy subjects7. The higher level of TA-CIN-specific prolifera-
tion seen compared with that detected with E6 and the absence of E7-specific T-cell 
proliferation might be explained by a strong response to HPV16 L2 or an epitope 
derivative from the L2/E6/E7 fusion (and absent from the HPV6 L2E7 control). A 
preponderance of L2 directed T-cell reactivity may also explain the lack of detec-
tion of booster activity by injection with TA-HPV encoding the E6 and E7 oncopro-
tein only when tested in a proliferation assay with TA-CIN as stimulating antigen. 
Interestingly, those patients with the lowest preexisting TA-CIN-specific response 
were most likely to respond vigorously upon vaccination with TA-CIN. This might 
be indicative of a preexisting response masking vaccination-induced changes, with 
respect to the quality or type of T-cell response, not measured by the proliferation 
assays. Therefore, vaccine-induced proliferative responses may only be detected in 
those patients with no preexisting proliferative responses. Indeed, none of 5 patients 
in whom an E6-specific vaccine-induced proliferative response was detected had 
evidence of a preexisting E6 response. These observations point to some limitations 
of the TA-CIN proliferation assay. 
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In some of the cases, a nonprotective type of immunity (e.g., Th2, Treg, or nonpolar-
ized) preexisting T-cell response may exist or the E6- and E7-specific T-cells could 
have been anergized through the presentation of the two oncogenes to the immune 
system in a noninflammatory context, as was found in a HPV16 mouse model13. The 
long period over which the E6 and E7 proteins are presented to the immune system 
in the noninflammatory context of AGIN compared with the lack of L2 production in 
these lesions may hamper the induction of a strong type 1 T-cell reactivity against 
the two oncogenes when compared with L2. Indeed, the frequency of HPV16 E6-spe-
cific IFNγ-T-cell responses were found to be greater in patients with a preexisting Th1 
type E6-response, whereas in the other patients, including those in which a vaccine-
induced proliferative response was detected, a more modest response was induced 
(ref 5; and this study). 
Although priming of E6-specific T-cell reactivity is achieved by vaccination with TA-
CIN (ref 7; and this study), the major increase in E6-specific T-cell reactivity is due to 
the booster vaccination with TA-HPV. Analysis of the proliferative group responses 
revealed that the E6-specific T-cell responses were significantly increased at week 16, 
which is 4 weeks after vaccination with TA-HPV. Furthermore, our previous analysis 
of T-cell reactivity in high-grade VIN patients also revealed that vaccination with 
TA-HPV enhanced especially the numbers of IFNγ-producing E6-specific T-cells5. 
Such HPV16 E6-specific T-cell immunity is frequently detected in healthy subjects, 
and this is supportive of a role in protection against persistent HPV infection and 
associated development of malignancies14. The fact that the heterologous prime-boost 
protocol increases the numbers of these effectors should therefore offer potential 
therapeutic value in some of the high-grade VIN patients.
Clinically, we observed objective responses in 6 patients and 19 had stable disease, 
and in 4 patients, there was evidence of progression. Table 4 summarizes these and 
the immunological responses. Of the 6 clinical responders, 2 patients showed both a 
proliferative TA-CIN-specific response and an E6-specific IFNγ response, whereas 3 
other patients displayed E6 reactivity only. Stable disease was recorded in 19 patients, 
8 of whom showed a concomitant TA-CIN-specific proliferative and/or E6-specific 
T-cell response, whereas in the other 11 patients, no vaccine-induced response could 
be detected. Of the 4 progressors, 2 failed to make a T-cell response and 2 responded 
by either proliferation or E6 ELISPOT alone. There is no statistically demonstrable 
association between clinical response and immunological response measured by 
either TA-CIN proliferation or ELISPOT or anti-E7 antibodies (odd ratios of 0.36, 
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0.11, and 0.16, respectively). However, such individual immune responses of patients 
were defined by 3-fold increases in activity from baseline and are thus a reflection 
of the magnitude of measurable vaccine-induced change rather than inherent HPV 
immunity. Focusing on combinations of immunological activity, outcome of vac-
cination in patients and other factors may give another perspective. Our previous 
analysis of vaccinated VIN patients showed that clinical responsiveness to treatment 
was dependent on the presence of lesion-associated CD4+, CD8+, and CD1a+-immune 
cells6, suggesting that not only the numbers of systemically present HPV16-specific 
T-cells are important but also their capacity to reach the target site. In the design 
of new trials, local immune infiltration will be an important factor to consider in 
relation to outcome. Preselection of high-grade VIN patients with lesions displaying 
T-cell infiltrate before vaccination may identify a group of subjects who benefits the 
most from vaccination. 
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Abstract
Purpose: Topical application of the immune response modifier imiquimod is an alter-
native approach for the treatment of human papillomavirus (HPV)-positive vulvar 
intraepithelial neoplasia (VIN) and aims at the immunologic eradication of HPV-
infected cells. We have charted HPV16-specific immunity in 29 patients with high-
grade VIN and examined its role in the clinical effect of imiquimod treatment.
Experimental design: The magnitude and cytokine polarization of the HPV16 E2-, 
E6-, and E7-specific CD4+ T-cell response was charted in 20 of 29 patients by prolif-
eration and cytokine bead array. The relation between HPV16-specific type 1 T-cell 
immunity and imiquimod treatment was examined in a group of 17 of 29 patients.
Results: HPV16-specific proliferative responses were found in 11 of the 20 patients. 
In 8 of these patients, T-cell reactivity was associated with IFNγ production. Fifteen 
of the women treated with imiquimod were HPV16+, of whom 8 displayed HPV16 
E2- and E6-specific T-cell immunity before treatment. Imiquimod neither enhanced 
nor induced such immunity in any of the subjects. Objective clinical responses (com-
plete remission or >75% regression) were observed in 11 of the 15 patients.  Of these 
11 responders, 8 patients displayed HPV16-specific type 1 CD4+ T-cell immunity, 
whereas 3 lacked reactivity. Notably, the 4 patients without an objective clinical 
response also lacked HPV16-specific type 1 T-cell immunity.
Conclusions: HPV16-specific IFNγ-associated CD4+ T-cell immunity, although not 
essential for imiquimod-induced regression of VIN lesions, may increase the likeli-
hood of a strong clinical response (p = 0.03). 
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Introduction
Genital infections with high-risk human papillomaviruses (HPV) are very common1-3. 
Fortunately, the majority of infected subjects clear the infection4,5. A persistent infec-
tion with a high-risk HPV, mostly HPV16, can lead to neoplasia of the anogenital 
tract, of which cervical intraepithelial neoplasia (CIN) and cervical carcinoma are the 
most well known6,7. HPV16 infection may also cause a chronic skin disorder of the 
vulva known as vulvar intraepithelial neoplasia (VIN)8-10. In contrast to CIN, which 
in general is effectively treated by eradication of the area involved, VIN is a chronic 
disease with high relapse rates after standard treatments11-13. 
Imiquimod therapy has been put forward as an alternative approach for the treat-
ment of VIN. This immune response modifier acts through Toll-like receptor 7 of the 
innate immune system resulting in the secretion of a multitude of proinflammatory 
cytokines. There is recent evidence that imiquimod also possesses direct proapop-
totic activity against tumor cells14-16. Topical application preserves the anatomy and 
function of the vulva, whereas surgical excision or ablation of affected skin may 
be extensive and disfiguring and can carry considerable psychosexual morbidity. 
Clinical success rates differ and are estimated on 30% to 87%17-21.
The HPV16 early antigens E2, E6, and E7 are among the first of proteins that are 
expressed in HPV-infected epithelia. Our previous studies on HPV-specific T-cell 
immunity against these early antigens showed that type 1 (IFNγ) T-cell memory 
against the early antigens can be detected in the majority of healthy sexually active 
individuals but is weak or absent in patients with HPV16-induced cervical neopla-
sia22-24.  In combination with earlier reports that point at a role for CD4+ T-cells in the 
protection against progressive HPV infection (reviewed in25), our data argue that the 
CD4+ type 1 T-cell response against the early antigens of HPV16 plays an important 
role in the protection against progressive HPV16-induced disease. 
To examine the role of HPV16-specific CD4+ T-cell immunity in the success or failure 
of treatment with imiquimod, we have done a detailed analysis with respect to the 
magnitude and cytokine polarization of the HPV16-specific CD4+ T-cell response in 
patients with high-grade VIN.  Furthermore, HPV16-specific type 1 immunity was 
analyzed before, during, and after topical treatment with imiquimod. Our data indi-
cate that chronic exposure of the immune system to the HPV16 viral proteins results 
in the induction of type 1 T-cell immunity in about half of the patients. Importantly, 
the presence of these type 1 T-cell responses is likely to be associated with a more 
favorable clinical response to imiquimod treatment.
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Methods
Patients
Twenty-nine women with high-grade VIN (age range, 24-73 years; median age, 47 
years) were recruited from the departments of gynecology of the Academic Medical 
Center and Leiden and Erasmus University Medical Center, The Netherlands. On the 
average, these patients had been diagnosed with VIN 3 5.4 years before enrollment 
in the study (range, 6 months to 15 years). Eighteen women had undergone previ-
ous treatments for VIN 3 (surgical excision, laser therapy, or imiquimod treatment 
(patients 20, 21, 24, 27)) before study entry. 
Seventeen of these 29 subjects (age, 29-60 years; median, 43 years) were experimen-
tally treated with a 5% imiquimod cream. The patients were asked to apply the cream 
to the affected areas on the vulva twice-weekly overnight for a maximum period 
of 16 weeks. To analyze the effect of imiquimod treatment on the HPV16-specific 
immune response, we collected serial blood and serum samples before the start of 
imiquimod treatment (T=0), after 8 weeks of treatment (T=8), and at the end of treat-
ment (T=16). Vulvar lesions were assessed by direct measurement and photographic 
records at entry and after 8 and 16 weeks of treatment. Clinical responses were 
defined as a complete response; a partial response type 1, as defined by a reduction in 
lesion diameter from 76% to 99%; a partial response type 2, as defined by a reduction 
in lesion diameter from 26% to 75%; or no clinical response.
From 20 of 29 women peripheral blood mononuclear cells (PBMC) were isolated and 
directly used to analyze HPV16-specific proliferative T-cell reactivity. Of these 20 
women, 8 patients had also participated in the imiquimod study. In 6 cases blood was 
taken 3 months (patient 1), 4 months (patient 10), 10 months (patient 5) to over 1 year 
(patients 12, 13 and 15) after the end of the imiquimod study, in the other 2 cases 
(patients 2 and 4) blood was taken within 4 weeks after the start of treatment. Serum 
was collected to study the presence of virus-like particle L1 (VLP)-specific antibodies.
All subjects were typed for HPV by GP5+/6+ PCR followed by reverse line blot analy-
sis as described previously26. The study design was approved by the Medical Ethical 
Committees and all women gave written informed consent. 
Antigens
A set of peptides spanning the whole HPV16 E2, E6, and E7 protein were used for the 
T-cell proliferation assays. The E2 peptides consisted of twenty-two 30-mer peptides 
with a 15-amino-acid overlap and the COOH-terminal peptide with a length of 35 
amino acids. For the T-cell proliferation assays, the E2 peptides, 32-mer peptides of 
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the E6 protein, and the 35-mer peptides of the E7 protein with an overlap of 14 amino 
acids were used in pools of two peptides per pool. For the IFNγ enzyme-linked immu-
nospot (ELISPOT) assays, the peptides used spanned the HPV 16 E2, E6, and E7 protein 
and consisted of the most immunogenic regions of the E2 30-mer peptides22 and 15 E6 
and 9 E7 overlapping 22-mer peptides. The peptides were synthesized and dissolved 
as decribed previously27. The peptide pools are indicated by the first and last amino 
acid of the region in the protein covered by the two peptides (e.g., E21-45, residues 
1-30 and 16-45). Memory response mix (MRM), consisting of a mixture of tetanus 
toxoid (0.75 limus flocculentius/ml final concentration; National Institute of Public 
Health and Environment, Bilthoven, The Netherlands), Mycobacterium tuberculosis 
sonicate (2.5 µg/ml; generously donated by Dr. P. Klatser, Royal Tropical Institute, 
Amsterdam, The Netherlands) and Candida albicans (0.005%, HAL Allergenen Lab., 
Haarlem, The Netherlands), was used as a positive control.
Short-term T-cell proliferation assay
Freshly isolated PBMC were incubated with 12 pools of HPV16 E2-derived 30-mer 
peptides, 4 pools of E6 32-mer peptides, and 2 pools of E7 35-mer peptides (each 
pool consisted of two overlapping peptides). PBMC were seeded at a density of 1.5 x 
105 cells per well in a 96-well U-bottomed plate (Costar, Cambridge, MA) in 125 µl of 
Iscove's medium (BioWhittaker, Verviers, Belgium) supplemented with 10% autolo-
gous serum. HPV16 E2-, E6-, and E7-derived peptides were added at a concentration 
of 10 µg/ml/peptide. Medium alone was taken along as a negative control, and mem-
ory response mix (dilution, 1:50) served as a positive control. For each peptide pool, 
eight parallel microcultures were incubated. Fifty microliters of supernatant from the 
microcultures were taken at day 6 after incubation and stored at -20°C until cyto-
kine analysis. Peptide-specific proliferation was measured at day 7 by [3H]thymidine 
incorporation. Cultures were scored positive when the proliferation of ≥ 75% of the 
test wells exceeded the mean proliferation + 3 x SD of the control wells containing 
medium only, and the stimulation index, defined as the mean of all test wells divided 
by the mean of the control wells, was ≥ 322. 
Analysis of cytokines associated with HPV16-specific proliferative responses
The detection of cytokines in the supernatants of the short-term proliferation assays 
was done using the cytometric bead array (CBA) (Becton Dickinson, Erebodegem-
Aalst, Belgium). This technique allows the simultaneous detection of six different Th1 
and Th2 cytokines IFNγ, tumor necrosis factor α, interleukin (IL)-2, IL-4, IL-5, and 
IL-10. The CBA was done according to the manufacturer's instructions. Cutoff values 
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were based on the standard curves of the different cytokines (50 pg/ml for IFNγ and 
10 pg/ml for the remaining cytokines). Antigen-specific cytokine production was 
defined as a cytokine concentration above cutoff level and > 2x the concentration of 
the medium control23,28.
Analysis of HPV16-specific T-cell reactivity by IFNγ enzyme-linked immunospot
The number of IFNγ producing HPV-specific T-cells, present in the peripheral blood 
of the 17 patients treated with imiquimod, was quantified using ELISPOT that was 
done as described previously29,30. Briefly, PBMC were thawed, washed, and seeded at 
a density of 2 x 106 cells per well of a 24-well plate (Costar) in 1ml of Iscove’s modi-
fied Dulbecco’s medium (Bio Whittaker) enriched with 10% human AB serum, in the 
presence or absence of indicated HPV16 E2, E6, and E7 peptide pools. Peptides were 
used in pools of 4 to 5 peptides at a concentration of 5 µg/ml/peptide. The peptides, 
as indicated by their first and last amino acid in the protein, were used in the follow-
ing pools: E2-I: 1-30, 16-45, 31-60, 46-75; E2-II: 61-90, 76-105, 91-120, 106-135; 
E2-III: 121-150, 136-165, 151-180, 166-195; E2-IV: 271-300, 286-315, 301-330, 
316-345, 331-365; E6-I: 1-22, 11-32, 21-42, 31-52; E6-II: 41-62, 51-72, 61-82, 71-
92; E6-III: 81-102, 91-112, 101-122, 111-132; E6-IV: 111-132, 121-142, 131-152, 
137-158; E7-I: 1-22, 11-32, 21-42, 31-52; E7-II: 41-62, 51-72, 61-82, 71-92, 77-98. 
Following 4 days of incubation at 37ºC, PBMC were harvested, washed, and seeded 
in four replicate wells at a density of 105 cells per well in 100 µl Iscove’s modified 
Dulbecco’s medium enriched with 10% FCS in a Multiscreen 96-well plate (Millipore, 
Etten-Leur, The Netherlands) coated with an IFNγ-catching antibody (Mabtech AB, 
Nacha, Sweden). Further antibody incubations and development of the ELISPOT was 
done according to the manufacturer’s instructions (Mabtech). Spots were counted 
with a fully automated computer-assisted video-imaging analysis system (Bio Sys). 
Specific spots were calculated by subtracting the mean number of spots + 2 x SD of 
the medium control from the mean number of spots in experimental wells provided 
that the mean number of spots of the medium control wells were either <10 or >10 
with a SD <20% of the mean. Antigen-specific T-cell frequencies were considered 
to be increased when specific T-cell frequencies were ≥ 1/10,000 and at least ≥ 2x 
background30. The background number of spots was 2,6 ± 2,2 (mean ± SD), with one 
exception (patient 23, 51 ± 10 spots).
HPV16 virus-like particle ELISA
For the detection of HPV16-specific antibodies in serum we used an ELISA method 
previously described by Kirnbauer et al.31. Each serum sample was tested for reactiv-
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ity against HPV16 VLPs (baculovirus-expressed capsids comprising the L1 protein) 
and against bovine papillomavirus capsids, the latter disrupted by treatment with 0.1 
mol/L carbonate buffer to serve as a negative control. Both VLP and bovine papil-
lomavirus were kindly provided by Prof. Dr. J. Dillner (LUNDS University, Sweden). 
The patients were tested for both HPV16-specific IgG and IgA. A set of sera of healthy 
children (n=8; mean age, 7.3 years; range, 4.3-14.1 years) was tested to determine 
background reactivity.  For HPV16 L1-VLP IgG type responses a cutoff absorbance 
value of 0.230 was used (mean A = 0.060; range –0.056 to 0.150; mean + 2 x SD 
= 0.230). For IgA type responses a cutoff of A = 0.215 was used (mean A = 0.189; 
range, 0.171 to 0.205).
Statistical analysis
Statistical analysis of the HPV16-specific proliferative responses associated with 
cytokine production was done using Fisher’s exact test. Fisher’s exact test (two tailed) 
was used to analyze HPV-specific immunity to clinical response upon treatment with 
imiquimod. 
Statistical analyzes were done using Graphpad Instat Software (version 3.0).
Results
HPV16-specific cellular and humoral responses in patients with high-grade VIN
VIN forms a unique aspect of HPV-induced disease because patients are frequently 
treated, but the infection often persists. HPV16 is found most often. To gain a more 
profound insight in the CD4+ T-cell response against HPV16 in VIN, we charted the 
magnitude, specificity, and functionality of HPV16 E2, E6, and E7-specific proliferative 
T-cell responses in a group of 20 women with HPV16-associated high-grade VIN.  
PBMC isolated from VIN patients were stimulated with peptides derived from HPV16 
proteins E2, E6, and E7 as well as with a mix of common recall antigens (memory 
response mix, MRM), in a short-term proliferation assay. We have previously shown 
that this assay is geared towards the detection of CD4+ T-cell responses23. HPV16-
specific proliferative T-cell responses against E2 and/or E6 were detected in 10 of 20 
patients (Figure 1A). E7-specific responses were detected in 5 of 20 subjects. Analysis 
of the supernatants of these T-cell cultures for the presence of type 1 and type 2 cyto-
kines revealed the secretion of the Th1 cytokine IFNγ in 8 of 20 patients. In some of 
the patients, the production of tumor necrosis factor α, IL-5, and IL-10 was occasion-
ally detected (Figure 1B). Although the overall frequency of proliferative responses is 
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Figure 1A. HPV16-specific proliferative T-cell responses in VIN
Freshly isolated PBMC from 20 patients with high-grade HPV16-associated VIN were tested in short-term 
proliferation assays using a complete set of HPV16 E2-, E6-, and E7-derived peptide pools. Responses were 
scored positive when the proliferation (cpm) of ≥ 6 of 8 test wells exceeded the mean proliferation + 3 x 
SD of the control (medium only) wells, and the mean stimulation index of all test wells over control wells 
was ≥ 3. Memory response mix (MRM), consisting of a mixture of recall antigens, was used as a positive 
control. The stimulation indices of responses scored positive are indicated.
Figure 1B. Supernatants of the positive proliferative responses indicated in A were analyzed for the 
presence of IFNγ, tumor necrosis factor-α (TNFα), IL-2, IL-4, IL-5, and IL-10 by cytometric bead array. 
The indicated layout is used for the six measured cytokines; a filled square represents antigen-spe-
cific cytokine production. Cutoff values were based on the standard curves of the different cytokines 
(50 pg/ml for IFNγ and 10 pg/ml for the remaining cytokines). Antigen-specific cytokine production 
was defined as a cytokine concentration above cutoff level and >2x the concentration of the medium 
control.
A
B
IL-2
IL-4 IL-5 IL-10
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similar when compared with that previously found for cervical cancer patients, the 
number of patients with IFNγ-associated HPV-specific T-cell responses in these VIN 
patients was higher (8 of 20 versus 4 of 17, respectively;23). 
In addition to T-cell immunity, the humoral response to HPV16 was measured in 
28 VIN patients by ELISA using HPV16 L1-VLP as antigen. Overall, HPV16 L1-VLP 
IgG and IgA antibodies were detected in 25 of 28 (89%) and 13 of 28 (46%) subjects, 
respectively (Table 1). Based on the absorbance values, the HPV16 L1-VLP-specific 
IgG response exceeded that of IgA (Table 1). In general, HPV16-specific IgA responses 
were detected when patients displayed relatively high levels of HPV16-specific IgG. If 
IgG absorbance values were ≥0.5, 11 of 19 (58%) of the samples contained HPV16 L1-
specific IgA, whereas at IgG levels <0.5 only 2 of 9 samples were IgA seropositive.
In conclusion, HPV16 L1-specific humoral immunity was detected in the great major-
ity of patients, whereas HPV16 E2-, E6-, and/or E7-specific IFNγ-associated type 1 
T-cell reactivity was detected in about half of the patients tested.
Table 1. Distribution of absolute absorbance values among IgG- and IgA-seropositive samples
 ∆ A 415 nm
Immunoglobulin type (n positive/28) Mean (SD) Median (range)
IgG seropositive (n=25) 1.10  (0.61) 1.22  (0-1.93)
 
IgA seropositive (n=13) 0.34  (0.26) 0.31  (0-0.88)
HPV16 L1 IgG and IgA antibodies detected in the sera of  28 VIN 3 patients. Serum antibody responses 
were measured by VLP-ELISA. Depicted are the absolute absorbance values at 415 nm. The absorbance 
values were calculated by subtraction of the background response value and the mean absorbance value 
of the young children’s sera. 
HPV16-specific immunity is associated with a more favorable clinical response 
upon immunomodulatory treatment with imiquimod
Our analysis of HPV16-specific proliferation indicates that a high number of the 
proliferative T-cell responses is associated with IFNγ production. To examine the role 
of these HPV16-specific type 1 T-cell responses in the success or failure of treatment 
with the immunomodulator imiquimod, we  studied this immune response in a group 
of patients with high-grade HPV16+ VIN. PBMC were isolated before (T=0), during 
(T=8), and after (T=16) treatment and stored in liquid nitrogen. HPV-specific T-cell 
reactivity against HPV16 peptides E2, E6, and E7 was analyzed by IFNγ ELISPOT. 
This is a sensitive method for the analysis of antigen-specific type 1 T-cell reactiv-
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ity on frozen material32,33. Three of these patients had been treated with imiquimod 
in the year before inclusion in our study (Table 2, patients 21, 24, and 27). Of these 
17 patients, 15 were HPV16-positive. Preexisting IFNγ-associated T-cell responses 
(T=0) were detected in 8 of 15 patients by IFNγ ELISPOT. In 5 of 15 patients, HPV16-
specific T-cell reactivity against E2 was detected, whereas 4 of 15 patients displayed 
Table 2. HPV16-specific T-cell responses in patients treated with imiquimod 
Patient*
HPV 
type
clinical 
response†
VLP‡ T
E2-peptides E6-peptides
E7-
peptides
MRM
1§
75
61
135
121
195
271
365
1
52
41
92
81
132
111
158
1
52
41
98
1 16 no ++ 8 - - - - - - - - - - 179
2 16 PR1 + 0 52 54 15 31 - - 3 - 9 - 295
4 16 CR ++ 0 - - - - - 1 - - - - 124
5 16 CR ++ 0 - 32 9 3 - - - - - - 32
10 16 PR1 - 0 - 4 - - - - 84 - 5 - 54
12 16 PR1 ++ 0 15 - - - - - - - - - 32
13 16 CR ++ 0 -** - - - - - 104 - - - 105
15 16 PR1 + 0 - - - - - - - - - - 179
21 neg PR1 ++ 0 - - - - - - - - - - 364
22 16 PR2 ++ 8 8 - - 4 - - - - - - 25
23 16 PR1 ++ 0 - 1 59 5 - 74 - - 21§§ 11 52
24 16 no ++ 0 - - - - - - - - - - 172
25 neg CR + 0 - - - 4 - - - - - - 444
26 16 CR ++ 0 - - - - - - - - - - 21
27 16 no ++ 0 - 4 - - - - - - - - 70
28 16 CR ++ 0 6 - 45 18 - 7 3 2 3 - 20
29 16 CR - 0 - 2 7 - - 40 - - - 2 157
Abbreviations: CR, complete response; PR, partial response; MRM, memory response mix.
* PBMC from 17 VIN 3 patients were tested for type 1 T-cell reactivity against HPV16 peptides. PBMC were 
stimulated with different pools of HPV16 E2, E6, and E7 peptides and tested for antigen-specific IFNγ pro-
duction by ELISPOT. 
† Clinical responses were defined as no clinical response, a partial response type 1, as defined by a reduction 
in lesion diameter from 76% to 99%; a partial response type 2, as defined by a reduction in lesion diameter 
from 26% to 75%; and a complete response (CR). 
‡ Sera of the patients were tested for the presence of HPV16 L1-VLP specific IgG antibodies. Indicated is the 
presence (+) or absence (-) of antibodies.  
§  The first and last amino acid in the indicated protein of the peptide pool used are indicated. 
** Per patient, T-cell responses on T=0 are shown. In case of a missing T=0 sample, data from T=8 are shown. 
Specific responses were calculated by subtracting the mean number of spots + 2 x SD of the medium con-
trol from the mean number of spots of experimental wells. The number of specific spots per 100,000 PBMC 
are given. Responses were considered positive if peptide pool-specific T-cell frequencies were ≥ 10/100,000 
PBMC. These values are indicated in bold. Values below this threshold are shown in italics. (-), no specific 
response to E6 or L1. MRM was used as a positive control.
§§ Responses considered negative because values did not exceed ≥ 2x the medium control.
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a response against E6 (Table 2).  None of these patients showed preexisting T-cell 
responses against HPV16 E7. In 2 cases the T=0 sample was not available and the 
reaction in PBMC from T=8 are shown (Table 2, patients 1 and 22).
Despite that for some patients one of the two follow-up samples was not available 
(patients 5, 13, 27, and 28), it was clear that we could not detect a direct influence 
of imiquimod on the numbers of HPV-specific T-cells. In none of the patients was 
a clear-cut increase of HPV16-specific T-cells detected upon imiquimod treatment 
(Figure 2A,B). In some cases, patients had already been treated with a course of 
imiquimod before this study, but even this repeated treatment did not result in an 
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Figure 2A and B. HPV16-specific IFNγ-associated T-cell responses in two representative patients 
with high-grade VIN (patient 2, left and patient 10, right). T-cell responses are shown at week 0 
(before imiquimod treatment), week 8 (during imiquimod treatment), and at week 16 (after imiqui-
mod treatment). Local application of 5% imiquimod containing cream does not result in enhanced 
systemic HPV16-specific T-cell responses. Note that the magnitude of the T-cell responses varies 
slightly over the different time points. The mean number of spots and SE induced by the medium 
control or the peptides present in the E2, E6, and E7 pools per 100,000 PBMC are depicted. As posi-
tive control, the memory recall mix (MRM) was used. 
Figure 2C and D. patients with preexisting HPV16-specific T-helper type 1 responses show objective 
clinical responses after imiquimod treatment. A typical example is shown. C. biopsy-proven VIN 3 
lesion of patient 5 before imiquimod treatment. D. the same vulvar area of patient 5 after 16 weeks 
of treatment. 
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increase of HPV16-specific T-cells (Table 2, patients 21 and 24). In addition, the 
HPV16 VLP-specific IgG and IgA response did not overly change when patients were 
treated with imiquimod  (Figure 3). 
Thirteen of the 17 women treated (76%) displayed an overt clinical response upon 
treatment with imiquimod as indicated by 76% to 100% reduction in the size of 
their lesion (complete response or partial response 1, Table 2 and Figure 2C,D). Three 
patients showed no reduction in size of the affected area of vulvar disease and one 
woman showed only minimal improvement upon treatment. 
Importantly, when the group of HPV16+ patients (n=15) was divided in patients 
either with or without an HPV-specific Th1 immune response, all 8 patients with 
an HPV-specific immune response displayed a complete or near complete clinical 
response (complete response or partial response 1) upon imiquimod treatment (Table 
2). In contrast, patients without an HPV-specific immune response were less likely to 
show such a clinical improvement (p = 0.03, two-sided Fisher’s exact test). 
Taken together, chronic viral antigen exposure can induce type 1 CD4+ T-cell immu-
nity against the HPV16 early antigens E2, E6, or E7 in patients with VIN 3. The pres-
ence of these HPV16-specific Th1 cells as detected by IFNγ ELISPOT, although not 
Figure 3. IgG and IgA reactivity to HPV16 VLPs over time in 17 VIN 3 patients treated with imiqui-
mod. At least two serum specimens were tested in every patient. Serologic responses are shown 
at week 0 (before imiquimod treatment), week 8 (during imiquimod treatment), and at week 16 
(after imiquimod treatment). The absorbance (OD) values are depicted as median ± SD of positive 
responses. The absorbance values were calculated by subtraction of the background response value 
and the mean absorbance value of the young children's sera. 
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essential for imiquimod-induced regression of VIN lesions, does increase the likeli-
hood of a strong clinical response. The presence of L1-specific humoral reactivity was 
not correlated with imiquimod-induced regressions.
Discussion
We have analyzed the HPV16 E2-, E6-, and E7-specific CD4+ T-cell responses in 
a group of 29 patients with high-grade VIN, 17 of whom were treated with the 
immunomodulator imiquimod. HPV16-specific type 1 (IFNγ) CD4+ T-cell prolifera-
tive immunity is present in about half of patients with VIN 3 (8 of 20).  Virus-spe-
cific CD4+ Th1-type T-cells have emerged as an essential component in the immune 
response to chronic viral infection, fulfilling a multifactorial role, including the acti-
vation of antigen-presenting cell maturation for efficient CD8+ priming, the release 
of cytokines important in CD8+ T-cell proliferation and differentiation, and in the 
recruitment of other effector cells such as eosinophils and macrophages. Indeed, a 
substantial number of patients with VIN 3 were reported to display high frequencies 
of HPV16-specific CD8+ T-cells34-36. In contrast, only in a few occasions HPV16-spe-
cific CD8+ T-cell reactivity was detected in patients with CIN 3 and cervical carci-
noma37-40. However, these latter types of patients display an impaired HPV16-specific 
CD4+ T-cell response23.
Topical application of imiquimod neither enhanced the preexistent HPV16-specific 
CD4+ T-cell responses nor resulted in the induction of such responses in any of 
the other subjects. Todd et al. made a similar observation with respect to HPV16-
specific CD8+ T-cells36. Notably, we found that a preexisting HPV-specific type 1 
T-cell response was associated with a more favorable clinical outcome upon topical 
imiquimod treatment of VIN 3. This indicates that a combination therapy, in which 
the HPV16-specific T-cell response is induced or boosted by vaccination and the 
affected skin is treated with imiquimod, may increase the number of patients that 
benefit from treatment.
Compared with normal vulvar skin, a number of VIN lesions display increased infil-
tration of CD4+ and CD8+ T-cells41-43. The clinical consequences of the infiltration 
of immune cells in these VIN lesions are poorly understood, but the immunologi-
cal make-up of the vulvar microenvironment may determine the clinical outcome43. 
The local cytokine microenvironment in high-grade cervical neoplasia is associated 
with a decreased expression of the proinflammatory Th1 cytokines tumor necro-
sis factor α and IFNγ44-46. It is conceivable that similar to CIN, the vulvar micro-
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environment also lacks proinflammatory cytokines. Imiquimod is known to directly 
stimulate Langerhans cells and macrophages17,47, of which the latter are increased in 
VIN lesions42. Furthermore, it stimulates natural killer cells and T-helper type 1 cells 
via indirect mechanisms17,47. Upon stimulation, the antigen-presenting cells release 
proinflammatory cytokines, predominantly IFNα, tumor necrosis factor α, and IL- 
1214,15 17,47. This may restore an inducive environment in which the innate effector 
cells, macrophages, and natural killer cells, as well as activated HPV16-specific T-
cells may act in concert to form an effective immune response. The requirement for 
these additional signals to activate T-cells is sustained by recent observations in 
animal models. In the HPV16 E7-transgenic skin transplantation model Matsumoto 
et al.48 showed that despite the presence of large numbers of E7-specific memory T-
cells, E7+ skin transplants were not rejected, except when these E7-specific memory 
T-cells were activated through vaccination. This suggested that the presence of the 
HPV16 E7 antigen itself is not sufficient to evoke a strong skin-destroying immune 
response but that additional activating signals were required. Similarly, Van Mierlo et 
al.49 showed that adenovirus-specific CD8+ T-cells developed in the draining lymph 
nodes of mice bearing adenovirus-positive tumors, indicating that tumor-antigen was 
detected by T-cells of the immune system. The tumor was rejected only when strong 
proinflammatory signals were provided. Likewise, HPV16-induced VIN 3 lesions may 
fail to endow the immune system with strong inflammatory signals and exogenously 
provided signals will be required to provide a state of inflammation. These signals 
can be delivered by imiquimod, electrocoagulation50 or by vaccines32,33,43.
Currently, it is not clear whether immune activation causes the HPV16-specific IFNγ-
producing CD4+ T-cells to migrate into the HPV-infected tissue or whether these T-
cells should simply provide help to activate effector cells in the draining lymph nodes. 
Therefore, we are currently examining both local and systemic immune response in 
patients with high-grade VIN. 
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Abstract
In a prospective study, we have examined the tumor-specific immune response in a 
group of 59 patients with human papillomavirus (HPV) 16-positive (HPV16+)-induced 
or HPV18+ induced cervical cancer. Local antitumor immunity was analyzed by the 
enumeration of tumor-infiltrating dendritic cells and CD4+, CD8+, and regulatory T-
cells as well as by calculation of the ratio of CD8+/CD4+ T-cells and CD8+/regulatory 
T-cells. Systemic tumor-specific immunity was assessed by determination of the HPV 
E6- and/or E7-specific T-cell response in the blood of these patients. Finally, these 
variables were evaluated with respect to known histopathologic prognostic variables, 
including the absence (LN-) or presence (LN+) of lymph node metastases. 
Stratification according to the lymph node status of patients revealed a significantly 
stronger CD8+ T-cell tumor infiltration, a higher CD8+/CD4+ T-cell ratio, and higher 
CD8+/regulatory T-cell ratio in the group of patients in which the tumor failed to 
metastasize to the tumor-draining lymph node. Subdivision according to the pres-
ence (IR+) or absence (IR-) of circulating HPV-specific T-cells disclosed that the high-
est number of tumor-infiltrating CD8+ T-cells was found in the group of LN- patients 
displaying a concomitant systemic tumor-specific immune response (LN-IR+). CD8+ 
T-cell infiltration in LN-IR- patients was comparable to that of LN+ patients.
In cervical cancer, the absence of lymph node metastases is strongly associated with 
a better prognosis. Our data indicate that, especially in a subgroup of LN- patients, 
a strong and effective interaction between immune system and tumor exists. This 
subgroup of cervical cancer patients may have the best prognosis.
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Introduction
Cervical cancer is caused by high-risk types of human papillomavirus (HPV), particu-
larly types 16 (HPV16) and 18 (HPV18), which account for approximately two-third 
of all cervical carcinomas1,2. It is the second most common cancer in women world-
wide3,4. Overall cure rates of early-staged tumors approach 85%. However, a spectrum 
of relapse risk exists depending on several prognostic factors. Clinical stage and 
lymph node status are the most powerful predictors of outcome in cervical cancer, 
but other histopathologic factors, including size of primary tumor, infiltration depth, 
and vasoinvasion, have effect on the prognosis too5-8. 
Cervical cancer cells highly express two well-known tumor-specific oncoproteins that 
are encoded by HPV. These proteins, E6 and E7, are constitutively expressed because 
they are required to maintain the malignant phenotype9. The tumor can be infiltrated 
by lymphocytes10,11, and both CD8+ and CD4+ T-cells isolated from tumors are able to 
recognize the E6 and E7 tumor antigens12-14 (and Piersma, manuscript in preparation) 
as well as to kill tumor cells in vitro15,16. Tumor-specific T-cells, directed against the 
two HPV-encoded oncoproteins, can be detected in the peripheral blood of almost 
50% of the patients albeit at low levels17-23. Therapeutic vaccination strategies aim-
ing at the activation of large numbers of E6- and/or E7-specific T-cells in patients 
with precursor cancer lesions showed promising results24-28, but no clear association 
between the presence of either a spontaneously induced or a vaccine-induced sys-
temic tumor-specific immune response and clinical outcome was established. 
Thus far, the only immunological determinant associated with a better prognosis is a 
pronounced infiltration of cervical carcinoma by lymphocytes10,11. However, thorough 
evaluations on the prognostic significance of tumor-infiltrating lymphocytes (TIL) in 
other human cancers revealed that especially intraepithelial infiltrating CD3+CD8+ 
T-cells contributed to a better prognosis29-31. On the other hand, the infiltration by 
CD3+CD4+ T-cells32,33 or a subpopulation of CD4+ T-cells with immunosuppressive 
properties, so called regulatory T-cells that were detected by staining for Foxp334, was 
reported to counteract the beneficial effect of CD8+ T-cells33-35. High ratios between 
CD8+ T-cells and the other cell types were associated with improved survival32,33. These 
types of analyses have not been done in patients with cervical carcinoma.
In the present study, we did an in-depth analysis of the tumor-specific immune 
response in patients with HPV-induced cervical cancer. Local antitumor immunity 
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was analyzed by the enumeration of tumor-infiltrating dendritic cells and CD4+, CD8+, 
and regulatory T-cells as well as by calculation of the ratio of CD8+/CD4+ T-cells and 
that of CD8+/regulatory T-cells. The presence of systemic tumor immunity was assessed 
by examination of HPV E6- and/or E7-specific T-cell immunity in the peripheral blood 
of these patients. Finally, these variables were evaluated with respect to the lymph node 
status of patients because of its strong prognostic value in cervical cancer. 
Methods
Subjects
Women presenting with histologically proven early-stage cervical carcinoma at 
the department of gynecology of the Leiden University Medical Center (Leiden, The 
Netherlands) and scheduled for radical hysterectomy were enrolled in the CIRCLE 
study that investigates cellular immunity against HPV16-positive cervical lesions 
after providing informed consent. The study design was approved by the Medical 
Ethical Committee of the Leiden University Medical Center. Patient characteristics 
are given in Table 1. Blood was drawn at day of treatment before surgery. Peripheral 
No. of patients 59
Age (years) 
 Median 44
 Range 29-76
FIGO stage 
 1B 49
 2A 8
 2B 2
HPV type 
 HPV16+ 45
 HPV18+ 14
Lymph node metastases 
 Positive 23
 Negative 36
Tumor size (cm) 
 < 4 35
 ≥ 4 24
Infiltration depth (mm) 
 < 15 34
 ≥ 15 21
 Unknown 4
Vasoinvasion 
 Yes 36
 No 15
 Unknown 8
Table 1. Patient characteristics
Abbreviation: FIGO, Fédération Internationale des Gynaecologistes et Obstetristes
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blood mononuclear cells (PBMC) were obtained for the analysis of HPV-specific T-
cell reactivity. The subjects were typed for HPV16 and HPV18 using HPV16- and 
18-specific primers on DNA isolated from surgical resection specimens36. HPV16+ 
and HPV18+ subjects were included in the immunologic and immunohistochemical 
analyzes. Due to the fact that the obtained materials of these patients are the subject 
of many different studies within the Leiden University Medical Center, a selection 
bias occurred for the inclusion of patients diagnosed with a bigger tumor volume. 
Because a larger tumor is associated with the presence of lymph node metastases37, 
a larger fraction of the selected patients harbored metastatic disease in the pelvic 
lymph nodes than would be expected at these early disease stages (Table 1). 
Histologic specimens of normal cervices from women (n=9; median age, 46 years; 
range, 31-60), who underwent hysterectomies for benign uterine diseases with no 
cervical abnormalities served as control for the cervical carcinoma group. These spec-
imens were obtained as paraffin-embedded blocks from the Department of Pathology 
of the Leiden University Medical Center. 
Antigens and T-cell assay
A set of peptides spanning the whole HPV16 and 18 E6 and E7 proteins was used 
for the T-cell proliferation assays. For these assays, 32-mer peptides of the HPV16 
E6 protein and the 35-mer peptides of the HPV16 E7 protein with an overlap of 14 
amino acids were used in pools of two peptides per pool. The HPV18 peptides con-
sisted of 15 E6 and 9 E7 22-mer peptides (overlap 12 amino acids) and were used 
in pools of four peptides per pool. The peptides were synthesized and dissolved as 
described previously38. The peptide pools are indicated by the first and last amino 
acid of the region in the protein covered by the two peptides (e.g., E61-50, residues 1-
32 and 19-50). To examine the presence of circulating HPV-specific T-cells, freshly 
isolated PBMCs were incubated with the indicated peptide pools in eight parallel 
microcultures as described previously17. Medium alone was taken along as a negative 
control, and the memory response mix or MRM (dilution, 1: 50) served as a posi-
tive control17. Supernatant (50 µl) from the microcultures was taken at day 6 after 
incubation and stored at -20°C until cytokine analysis. Peptide-specific proliferation 
was measured at day 7 by [3H]thymidine incorporation. Cultures were scored positive 
when the proliferation of ≥ 75% of the test wells exceeded the mean proliferation + 3 
x SD of the control wells containing medium only, and the stimulation index, defined 
as the mean of all test wells divided by the mean of the control wells, was ≥ 339. 
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Cytokine analysis
The detection of cytokines in the supernatants of the short-term proliferation assays 
was done using the cytometric bead array (CBA; Becton Dickinson, Etten-Leur, the 
Netherlands). This technique allows the simultaneous detection of six different T-
helper (Th) 1 and Th2 cytokines:  IFNγ, tumor necrosis factor α, interleukin (IL)-2, 
IL-4, IL-5, and IL-10. The CBA was done according to the manufacturer's instruc-
tions. Cutoff values were based on the standard curves of the different cytokines (100 
pg/ml for IFNγ and 10 pg/ml for the remaining cytokines). Antigen-specific cytokine 
production was defined as a cytokine concentration above cutoff level and more than 
twice the concentration of the medium control17,40.
Quadruple immunostaining of tumor tissues and infiltrating lymphocytes
A newly developed technique for simultaneous immunohistochemical staining of 
four different epitopes was applied to 4 µm formalin-fixed, paraffin-embedded tissue 
sections41. The AE1/AE3 antibody (IgG1; DAKO, Glostrup, Denmark) was added and 
slides were incubated overnight. Slides were washed and incubated first with cationic 
BSA (Aurion, Wageningen, the Netherlands). After 2 h of incubation with ultrasmall 
gold-labeled goat anti-mouse antibody (Aurion), silver enhancement was done using 
the Aurion enhancement kit. 
The silver-stained slides were incubated overnight with a mix of either ab828 (anti-
CD3, rabbit polyclonal antibody; Abcam, Cambridge, United Kingdom), hNK-1 (anti-
CD57, mouse IgM, culture supernatant of a hybridoma grown in our own labora-
tory), and 4B11 (anti-CD8, mouse IgG2b; Novocastra, Newcastle upon Tyne, United 
Kingdom) or anti-CD4 (rabbit polyclonal IgG, Santa Cruz Biotechnology, Santa Cruz, 
CA) and CD45RO (mouse monoclonal IgG2a, DAKO). Slides were washed and incu-
bated with the appropriate combination of fluorescent antibody conjugates (goat 
anti-rabbit IgG-Alexa Fluor 546, goat anti-mouse IgM-Alexa Fluor 488, and goat 
anti-mouse IgG2b-Alexa Fluor 647 or goat anti-rabbit IgG-Alexa Fluor 546 and 
goat anti-mouse IgG2a-Alexa Fluor 647). Alexa Fluor conjugates were obtained from 
Molecular Probes (Leiden, The Netherlands). 
Our pilot study revealed that, without counterstaining with anti-CD3, the enumera-
tion of infiltrating CD4+ T-cells based only on their morphologic appearance was 
difficult. In a selected set of tumors, we compared the numbers of CD4+ T-cells by 
direct staining with anti-CD4 or by indirect identification using a double staining of 
anti-CD3 and anti-CD8 by counting the CD3+CD8- cells. Because the indirect tech-
nique resulted in similar numbers of T-cells, we used CD3+CD8- cells as a marker for 
CD4+ T-cells in all other tumor sections. 
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The images were captured with a confocal laser scanning microscope (Zeiss LSM510, 
Zeiss, Jena, Germany). Fifteen images were scanned per slide. For each case, one suc-
cessive negative control slide was included. These controls were silver stained but the 
primary lymphocyte-specific antibody step was omitted to ensure the specificity of 
the secondary antibody binding. Three images were taken at different positions on 
the control slide using exactly the same confocal laser scanning microscope multi-
track settings as for the respective case. Intraepithelial and stromal infiltrating lym-
phocyte cell counts were done by two independent investigators (MvP and ESJ) and 
represented as the number of cells per mm2. 
Immunostaining of immature/activated dendritic cells and regulatory Foxp3+ T-cells
Paraffin sections (4 µm) were used for standard immunohistochemical staining of 
infiltrating antigen-presenting cells. The mouse monoclonal antibodies directed 
against CD1a (IgG1; Neomarkers-Lab Vision, Fremont, CA) and DC-Lamp (IgG1; 
Immunotech, Marseille, France) were used for staining immature or activated dendritic 
cells, respectively. The mouse monoclonal Foxp3 antibody (clone 236A/E7; Abcam, 
Cambridge, MA) was used for detecting regulatory T- cells. Briefly, slides were depa-
raffinized and antigen retrieval was done using EDTA for the DC-Lamp staining and 
trypsin pretreatment for the CD1a staining. After an overnight incubation, the biotin-
labeled rabbit anti-mouse immunoglobulins and a biotinylated horseradish peroxi-
dase-streptavidin complex (both were from Dako) were applied. To visualize immune 
complexes, a 0.05% solution of diaminobenzidine (Sigma, St. Louis, MO) containing 
0.0018% H2O2 in a 0.05 mol/L Tris-HCl buffer (pH 7.6) was used. Counterstaining of 
the slides was done with Mayer’s hematoxylin. Cells were quantified by counting the 
tumor-infiltrating Langerhans cells and the stromal DC-Lamp+ cells per 10 randomly 
selected high-power fields (x 400 magnification). Foxp3+ T-cells were counted sepa-
rately both in the tumor fields and in the stromal compartment and represented as 
the number of cells per mm2. 
Statistical analysis
A two-tailed t test with Welch correction or Mann-Whitney test (when applicable) 
was applied for the analysis of the numbers of infiltrating immune cells or ratios in 
the different patient groups divided into categories that were based on the following 
clinical prognostic factors:  invasion depth of tumor in cervical tissue (< 15 or ≥ 15 
mm), tumor size (< 4  or ≥ 4 cm), vasoinvasion, and lymph node metastases5,7,8.
Chi-square analyses for trend were used to test the relationship between different cat-
egories of CD8+ T-cell infiltration versus lymph node status. Categories were based 
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on 25th percentile and 75th percentile. Spearman rank analysis was done to test the 
association between the different types of infiltrating immune cells. Fisher’s exact test 
(two-tailed) was used to analyze both the HPV-specific immunity and lymph node 
metastases and the relationship between different categories of infiltrating CD8+ 
T-cells, CD4+ T-cells and regulatory T-cells and combinations hereof versus lymph 
node status. Statistical analyses were done using Graphpad Instat software (version 
3.0) and GraphPad Prism 4 (GraphPad Software, San Diego, CA).
Results
The tumors of cervical carcinoma patients display a wide variety in the number of 
tumor-infiltrating T-cells
A detailed examination of the antitumor response was done in a group of 59 patients 
with HPV16+ or HPV18+ cervical cancer (Table 1). The numbers of CD3+ T-cells and 
regulatory T-cells (Foxp3+) present in stroma or between epithelial tumor cells were 
counted. Because previous reports strongly indicated that, especially intraepithelial 
infiltration by T-cells was correlated with prognosis in cervical cancer10,11, the numbers 
of CD3+CD8+ T-cells, CD3+CD8+CD57+ T-cells, and CD3+CD8- (CD4) T-cells specifi-
cally infiltrating the tumor epithelium were examined. Additionally, tumor-infiltrat-
ing immature dendritic cells (CD1a+) and activated dendritic cells (DC-Lamp+) in the 
tumor were enumerated. To be able to assess to which degree immune infiltration was 
due to tumor-specific immunity, we also analyzed the infiltration of immune cells in 
sections of normal cervical epithelium that had been obtained from a group of nine 
patients with no evidence of cervical abnormalities. In figure 1A, an example of the 
analysis of CD3+ (red) and CD3+CD8+ (purple) T-cell infiltration by quadruple-color 
confocal miscroscopy is shown. CD3+ T-cells were present both in normal cervical 
tissue and in tumors. More stroma resident CD3+ T-cells were detected in tumor 
tissue than in normal cervical tissue (patients:  mean, 966±635 cells per mm2; con-
trols:  mean, 385±96 cells per mm2; p<0.0001). The mean number of intraepithelial 
CD3+CD8+ or CD3+CD8- (CD4) T-cells that infiltrated tumors of all patients was 
about as twice as high when compared with those infiltrating normal cervices, but 
the number of intraepithelial tumor-infiltrating T-cells varied enormously (range 2.9-
592 per mm2) between patients (Figure 2). The number of both intraepithelial (range 
0.6-56 mm2) and stroma (range 22-249 per mm2) resident regulatory (Foxp3+) T-cells 
was significantly enhanced in cervical carcinoma when compared to control cervi-
cal tissue (p<0.001; Figures 1 and 2). Furthermore, small numbers of intraepithelial 
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A. To detect tumor-infiltrating T-cells, 4 µm tissue sections were stained with anti-CD3 (red), anti-CD8 
(blue), and anti-CD57 (green) followed by the appropriate combination of fluorescent antibody 
conjugates. Images were captured with a confocal laser scanning microscope (Zeiss LSM510) and 
used to count all T-cells that were located intraepithelial and in the stroma of 15 different (tumor) 
fields in each tissue section. The number of T-cells per tumor area (T-cells/ mm2 tumor epithelium) 
was calculated. Three representative examples are shown. Left, example of a normal cervix. Middle, 
tumor tissue of a patient without lymph node metastases displaying a systemic immune response 
to HPV (patient 161) that shows intraepithelial infiltration by CD3+CD8- (CD4) T-cells (red) and 
CD3+CD8+ (purple) T-cells. Right, tumor tissue of a patient with lymph node metastases and no 
systemic immune response (patient 148). 
B. To detect regulatory T-cells, 4 µm paraffin sections were stained with the mouse monoclonal Foxp3 
antibody (clone 236A/E7).  The number of positive cells per 10 randomly selected high-power fields 
(x400 magnification) was counted separately both in the tumor fields and in the stromal compart-
ment and represented as the number of cells per mm2. Example of a normal cervix (left) and lymph 
node-negative patient 161 (middle) showing rare infiltration by regulatory T-cells (arrow).  Right, 
tumor tissue of a patient with lymph node metastases and strong infiltration by regulatory T-cells 
(patient 148).
Figure 1. Intraepithelial infiltrating T-cells in cervical cancer patients and in healthy controls. 
CD3+CD8+CD57+ terminally activated effector T-cells42, and natural killer (NK)-like 
cells (CD3-CD57+) were observed in cervical tumors (Figure 2). 
The degree of intraepithelial infiltration by CD8+ T-cells was paralleled by other 
types of immune cells infiltrating the tumor. Spearman rank analysis revealed signifi-
cant correlations between the number of intraepithelial CD3+CD8+ T-cells and the 
number of CD3+CD8- T-cells (r=0.64, p<0.0001), CD3+CD8+CD57+ T-cells (r=0.71, 
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p<0.0001), CD3-CD57+ NK-like cells (r=0.43, p<0.001) and regulatory T-cells (r=0.45, 
p<0.001) that infiltrated the tumor of each patient. 
The number of tumor-infiltrating immature (CD1a+) dendritic cells approximated two 
to three cells per 10 high-power fields both in the controls and in the patients. Small 
numbers of activated dendritic cells (DC-Lamp+) were detected in all tumors but were 
virtually absent in the normal cervices (p<0.001; Figure 2). In general, the number of 
tumor-infiltrating immature and activated dendritic cells was correlated per tumor 
(Spearman rank analysis r=0.34, p=0.008). Together, these data indicate that there is 
great variation in the number of immune cells that can infiltrate HPV-induced cervi-
cal tumors. Furthermore, on the recruitment of higher numbers of CD8+ T-cells, there 
is also a more effective infiltration of the tumor by other immune cells, suggesting 
an intense interaction between tumor and immune system. 
Strong tumor immunity is present in a subset of patients without lymph node 
metastases
Histopathologic factors known to affect the prognosis of patients are vasoinvasion, 
(Left) Cell densities of only the  intraepithelial tumor-infiltrating T-cells  (expressed as cell number/mm2 ± 
SD) were enumerated because of previous reports stating that the infiltration of cervical cancer cell nests 
displays the strongest correlation with prognosis10,11. The number of both intraepithelial (IE) and stromal 
tumor-infiltrating regulatory T (Treg) cells, identified through Foxp3+ staining, was quantified because 
there were no data to support that either location is more important.
(Right) Cell densities of intraepithelial and stromal tumor-infiltrating CD1a and DC-Lamp+ dendritic cells 
(DC) depicted per 10 high-power fields ± SD. 
Figure 2. Comparison of immune cells infiltrating normal cervical tissue or cervical carcinoma. 
Cervical cancer infiltrating T-cells versus prognosis 141
the size of a tumor, and the depth of tumor invasion into the normal cervical stroma5-
8. Especially, the presence of lymph node metastases is a strong independent prognos-
tic factor associated with a decrease in overall and disease-specific survival and an 
increase of recurrence in cervical cancer5,6. Stratification of the patient group based 
on clinical prognosis, as predicted by these histopathologic factors, revealed that 
the mean number of intraepithelial CD8+ T-cells was higher in the group of patients 
without lymph node metastases (LN-) than in the group of patients with a poor 
prognosis (LN+; 151±126 versus 108±147, respectively; p=0.02). No differences were 
observed when other types of infiltrating immune cells, including CD3-CD57+ (NK) 
and CD8CD57+ cells known to play a role in controlling tumor metastases in other 
cancers43, 44, were analyzed. For the other histopathologic factors, we found a cor-
relation neither between vasoinvasion (p=0.10), infiltration depth of tumor (p=0.14), 
or tumor size (p=0.31) and CD8+ T-cell infiltration nor for the infiltration by other 
immune cells. 
To confirm the relationship between intratumoral CD8+ T-cell infiltration and lymph 
node status, we reanalyzed our patient group and stratified patients according to 
either weak infiltration (25 percentile:  ≤49.9 intraepithelial CD8+ T-cells per mm2; 
n=5 LN-; n=10 LN+), intermediate infiltration (25-75 percentile, n=19 LN-; n=10 
LN+) or strong infiltration (75 percentile:  ≥144 intraepithelial CD8+ T-cells per mm2; 
n=12 LN-; n=3 LN+) with intraepithelial CD8+ T-cells. Based on the fraction of LN- 
patients within these groups, there was a significant association between the number 
of infiltrating CD8+ T-cells and the absence of lymph node metastases (Chi-square 
for trend 6.9, p<0.01; Figure 3). 
In other cancers, a high ratio between the CD8+ T-cells and CD4+ T-cells or regula-
tory T-cells is associated with favorable prognosis32,33, indicating that especially the 
proportion between the different subtypes of immune cells within the tumor of each 
individual patient is important. In view of the wide ranges observed for the numbers 
of infiltrating CD3+CD8+, CD3+CD8- and regulatory T-cells cells, the mean num-
ber of each type of infiltrating immune cells may not differ considerably between 
subgroups of patients, whereas the ratio between these subtypes can. Therefore, the 
ratios between CD3+CD8+, CD3+CD8-, and regulatory T-cells cells were calculated 
for each patient. The mean CD8+/CD8- (CD4) T-cell ratio did not differ between 
normal tissue and that of the group of all patients (3.1±2.4 vs. 2.8±2.8, respectively). 
However, the CD8/CD4 T-cell ratio was considerably lower in the LN+ patient group 
(1,9±1,7) than in the LN- patient group (p=0.01), who displayed a CD8+/CD8- (CD4) 
T-cell ratio (3,3±3,2) similar to what is found in normal cervices. The ratio between 
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intraepithelial CD8+ T-cells and either stromal (1.4±1.4) or intraepithelial (27±56) 
regulatory T-cells was much lower in cancer patients than in normal cervical tis-
sue (22±18 and 118±100, respectively; p<0.001). Importantly, a higher CD8+/stromal 
regulatory T-cell ratio was found in the LN- patient group than for the LN+ patient 
group (1.6±1.5 vs. 0.9±1.0; p<0.05). Thus, evaluation of cervical cancer patients with 
respect to their lymph node status revealed that the LN- patient group, which in 
general has a good prognosis, displays significantly higher number of intraepithelial 
CD8+ T-cells, a higher CD8+/CD4+ T-cell ratio, and a higher CD8+/regulatory T-cell 
ratio than the group of patients with lymph node metastases.
To assess the influence of CD4+ T-cells or regulatory T-cells on the association of 
infiltrating CD8+ T-cells with lymph node status, two groups of patients that repre-
sented the two most extreme situations of tumor-infiltrating T-cells were analyzed. 
In these two groups, patients who displayed either a favorable constitution of tumor 
infiltration (higher number of intraepithelial CD8+ T-cells, a higher CD8+/CD4+ T-
Patients (n=59) were stratified according to weak infiltration  (25 percentile: ≤49.9 intraepithelial CD8+ 
T-cells per mm2), intermediate infiltration (25-75 percentile), or strong infiltration (75 percentile: ≥144 
intraepithelial CD8+ T-cells per mm2) with intraepithelial CD8+ T-cells. The percentage of patients with 
lymph node metastases of the tumor (LN+, n=23) or without lymph node metastases (LN-, n=36) is indi-
cated per subgroup. The group of patients with weak infiltration consisted of 5 LN- and 10 LN+ patients, 
the group of patients with intermediate infiltration consisted of 19 LN- and 10 LN+ patients, and the group 
of patients with strong infiltration consisted of 12 LN- and 3 LN+ patients.  There was a significant asso-
ciation between a higher number of infiltrating CD8+ T-cells and the absence of lymph node metastases 
(Chi-square 6.9; p<0.01). 
Figure 3. The prognostic value of intraepithelial tumor-infiltrating CD8+ T-cells, CD4+ 
T-cells, and regulatory T-cells. 
intraepithelial tumor-infiltrating CD8+ T-cells
(per mm2 tumor)
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cell ratio, and a higher CD8+/regulatory T-cell ratio) or a nonfavorable constitution 
of infiltration (lower CD8+ T-cell count and a low CD8+/CD4+ and CD8+/regulatory 
T-cell ratio) were included. Although the fraction of LN- patients was higher among 
the patients with a higher CD8+ T-cell infiltration (≥95.2 cells per mm2; 50 percen-
tile), this was not significant (p=0.06). Selection based on CD8+ T-cells and both 
the CD8+/CD4+ T-cell ratio (50 percentile ratio, 2.235) and CD8+/stromal regulatory 
T-cell ratio (50 percentile ratio, 0.747) resulted in significantly increased fraction of 
LN- patients within the group of patients with a favorable tumor infiltration when 
compared with the group of patients with a less favorable infiltration (p=0.01), but 
this increase was not significant when compared with the fraction of LN- patients 
within the group of patients selected only based on a higher CD8+ T-cell infiltra-
tion. These data suggest that coinfiltrating CD4+ T-cells and regulatory T-cells have 
a subtle influence on the lymph node status of patients but only in cases that they 
match the number of infiltrating CD8+ T-cells. However, the absence of lymph node 
metastases is most prominently associated with a robust CD8+ tumor-infiltration. 
Strong CD8+ T-cell infiltration is predominantly observed in the subgroup of 
LN- patients with circulating HPV-specific T-cells
From 50 patients, sufficient amounts of PBMC were available to study the systemic 
HPV-specific T-cell response using a methodology that detects CD4+ T-cell responses 
against the HPV early antigens17,19,45. In this group, 24 patients displayed a systemic 
HPV-specific T-cell response against one or more of the E6 and/or E7 peptide pools 
while 26 patients failed to produce a detectable T-cell response, a frequency that 
is in line with our previous findings17. Examples shown in Figure 4A reveal that 
some patient PBMC samples show proliferative T-cell reactivity against only a single 
peptide pool, whereas other samples display a broader response against up to three 
peptide pools. As illustrated in Figure 4B, IFNγ-production is found in some of the 
culture supernatants, but this did not depend on the strength of the proliferative 
response (compare patients 239 and 161 in Figure 4). Ten of the 24 patients with a 
systemic HPV-specific immune response produced IFNγ on stimulation with at least 
one of the peptide pools. There was no direct relationship between the presence (IR+) 
or absence (IR-) of circulating HPV-specific T-cells and the lymph node status of 
patients (p=1.0) or with the magnitude of tumor-infiltrating T-cells (e.g., IR status 
versus CD8+ T-cells; p=0.31). 
Therefore, the group of patients was further subdivided according to both the HPV 
immune status and lymph node status (Table 2). Considerable differences were found 
in the groups of patients that displayed a systemic antitumor response. The group 
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of LN-IR+ patients displayed a significant higher number of intraepithelial tumor-
infiltrating CD8+ T-cells than LN- patients without a concomitant systemic immune 
response (p=0.02; Table 2). Furthermore, within the group of LN- patients, not only 
intraepithelial CD8+ T-cells but also the number of CD8+CD57+ terminally activated 
effector T-cells and regulatory (Foxp3+) T-cells as well as CD8+/CD4+ T-cell ratio 
were increased in the group of LN-IR+ patients (p=0.03; Table 2). These data suggest 
that, within the group of LN- patients who in general display a better prognosis, a 
subgroup can be identified. The patients within this subgroup mount a significantly 
stronger antitumor response, which is reflected by circulating tumor-specific T-cells, 
a robust CD8+ tumor infiltration, and a higher CD8+/CD4+ T-cell ratio.
Unexpectedly, the LN+IR+ group displayed the lowest numbers of tumor-infiltrat-
ing immune cells (Table 2). In addition, this group displayed a significantly lower 
CD8+/CD8- (CD4) ratio (p=0.003) when compared with the LN-IR+ group (Table 2). 
Figure 4. Two representative examples of patient-derived T-cell cultures that recognize HPV-specific 
peptide pools of HPV16 or 18 but display different cytokine profiles. 
A. proliferative responses of patients 239 (left) and 161 (right). Each circle represents the prolifera-
tion of an individual microculture (n=8); supernatants of the positive responses (arrows) were 
tested for cytokine production.
B. corresponding cytokine levels produced on antigenic stimulation of these microcultures are 
depicted, indicating that IFNγ production is found in some but not all of the supernatants iso-
lated from the HPV-specific T-cell proliferative cultures.
Cervical cancer infiltrating T-cells versus prognosis 145
Furthermore, regulatory T-cells residing in the tumor stroma readily outnumbered 
infiltrating CD8+ T-cells, resulting in a low CD8+/ regulatory T-cell ratio (Table 2). 
In contrast, in the group of LN-IR+ patients, the number of infiltrating CD8+ T-cells 
surpassed that of regulatory T-cells in the stroma despite the fact that in this group 
also more regulatory T-cells were recruited into the tumor. Consequently, the ratio 
between intraepithelial CD8+ T-cells and regulatory T-cells in the stroma is higher in 
the group of LN-IR+ than in the LN+IR+ group (p<0.001). There were no significant 
differences between the groups of LN- or LN+ patients without circulating HPV-spe-
cific T-cells (IR-).
Table 2. Summary of the number of tumor-infiltrating immune cells in groups of patients 
stratified according to the absence (LN–) or presence (LN+) of lymph node metastases and 
circulating HPV-specific T-cells.
 LN– LN+
 
 IR– (n=17) IR+ (n=14) IR– (n=9) IR+ (n=10)
CD8+ T-cellsa 90±65 200±145  129±190 58±46
CD8- (CD4+) T-cells 42±29 62±46  54±75 61±69
CD3+CD8+CD57+ T-cells 9,8±12 13±15  8,4±16 5,6±8,5
CD3-CD57+ NK-like cells 4,4±6,7 3,1±2,5  3,8±5,9 2,0±2,2
IE Foxp3+ T-cellsb 7,5±7,1 15±9,5  10±15 7,1±5,8
stromal Foxp3+ T-cells 100±69 136±69  100±44 104±42
CD8+/CD8- (CD4) T-cell ratioc 2,3±1,3 4,4±4,5  2,6±2,1 1,5±1,6
CD8+/IE regulatory T-cell ratioc 27±47 28±40  51±112 9,7±11
CD8+/stromal regulatory T-cell ratioc 1,3±1,3 1,8±1,6  1,2±1,3 0,4±0,2
a Cell densities of only the intraepithelial tumor-infiltrating T-cells (expressed by cell number/mm2 ± SD) 
were enumerated because of previous reports stating that the infiltration of tumor cell nests displays the 
strongest correlation with prognosis10,11,29,30,31,33.
b The number of both intraepithelial (IE) and stromal tumor-infiltrating regulatory (Foxp3+) T-cells was 
quantified because there is no evidence that either location is more important. 
c The ratio of intraepithelial CD8+ and intraepithelial CD8- (CD4+) T-cells was determined as well as the 
ratio between intraepithelial CD8+ T-cells and regulatory (Foxp3+) T-cells.
C
ha
pt
er
 7
146
Discussion
In cervical carcinoma, infiltration of intratumoral lymphocytes has been associated 
with an improved clinical outcome10,11. In the present study, we did a detailed analy-
sis of the immune response in patients with HPV-induced cervical cancer. Although 
infiltration of most TIL subtypes positively correlated with each other, intraepithelial 
CD8+ T-cells were the only subtype that correlated with a lack of pelvic lymph node 
spread and, therefore, might have a better prognosis. This observation is consistent 
with other studies, indicating that strong intraepithelial CD8+ T-cell infiltration is 
associated with a favorable course of disease in colorectal cancer29,30, ovarian can-
cer33,46 and endometrial carcinoma31. In addition, we showed that failure of CD8+ T-
cells to substantially infiltrate the tumor results in a significantly lower CD8+/CD4+ 
T-cell ratio in patients with lymph node metastases when compared with patients 
without metastatic disease or to normal cervical tissue. Similar observations were 
made in colorectal and ovarian cancer32,33. Importantly, recently, we detected and 
isolated HPV-specific CD4+ Th1 cells as well as HPV-specific CD4+Foxp3+ regula-
tory T-cells from several lymph nodes and tumors derived from patients with cervi-
cal cancer49, indicating that part of the cervical tumor-infiltrating CD4+ T-cells can 
suppress local immunity. The number of regulatory T-cells in cervical carcinoma was 
directly examined by detection of Foxp3, serving as specific marker for at least a 
subset of regulatory T-cells34. In healthy cervices, such regulatory T-cells were almost 
absent. In contrast, cervical tumor tissue was strongly infiltrated by Foxp3+ T-cells 
(Figure 2). We did not find a direct correlation between the presence of regulatory 
T-cells and the lymph node status of patients, but patients without such metastases 
displayed a significantly more favorable intraepithelial CD8+/regulatory T-cell ratio. 
As expected, the strongest correlation was found when the CD8+/regulatory T-cell 
ratio was determined with Foxp3+ T-cells present in the tumor stroma, where also 
most of the CD4+ T-cells reside (Figure 1). This suggests that a robust CD8+ T-cell 
infiltration can overcome the negative effects of tumor resident CD4+ regulatory T-
cells resulting in a failure of the tumor to metastasize to the lymph nodes. A recent 
comprehensive study of the percentage of CD8+ T-cells, CD4+ T-cells, and regula-
tory T-cells in both tumor-draining lymph nodes and tumor of mice suggests that 
this concept may indeed be true. In comparison with lymph nodes, CD8+ T-cells are 
underrepresented in the tumor when compared with CD4+ T-cells and regulatory T-
cells47. Releasing the breaks on T-cells by anti-CTLA-4 therapy strongly increased the 
number of tumor-infiltrating CD8+ T-cells, resulting in a significant increase of the 
CD8+/ regulatory T-cell ratio, and this correlated with tumor rejection. Interestingly, 
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a therapy-induced decrease in this ratio was observed in the tumor draining lymph 
node47.
In addition to the local immune response, we also analyzed systemic antitumor 
immunity. For this, we exploited the T-cell response against the tumor-specific anti-
gens E6 and E7 encoded by HPV. Previous studies indicated that the expression of 
E6 and E7 in cervical carcinoma results in the induction of a detectable HPV-specific 
proliferative CD4+ T-cell response in approximately half of all cases17-19,22,23,48. Here, 
circulating HPV-specific proliferative T-cells were detected in 24 of 50 cases. There 
was no direct correlation between the presence of HPV-specific systemic immunity 
and lymph node metastases, which were present in approximately half of the 24 
patients displaying HPV-immunity. However, subdivision according to both lymph 
node status and HPV-immune status revealed an intriguing picture. 
First, the higher number of CD8+ T-cells, higher CD8+/CD4+ T-cell ratio and higher 
CD8+/regulatory T-cell ratio that was found in the group of LN- patients, when 
compared with the group of LN+ patients, could be attributed to those LN- patients 
displaying a concomitant systemic tumor-specific immune response (LN-IR+; Table 
2). The number of infiltrating CD8+ T-cells was higher in this subgroup of patients 
than in the LN- patients without such a response. Strikingly, CD8+ T-cell infiltration 
in the LN-IR- patient group was comparable with that of LN+ patients. In ovarian, 
endometrial, and colorectal cancer, strong intraepithelial CD8+ T-cell infiltration has 
a favorable prognostic effect29-31,33,46 suggesting that especially the LN-IR+ subgroup 
of lymph node-negative cervical cancer patients will display a better disease course.
Second, we observed that the most extreme differences occurred among the patients 
with a positive HPV immune status. Whereas in the LN- patient group the presence 
of circulating HPV-specific T-cells was associated with higher numbers of infiltrat-
ing T-cells (LN-IR+), the opposite was observed in the LN+ patient group (Table 2). 
The LN+IR+ group displayed the lowest number of intratumoral CD8+ T-cells, and 
the lowest CD8+/regulatory T-cell ratio. These data suggests that the presence of 
circulating HPV-specific T-cells not necessarily reflects a proper antitumor response 
and implies that the presence of tumor cell metastases in the draining lymph nodes 
may direct the development of unwanted tumor-specific T-cell responses that can 
counteract the recruitment of effector cells in the tumor. Indeed, HPV16 E6-specific 
CD4+ Foxp3+ regulatory T-cells isolated from tumor-positive lymph nodes can sup-
press the action of antigen-specific T-cells at a one-to-one ratio49. Notably, ratios of 
one to one and even two to one (regulatory T-cells/ CD8+ T-cells) are present in the 
tumors of LN+ patients (Table 2). 
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In conclusion, our results show that the presence of intraepithelial CD8+ T-cells infil-
trating tumor cells is associated with the lack of tumor metastases in the draining 
lymph nodes of cervical cancer patients. Because the absence of lymph node metas-
tases is strongly associated with a better prognosis, patients with strong CD8+ T-cells 
infiltrating tumor cells are likely to display an improved clinical outcome in cervical 
cancer. Moreover, our data suggest that a subgroup of patients within the cohort of 
LN- patients, who may experience the relatively best course of disease, exists. In view 
of our current data on the relationships among lymph node status, systemic antitumor 
immunity, and tumor-infiltration, studies evaluating immunocorrelations between 
vaccine-induced tumor-specific T-cell responses and clinical outcome should include 
an examination of the constitution of the local immune response.
Acknowledgments
We thank all patients who have participated in this study. We also thank F. Prins for 
his excellent help in the analysis of tissue sections by confocal microscopy. 
Cervical cancer infiltrating T-cells versus prognosis 149
References
 1. Bosch FX, Manos MM, Munoz N, et al. Prevalence 
of human papillomavirus in cervical cancer:  a 
worldwide perspective. International biological 
study on cervical cancer (IBSCC) Study Group. J 
Natl Cancer Inst 1995;  87:  796-802.
 2. Munoz N, Bosch FX, de Sanjose S, et al. 
Epidemiologic classification of human papillo-
mavirus types associated with cervical cancer. N 
Engl J Med 2003; 348(6): 518-527.
 3. zur Hausen H. Papillomaviruses and cancer: 
from basic studies to clinical application. Nat Rev 
Cancer 2002; 2: 342-350.
 4. Bosch FX, de Sanjose S. Human papillomavirus 
and cervical cancer--burden and assessment of 
causality. J Natl Cancer Inst Monogr 2003: 3-13.
 5. Singh N, Arif S. Histopathologic parameters of 
prognosis in cervical cancer--a review. Int J 
Gynecol Cancer 2004; 14: 741-750.
 6. Thomas GM. Adjuvant therapy after primary sur-
gery for stage I-IIA carcinoma of the cervix. J 
Natl Cancer Inst Monogr 1996: 77-83.
 7. Snijders-Keilholz A, Hellebrekers BW, Zwinderman 
AH, et al. Adjuvant radiotherapy following radi-
cal hysterectomy for patients with early-stage 
cervical carcinoma (1984-1996). Radiother Oncol 
1999; 51: 161-167.
 8. Kenter GG, Hellebrekers BW, Zwinderman KH, 
et al. The case for completing the lymphadenec-
tomy when positive lymph nodes are found dur-
ing radical hysterectomy for cervical carcinoma. 
Acta Obstet Gynecol Scand 2000; 79: 72-76.
 9. zur Hausen H. Papillomavirus infections - a 
major cause of human cancers. Biochimica et 
Biophysica Acta 1996; 1288: F55-F78.
10. Bethwaite PB, Holloway LJ, Thornton A, et al. 
Infiltration by immunocompetent cells in early 
stage invasive carcinoma of the uterine cervix:  a 
prognostic study. Pathology 1996; 28: 321-327.
11. Chao HT, Wang PH, Tseng JY, et al. Lymphocyte-
infiltrated FIGO Stage IIB squamous cell carci-
noma of the cervix is a prominent factor for dis-
ease-free survival. Eur J Gynaecol Oncol 1999; 
20: 136-140.
12. Evans EM, Man S, Evans AS, et al. Infiltration of 
cervical cancer tissue with human papillomavi-
rus-specific cytotoxic T-lymphocytes. Cancer Res 
1997; 57: 2943-2950.
13. Hohn H, Pilch H, Gunzel S, et al. Human papil-
lomavirus type 33 E7 peptides presented by HLA-
DR*0402 to tumor-infiltrating T cells in cervical 
cancer. J Virol 2000; 74: 6632-6636.
14. Hohn H, Pilch H, Gunzel S, et al. CD4+ tumor-
infiltrating lymphocytes in cervical cancer rec-
ognize HLA-DR- restricted peptides provided by 
human papillomavirus-E7. J Immunol 1999; 163: 
5715-5722.
15. Hilders CG, Ras L, van Eendenburg JD, et al. 
Isolation and characterization of tumor-infiltrat-
ing lymphocytes from cervical carcinoma. Int J 
Cancer 1994; 57: 805-813.
16. Santin AD, Bellone S, Palmieri M, et al. Induction 
of tumor-specific cytotoxicity in tumor infiltrat-
ing lymphocytes by HPV16 and HPV18 E7-pulsed 
autologous dendritic cells in patients with cancer 
of the uterine cervix. Gynecol Oncol 2003; 89: 
271-280.
17. de Jong A, van Poelgeest MI, van der Hulst JM, et 
al. Human papillomavirus type 16-positive cervi-
cal cancer is associated with impaired CD4+ T-
cell immunity against early antigens E2 and E6. 
Cancer Res 2004; 64: 5449-5455.
18. van der Burg SH, Ressing ME, Kwappenberg KM, 
et al. Natural T-helper immunity against human 
papillomavirus type 16 (HPV16) E7-derived pep-
tide epitopes in patients with HPV16-positive 
cervical lesions:  identification of 3 human leu-
kocyte antigen class II-restricted epitopes. Int J 
Cancer 2001; 91: 612-618.
19. Welters MJ, de Jong A, van den Eeden SJ, et 
al. Frequent display of human papillomavirus 
type 16 E6-specific memory t-Helper cells in the 
healthy population as witness of previous viral 
encounter. Cancer Res 2003; 63: 636-641.
20. Welters MJ, van der Logt P, van den Eeden SJ, et 
al. Detection of human papillomavirus type 18 
E6 and E7-specific CD4+ T-helper 1 immunity 
in relation to health versus disease. Int J Cancer 
2006; 118: 950-956.
21. Ressing ME, van Driel WJ, Celis E, et al. 
Occasional memory cytotoxic T-cell responses of 
patients with human papillomavirus type 16-pos-
itive cervical lesions against a human leukocyte 
antigen-A*0201-restricted E7-encoded epitope. 
Cancer Res 1996; 56: 582-588.
22. Bontkes HJ, de Gruijl TD, van den Muysenberg 
AJ, et al. Human papillomavirus type 16 E6/E7-
specific cytotoxic T lymphocytes in women with 
cervical neoplasia. Int J Cancer 2000; 88: 92-98.
23. Luxton JC, Rowe AJ, Cridland JC, et al. 
Proliferative T cell responses to the human pap-
illomavirus type 16 E7 protein in women with 
cervical dysplasia and cervical carcinoma and 
C
ha
pt
er
 7
150
in healthy individuals. J Gen Virol 1996; 77: 
1585-1593.
24. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 
study of HPV16-specific immunotherapy with 
E6E7 fusion protein and ISCOMATRIX adjuvant 
in women with cervical intraepithelial neoplasia. 
Vaccine 2004; 23: 172-181.
25. Davidson EJ, Boswell CM, Sehr P, et al. 
Immunological and clinical responses in women 
with vulval intraepithelial neoplasia vaccinated 
with a vaccinia virus encoding human papillo-
mavirus 16/18 oncoproteins. Cancer Res 2003; 
63: 6032-6041.
26. Muderspach L, Wilczynski S, Roman L, et al. A 
phase I trial of a human papillomavirus (HPV) 
peptide vaccine for women with high-grade cer-
vical and vulvar intraepithelial neoplasia who 
are HPV 16 positive. Clin Cancer Res 2000; 6: 
3406-3416.
27. Smyth LJ, Van Poelgeest MI, Davidson EJ, et al. 
Immunological responses in women with human 
papillomavirus type 16 (HPV-16)-associated ano-
genital intraepithelial neoplasia induced by het-
erologous prime-boost HPV-16 oncogene vacci-
nation. Clin Cancer Res 2004; 10: 2954-2961.
28. Baldwin PJ, van der Burg SH, Boswell CM, et al. 
Vaccinia-expressed human papillomavirus 16 
and 18 e6 and e7 as a therapeutic vaccination for 
vulval and vaginal intraepithelial neoplasia. Clin 
Cancer Res 2003; 9: 5205-5213.
29. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells 
infiltrated within cancer cell nests as a prognos-
tic factor in human colorectal cancer. Cancer Res 
1998; 58: 3491-3494.
30. Menon AG, Fleuren GJ, Alphenaar EA, et al. 
A basal membrane-like structure surrounding 
tumour nodules may prevent intraepithelial leu-
cocyte infiltration in colorectal cancer. Cancer 
Immunol Immunother 2003; 52: 121-126.
31. Kondratiev S, Sabo E, Yakirevich E, et al. 
Intratumoral CD8+ T lymphocytes as a prognostic 
factor of survival in endometrial carcinoma. Clin 
Cancer Res 2004; 10: 4450-4456.
32. Diederichsen AC, Hjelmborg JB, Christensen PB, 
et al. Prognostic value of the CD4+/CD8+ ratio 
of tumour infiltrating lymphocytes in colorec-
tal cancer and HLA-DR expression on tumour 
cells. Cancer Immunol Immunother 2003; 52: 
423-428.
33. Sato E, Olson SH, Ahn J, et al. Intraepithelial 
CD8+ tumor-infiltrating lymphocytes and a high 
CD8+/regulatory T cell ratio are associated with 
favorable prognosis in ovarian cancer. Proc Natl 
Acad Sci USA 2005; 102: 18538-18543.
34. Wolf D, Wolf AM, Rumpold H, et al. The expres-
sion of the regulatory T cell-specific forkhead 
box transcription factor FoxP3 is associated with 
poor prognosis in ovarian cancer. Clin Cancer Res 
2005; 11: 8326-8331.
35. Curiel TJ, Coukos G, Zou L, et al. Specific recruit-
ment of regulatory T cells in ovarian carcinoma 
fosters immune privilege and predicts reduced 
survival. Nat Med 2004; 10: 942-949.
36. Claas EC, Melchers WJ, van der Linden HC, et 
al. Human papillomavirus detection in paraffin-
embedded cervical carcinomas and metastases of 
the carcinomas by the polymerase chain reaction. 
Am J Pathol 1989; 135: 703-709.
37. Chen AC, Sung WH, Wang PH, et al. Correlation 
of three-dimensional tumor volumetry with cervi-
cal cancer prognostic parameters. Eur J Gynaecol 
Oncol 2002; 23: 401-404.
38. van der Burg SH, Kwappenberg KM, Geluk A, 
et al. Identification of a conserved universal Th 
epitope in HIV-1 reverse transcriptase that is pro-
cessed and presented to HIV-specific CD4+ T cells 
by at least four unrelated HLA-DR molecules. J 
Immunol 1999; 162: 152-160.
39. de Jong A, van der Burg SH, Kwappenberg KM, 
et al. Frequent detection of human papillomavi-
rus 16 E2-specific T-helper immunity in healthy 
subjects. Cancer Res 2002; 62: 472-479.
40. van der Burg SH, Menon AG, Redeker A, et al. 
Magnitude and polarization of P53-specific T-
helper immunity in connection to leukocyte infil-
tration of colorectal tumors. Int J Cancer 2003; 
107: 425-433.
41. van Vlierberghe RL, Sandel MH, Prins FA, et al. 
Four-color staining combining fluorescence and 
brightfield microscopy for simultaneous immune 
cell phenotyping and localization in tumor tissue 
sections. Microsc Res Tech 2005; 67: 15-21.
42. Mollet L, Sadat-Sowti B, Duntze J, et al. 
CD8hi+CD57+ T lymphocytes are enriched in 
antigen-specific T cells capable of down-modu-
lating cytotoxic activity. Int Immunol 1998; 10: 
311-323.
43. Tachibana T, Onodera H, Tsuruyama T, et al. 
Increased intratumor Valpha24-positive natural 
killer T cells:  a prognostic factor for primary 
colorectal carcinomas. Clin Cancer Res 2005; 11: 
7322-7327.
44. Menon AG, Janssen-van Rhijn CM, Morreau H, 
et al. Immune system and prognosis in colorectal 
cancer:  a detailed immunohistochemical analy-
sis. Lab Invest 2004; 84(4): 493-501.
45. de Jong A, van der Hulst JM, Kenter GG, et al. 
Rapid enrichment of human papillomavirus 
Cervical cancer infiltrating T-cells versus prognosis 151
(HPV)-specific polyclonal T cell populations for 
adoptive immunotherapy of cervical cancer. Int J 
Cancer 2005; 114: 274-282.
46. Zhang L, Conejo-Garcia JR, Katsaros D, et al. 
Intratumoral T cells, recurrence, and survival in 
epithelial ovarian cancer. N Engl J Med 2003; 
348: 203-213.
47. Quezada SA, Peggs KS, Curran MA, et al. CTLA4 
blockade and GM-CSF combination immuno-
therapy alters the intratumor balance of effector 
and regulatory T cells. J Clin Invest 2006; 116: 
1935-1945.
48. van der Burg SH, de Jong A, Welters MJ, et al. 
The status of HPV16-specific T-cell reactivity 
in health and disease as a guide to HPV vaccine 
development. Virus Res 2002; 89: 275-284.
49. van der Burg SH, Piersma SJ, de Jong A, et al. 
Association of cervical cancer with the presence 
of CD4+ regulatory T-cells specific for human 
papillomavirus antigens. Proc Natl Acad Sci USA 
2007; 104: 12087-12092.

C H A P T E R  8
Summary and general discussion

Summary and general discussion 155
Summary
The studies in this thesis analyzed the spontaneous and vaccine-induced HPV16-spe-
cific CD4+ T-cell responses in healthy individuals and in women with HPV-induced 
anogenital disease. The impact of type 1 Th-cell immunity on the clinical outcome 
of topical treatment with an immune modifier in patients with high-grade VIN was 
described. In addition, a detailed analysis of the local immune microenvironment in 
patients with cervical cancer and its relationship with the presence of systemic HPV-
specific T-cell responses and clinically important prognostic factors was performed. 
We conclude that in contrast to healthy individuals, patients with HPV-induced ano-
genital neoplasia display either impaired or absent systemic type 1 HPV-specific Th-
cell responses against the early antigens (chapters 2,3, and 4). Strong type 1 T-cell 
immunity against the early antigens can be induced or restored in patients with ano-
genital intraepithelial neoplasia (AGIN) by HPV vaccination, and in combination with 
a local supportive environment HPV-specific Th-cell responses may improve clinical 
outcomes in the treatment of patients with high-grade VIN (chapters 5 and 6). In 
chapter 7, we showed that cervical cancer patients without lymph node metastases, 
which is a well-known positive prognostic factor, display a high number of infiltrat-
ing CD8+ T-cells, and provided evidence that regulatory T-cells, like in other cancers, 
play an important role in the natural course of cervical cancer. 
Below, the main conclusions of the presented studies are put into perspective and a 
personal view is given on the implications of these findings for future immunothera-
peutic strategies in HPV-induced diseases.
HPV16-specific type 1 CD4+ T-cell immunity against early antigens but not 
the late antigen L1 is important in preventing the development or progression 
of anogenital neoplasia
Animal models showed a role of HPV-specific type 1 T-cell immunity against early 
antigens in the protection against HPV-induced disease. Vaccination with HPV16 E6 
and E7 long peptides induced strong HPV-specific CD4+ and CD8+ T-cell responses 
and HPV16-induced tumors were effectively eradicated in mice1. In the cottontail-
rabbit papillomavirus (CRPV) model it was shown that therapeutic vaccination with 
a similar vaccine was effective in the prevention of CRPV induced papillomas and 
latent infections2. Vaccination of mice with HPV16 E7 protein in combination with 
CpG, which is known to induce a Th1 like pattern of cytokine production3, resulted 
in a strong IFNγ-associated CD4+ T-cell response and suppression of tumor growth 
in the majority of animals4. Furthermore, in the canine oral papillomavirus (COPV) 
model, beagle dogs that were injected with a vaccine expressing the E2 and E7 genes 
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were protected from developing papillomas, and this protection was accompanied 
by significant IFNγ responses upon stimulation of PBMC with peptides of these early 
genes5. 
One main conclusion of the studies presented in this thesis is that unlike HPV16-spe-
cific T-cell responses against the structural protein L1, type 1 T-cell immunity against 
the early proteins E2 and E6 is more likely to protect against the development and 
progression of HPV-induced disease in humans. This is illustrated by the presence of 
IFNγ-producing HPV16-specific CD4+ T-cell responses against the early antigens E2 
and E6 in the blood of the majority of healthy subjects while such responses are weak 
or absent in patients with HPV16-positive cervical carcinoma (chapters 2,3, and 4). 
Instead, HPV16 L1 peptide-specific IFNγ-associated T-cell responses were found in 
the majority of both patients with cervical lesions and healthy individuals, and with 
similar magnitude (chapter 3), suggesting that type 1 T-cell immunity against the 
structural protein L1 does not correlate with health or disease. Indeed, COPV-infected 
beagle dogs that were therapeutically vaccinated with the L1 protein developed pap-
illomas at multiple sites of the body in 100% of cases5. The loss of expression of L1 
in progressive CIN lesions and cervical carcinoma6,7 may explain why L1 peptide-
specific T-cell responses do not protect against the development or progression of 
established HPV16-induced anogenital lesions. 
Despite all our studies we still have to show formally that the CD4+ T-cell response 
is important and as such that a failure to either mount such a response (chapters 2,3, 
and 4), or a lack of infiltration of T-cells in the lesion (chapters 6 and 7), may explain 
why a small proportion of HPV-infected patients is not capable to combat persistent 
infections and subsequent HPV-induced anogenital diseases (Figure 1). However, as 
already noted, the failure of immunodeficient HIV-infected subjects with low CD4 
counts to fight HPV-infections8,9 and the presence of strong HPV-specific memory 
responses in healthy subjects10,11 provide strong evidence for the notion that HPV-
specific CD4+ T-cell reactivity is important in the protection against HPV-induced 
anogenital disease. 
Cervical cancer patients are not profoundly predisposed to an overall Th2 
immune response
Human cancers and infectious diseases are frequently associated with an imbalance 
of the equilibrium between the production of type 1 and type 2 cytokines, in favor of 
the latter12,13. This is called the Th1/Th2 paradigm. Production of type 2 cytokines, in 
particular IL-10, was reported to be abnormally elevated in different human cancers, 
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including renal cell cancers, lymphomas, and melanomas14-16. Similar, IL-10 produc-
tion was reported to be abnormally elevated in PBMC of patients with HPV-associated 
CIN and cervical cancer17-20. Clerici et al. showed that extensive HPV-induced cervical 
intraepithelial neoplasia was strongly associated with a pronounced shift from the 
production of type 1 to type 2 cytokines, suggesting that cervical cancer may occur 
in patients predisposed to develop Th2-like immune responses17. We showed that 
the HPV-specific CD4+ T-cell responses detected in healthy subjects comprise IFNγ 
and IL-5 producing T-cells reactive to the early antigens E2 and E6, as well as IFNγ-
producing T-cells directed at L1, indicating that HPV infections naturally induce a 
mixed Th1/Th2 immune response (chapter 2). In patients with cervical cancer we 
observed an HPV-specific T-cell response to these early antigens that was associated 
The strong HPV16-specific CD4+ T-cell responses found against the early proteins and late protein L1 in 
healthy individuals (left) may explain why the majority of infected subjects clear HPV infections and HPV-
induced anogenital disease. In contrast, patients with HPV-induced anogenital disease (right)	frequently 
fail to mount T-cell responses against the early antigens and this may lead to the development or progres-
sion of anogenital neoplasia.
Figure 1. Hypothesis: summary of HPV16-specific immunity in health and disease. 
HPV16 infection
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with a lack of the production of type 1 cytokines, but also with a lack of the produc-
tion of the prototypic Th2 cytokine IL-5, suggesting that the HPV-specific immune 
response in these patients was not just characterized by a shift to production of type 
2 cytokines (chapter 2). Importantly, analysis of the reactivity of PBMC to the HPV16 
late gene product L1 showed a strong IFNγ-associated L1-specific Th-cell responses 
in these patients (chapter 3). The strong type 1 L1-specific immune responses are 
likely to represent memory CD4+ T-cell responses as previously shown for the Th-cell 
responses against the early antigens of HPV10. Taken together, the presence of both 
strong HPV16 L1-specific Th1 responses and impaired T-cell responses to the early 
antigens shows that these patients are not predisposed to an overall type 2 immune 
response (chapter 3). Thus now that it seems unlikely that the patients are predis-
posed to a Th2 response, is it then possible that gradually the Th2 response becomes 
more dominant? 
We observed that only a small minority of patients with high-grade CIN develop HPV-
specific T-cell responses against the early antigens, while more than half of patients 
with cervical cancer display HPV-specific T-cell reactivity. These observations do 
not correspond with the idea of a gradual shift of HPV16 early antigen-specific Th1-
type to early antigen-specific Th2 type T-cell responses during disease progression 
(chapter 2 and unpublished data). A potential explanation for such a shift may be the 
loss of expression of L1 in progressive HPV-induced anogenital neoplasia7. When the 
lesion stops to provide L1 antigen that can be taken up and presented by antigen pre-
senting cells, L1-specific T-cells are not likely to become activated to produce IFNγ 
anymore. In contrast to L1, the expression of the oncogenes E6 and E7 is increased 
in progressive anogenital neoplasia, but the T-cell response against these antigens 
is not associated with the production of IFNγ. Thus, it is not likely that a Th1/Th2 
shift occurs among T-cells responding to the same antigen, but more likely reflects a 
gradual loss of Th1 cells responding to L1 and the activation of non-proinflamma-
tory T-cells responding to the early antigens of HPV. As a result Th2 type cytokines 
may dominate. 
Problems in the restoration of an effective type 1 HPV16-specific T-cell response 
The immunological events leading to the rejection of (pre)malignant tissue can be 
divided into 4 steps21. First, activation and migration of antigen-presenting cells to 
the loco-regional lymph nodes is necessary to initiate the adaptive immune response. 
Second, activation and systemic spread of antigen-specific T-cells. Third, migration 
of these T-cells into the target lesion. Fourth, at the target site CD4+ T-cells should 
activate tumoricidal cells of the innate immune system and the CD8+ T-cells to kill 
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the tumor cells22,23. The consecutive steps involved in the rejection of HPV-induced 
lesions in relation to the findings from the studies decribed in this thesis and from 
other studies are depicted in Figure 2. Problems in the induction or restoration of 
HPV-specific immunity and immune escape mechanisms of HPV-infected and tumor 
cells are discussed in the text and possible solutions are given.  
Induction and restoration of systemic HPV-specific Th-cell responses
Spontaneously induced circulating T-cells directed against various tumor antigens 
have been described in patients with melanomas, leukemias, and in various epithelial 
tumors24-26. Most studies analyzing T-cell responses to tumor antigens have focused 
on CD8+ T-cells, however, underlying CD4+ T-cell responses are highly likely to 
play a role because they are of pivotal importance in the induction and activation 
Problems in the induction or restoration of HPV-specific immunity and possible solutions are discussed 
throughout the text. 
Figure 2. Immunological events leading to the rejection of (pre)malignant tissue 
              (adapted from21, and this thesis). 
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of effector CD8+ T-cells. Spontaneous CD4+ T-cell responses against tumor antigens 
have also been described for instance for prostate-specific antigen in prostate cancer 
and for her-2/ neu in breast cancer27,28. These studies indicate that tumor-antigen is 
taken up and presented by APC to T-cells. So far, little is known about whether these 
circulating tumor-specific CD4+ T-cells influence the clinical course of disease. Type 
1 Th-cell immunity was shown to prevent or delay relapses in patients with different 
hematological malignancies who underwent peripheral blood stem cell transplanta-
tion29. Although data from a number of other studies in selected patients suggest a 
favorable clinical course in patients with antigen-specific T-cells25,30,31, no study has 
systematically compared patients with and without tumor-specific T-cell responses. 
Others and we have shown that the spontaneously induced HPV-specific T-cell 
response does not fulfill all criteria necessary for an effective immune response 
because it is usually absent or weak in patients with HPV-induced disease (chapters 2, 
3, 5, and 6). Therapeutic vaccination aiming at the induction of HPV-specific T-cells 
against the early antigens should overcome the first two criteria. A number of stud-
ies have shown the immunogenicity of different HPV oncogene vaccines in patients 
with anogenital neoplasia32-35 (and Kenter, van der Burg and Melief, unpublished 
results). We have shown that the combination of an HPV16 L2E6E7 fusion protein 
(TA-CIN) and a recombinant vaccinia virus expressing HPV16 and 18 E6E7 (TA-HPV) 
in women with AGIN was effective in the induction of strong HPV16-specific type 
1 CD4+ T-cell responses (chapter 5). Furthermore, even in late-stage cervical cancer, 
the administration of a therapeutic HPV16 E6 and E7 long peptide vaccine leads to 
IFNγ-producing CD4+ T-cell responses (Kenter, vd Burg, Melief, unpublished results). 
In addition, vaccination of a patient with advanced HPV18-positive cervical cancer 
with E7-peptide pulsed autologous DC and infusions of T-cells stimulated with E7-
pulsed DC was associated with a delayed-type hypersensitivity response to HPV18 
E7 and disease stabilisation for 18 months36. These studies indicate that vaccines can 
restore the HPV-specific CD4+ and CD8+ T-cell response. The adoptive transfer of 
HPV16-specific T-cells may form an alternative treatment modality for patients with 
advanced cervical cancer. Clinical responses to adoptive transfer of autologous CD8+ 
T-cells or a mixture of CD4+ and CD8+ T-cells have been described for patients with 
advanced renal cell carcinoma37 and metastatic melanoma38. One of the main obsta-
cles for the large-scale and effective implementation for adoptive immunotherapy 
may be the difficulty of obtaining sufficient numbers of antigen-specific autologous 
T-cells. A recent study reported on the successful isolation and expansion of large 
amounts of HPV16-specific T-cell populations with broad specificity from healthy 
donors within a time span of 2-3 weeks39. It can be envisaged that healthy donor-
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derived HPV16-specific type 1 T-cells are transferred into cervical cancer patients 
following allogeneic stem cell transplantation and eradication of host immune cells. 
The reactivity of these adoptively transferred T-cells may then be boosted by specific 
vaccination.
From all HPV vaccination studies in patients with anogenital disease that have been 
performed so far, it is clear that there is no simple relationship between the induction 
or restoration of large numbers of HPV-specific T-cells and clinical responses. Some 
patients even had progressive disease in the presence of very high levels of HPV-spe-
cific T-cells (chapter 5,32,33), and this is in line with the results of peptide vaccination 
studies in various human cancers, like melanomas40,41, renal cell carcinomas42, and 
advanced malignant gliomas43. Together, these data indicate that the induction of 
large numbers of circulating tumor-specific T-cells is not sufficient for the regres-
sion of developing lesions in a substantial part of patients with human cancers. The 
efficacy of strong antitumor T-cell immunity is highly likely to depend on a sup-
portive local environment, which is the battlefield between the immune system and 
developing neoplasia.
The impact of the local microenvironment on clinical outcome in patients with AGIN
The epithelial dendritic cell (Langerhans cell, LC) is the key antigen-presenting cell 
involved in the induction and modulation of HPV-specific immunity because HPV 
infections are strictly confined to the epithelium and HPV-infected keratinocytes 
cannot reach the draining lymph nodes44. In the absence of any inflammation or 
pathogenic elements, most dendritic cells have a resting, immature phenotype char-
acterized by low surface expression of MHC- and costimulatory molecules45. The 
activation and migration of DC requires strong inflammatory signals46. Upon interac-
tion with proinflammatory cytokines, CpG, or CD40-ligand, DCs rapidly acquire an 
activated phenotype, and mature DCs are very efficient in the activation of T-cells. 
Davidson et al. showed that clinical responses upon vaccination with TA-HPV in 
patients with high-grade VIN were significantly associated with a preexisting infil-
trate by CD4+ and CD8+ T-cells as well as CD1a+ dendritic cells. The presence of 
these immune cells suggests that in these patients the local environment supports 
the infiltration of T-cells, including vaccine-induced HPV-specific T-cells33. Poor 
response rates to photodynamic therapy in women with VIN have been attributed 
to decreased numbers of Langerhans cells and CD8+ T-cells within the lesions47. 
In several types of human cancers patients display huge differences in the number 
of intraepithelial immune cells that infiltrated the tumor cell nests48-50. Either some 
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patients did not develop a tumor-specific immune response or the tumor-specific T-
cells failed to infiltrate the tumor. We showed that even in patients with circulat-
ing tumor-specific T-cells, strong tumor-infiltration does not always occur (chapter 7) 
or that the type of tumor-specific T-cell response prevents infiltration of effector T-
cells. This suggests that the local environment supports infiltration in some patients but 
not in others. Notably, the presence of high numbers of tumor-infiltrating T-cells was 
shown to be a prognostic factor correlating with improved survival of patients48-50. A 
change in the local environment may alter the course of disease. In a murine model, it 
was shown that adenovirus specific CD8+ T-cells developed in draining lymph nodes of 
mice with adenovirus-positive tumors, but that rejection of tumors only occurred when 
strong inflammatory agents were locally injected51.
Earlier studies have suggested that topical application of inflammatory agents may 
alter the natural course of anogenital disease. Intralesional treatment with beta-inter-
feron was significantly associated with the regression of CIN 2 lesions52. A large, 
randomized phase III trial in 301 women with CIN 2/3 showed that topical application 
of all-trans-retinoic acid (RA), a chemopreventive agent that inhibits cellular prolif-
eration, increased the complete histologic regression rate of CIN 2 from 27% to 43% 
compared to the placebo group53. Interestingly, another study showed that low-dose 
topical administration of RA was not more effective than placebo in the regression 
of lesions, suggesting that the serial biopsies that had been taken from all women 
and its induction of associated inflammation may have been an effective treatment 
by itself54. A recent study has shown that local invasive procedures strongly enhance 
systemic HPV16-specific type 1 T-cell responses in patients with HPV16-induced 
cervical cancer55. Especially those patients who had undergone previous invasive 
procedures showed the strongest enhancement of HPV16-specific IFNγ-associated 
T-cell responses, suggesting a boosting effect of the second invasive procedures55. 
The strong enhancement of T-cell responses was not seen in CIN patients. Similar, 
we could not detect a direct influence of topical application of Imiquimod on the 
numbers of circulating HPV-specific Th cells in our patients with high-grade VIN 
(chapter 6). 
A number of studies in human (pre)malignant diseases have shown that the presence 
of circulating antigen-specific T-cells in combination with local inflammation was 
associated with better clinical responses. In patients with stage III melanoma, pre-
existing IFNγ-producing CD4+ T-cell responses against melanoma antigens in com-
bination with a strong inflammatory agent were associated with overall survival56. 
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After electrocoagulation of her VIN 3 lesions, clinical regression was observed in 
a woman displaying strong systemic preexisting HPV16 E6 and E7-specific T-cell 
responses and local infiltration of CD4+ and CD8+ T-cells57. We found that topical 
application of the immune response modifier Imiquimod was significantly associated 
with a better clinical outcome in a group of patients with HPV-induced high-grade 
VIN, especially in those who display a systemic HPV-specific type 1 T-cell response 
(chapter 6). This may be explained by a number of immunological mechanisms. 
First, Imiquimod induces a type 1 adaptive immune response through activation of 
macrophages and dendritic cells via binding to cell surface receptors like TLR (toll-
like receptors) 7 and 858-60. Second, Imiquimod has been shown to increase antigen 
presentation and maturation of Langerhans cells61,62. Third, topical application of 
Imiquimod was shown to increase the number of infiltrating CD4+ and CD8+ T-
cells in cutaneous squamous cell carcinoma specimens60. Taken together, it is likely 
that topical application of Imiquimod leads to the induction of a more favorable 
local environment by counteracting type 2 cytokines, a better presentation of HPV 
antigens to the adaptive immune system, and increased infiltration of HPV-specific 
T-cells to lesions, leading to objective clinical responses in patients with high-grade 
VIN after treatment with this agent. Overall the results of these studies indicate that 
the induction of an inflammatory reaction in the lesion or tumour is necessary to 
induce tumor-specific T-cell infiltration and clinical success.
 
Imiquimod may also be useful in HPV vaccination schedules as vaccine adjuvant. 
Subcutaneous injection at the vaccination site of Imiquimod in mice was found to 
increase the number and maturation status of dendritic cells in draining lymph nodes, 
and to enhance IFNγ-associated CD4+ and CD8+ T-cell responses63. A limited number 
of phase I studies in humans have reported that oral or subcutaneous administration 
of Imiquimod seems safe and leads to increased levels of pro-inflammatory cytokines 
in serum64,65. Furthermore, the use of imiquimod as adjuvant supported the induction 
of melanoma-specific T-cells when skin areas were pretreated with imiquimod by 
topical application to the vaccine sites 24 h and 2 h prior to peptide vaccination66. 
Regulatory CD4+CD25+ T-cells
In 1995, Sakaguchi et al. identified so-called “regulatory” T-cells (Treg cells) by iden-
tifying a population of CD4+ T-cells highly expressing the IL-2 receptor α-chain 
(CD25) and preventing autoimmunity in a murine model67. More recent studies have 
shown that the transcription factor forkhead box P3 (FOXP3) is a crucial devel-
opmental and functional factor for CD4+CD25+ Tregs68,69. Numerous reports in the 
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following years have shown that regulatory T-cells suppress the activation and 
function of other T-cells70,71. Their physiological role is to protect the host against 
the development of autoimmunity by regulating immune responses against anti-
gens expressed by normal tissues72,73. Since tumor antigens are mainly self-antigens, 
Tregs may also prevent the tumor-bearing host from mounting an effective antitu-
mor response. Previous studies have shown that elevated numbers of circulating and 
tumor CD4+CD25+ Tregs can be found in patients with different types of cancer74-
77. Regulatory T-cells producing the type 2 cytokine TGFβ were increased in tumor 
specimens from patients with late stage ovarian cancer as compared with control 
CD4+ T-cells from healthy donor peripheral blood75. Furthermore, high numbers of 
intratumoral Tregs were found to be associated with reduced survival in patients 
with ovarian cancer78. It is likely that there is a balance between tumor-promoting 
and tumor-inhibiting lymphocytes within tumor microenvironments, and therefore 
the local presence of Tregs may explain why HPV-specific T-cells do not succeed in 
rejection of HPV-induced cervical tumors. Earlier studies in cervical cancer patients 
have found that CD4+CD25+ T-cells are predominantly detected in tumor drain-
ing lymph nodes79. We have shown that cervical cancers were infiltrated stronger 
with Foxp3+ T-cells compared to healthy cervices (chapter 7). Importantly, a higher 
CD8+/Treg ratio was detected in cervical cancer patients without lymph node metas-
tases, which is in general a positive prognostic factor. Interestingly, we found that 
the patients with lymph node metastases displaying a systemic HPV-specific T-cell 
response showed the lowest CD8+/Treg ratio when compared to all other groups. 
However, a direct relationship between the presence or absence of systemic HPV-
specific T-cells and the lymph node status was not detected. These data suggest that 
the presence of circulating HPV-specific T-cells not necessarily reflect an effective 
antitumor response and that evasion of tumor cells, especially in the lymph nodes, is 
a prerequisite for the induction of HPV-specific T-cell responses that can counteract 
the recruitment of effector cells in the tumor. Indeed, recent data from our group have 
shown that HPV16 E6-specific CD4+ Tregs are present in the tumor and lymph nodes 
of patients with cervical cancer and are able to suppress the action of naive CD4+ 
T-cells97. In addition, a low CD8+/ regulatory T-cell ratio was significantly associ-
ated with worse survival of patients with cervical cancer (Jordanova ES, personal 
communication). 
Note that not only tumors but possibly also therapeutic vaccination strategies, 
although designed to enhance CD4+ and CD8+ T-cell effector immunity against the 
E6 and E7 oncoproteins of HPV16 and/or 18, may lead to the unwanted induc-
tion and/or activation of regulatory T-cells. Recently, Hussain et al. showed that 
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an HPV16 E7 vaccine induced high numbers of IL-10 and TGFβ-secreting tumor-
infiltrating CD4+CD25+ Tregs in mice80. Notably these animals showed no or little 
regression of their established E7-expressing tumors 80. A similar study by Zhou et 
al. elegantly showed that vaccination of tumor-bearing hosts harboring a mixture of 
antigen-specific responder and regulatory T-cells resulted in concomitant expansion 
of both T-cell populations. Importantly, the net effect of vaccination in this setting 
was failure of the antitumor immune response81.
Preclinical studies in mice have indicated that depletion of Tregs using anti-CD25 
antibodies can induce effective antitumor immunity and positively affect survival82-
84. Two recent studies in humans have shown that in vivo elimination of CD25-
expressing Tregs by ONTAK (recombinant IL-2 diphteria toxin conjugate DAB389IL-
2) enhanced the magnitude of vaccine-mediated tumor-specific T-cell responses in 
the blood of patients with metastatic renal cell carcinoma and ovarian cancer85,86. 
Cyclophosphamide is known to decrease the number of circulating CD4+CD25+ 
regulatory T-cells in both animals and humans87,88. In a rat colon cancer model, 
administration of cyclophosphamide depleted Treg cells and delayed the outgrowth 
of tumors89. Interestingly, combining cyclophosphamide and immunotherapy even 
cured the mice, whereas both strategies applied alone had no curative effect. In mela-
noma patients, the combination of adoptive transfer of ex vivo activated tumor-spe-
cific T-cells to patients after chemotherapy with cyclophosphamide and fludarabine 
induced tumor regression in up to 50% of patients treated90.   
Rather than depleting Tregs, interfering with their regulatory function is an alterna-
tive approach to improve effector T-cell responses in the treatment of human cancers. 
Peng et al. have reported the expression of TLR-8 on human Tregs, and they have 
identified a simple poly-guanine oligonucleotide that acts directly on Tregs to pre-
vent suppression of effector T-cells91. Because Imiquimod acts through TLR-7 and 8, 
part of its action may rely on the counteraction of the negative regulation of Tregs 
at the local environment. In combination with circulating HPV-specific T-cells, this 
may contribute to better clinical responses in patients with high-grade VIN after 
imiquimod therapy (chapter 6). 
Current knowledge about Treg migration is still limited. In patients with ovarian can-
cer, Tregs expressing the CCR4 receptor migrated preferentially and predominantly 
to the CCR4-ligand (CCL22) positive tumor and the associated malignant cells in the 
ascites rather than the draining lymph nodes78. Also in lung cancer tissues increased 
percentages of CXCR4 positive CD4+CD25+Foxp3+ T-cells were found when com-
pared with normal lung tissue92. So far, it is unknown what chemokine receptor/ 
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ligand pair is important for the migration and homing of Tregs in HPV-induced 
anogenital disease, and whether Tregs would exclusively use such a receptor/ligand 
pair. This has to be examined before blocking the migration of regulatory T-cells by 
chemokine receptor antagonists becomes an option for immunotherapeutic interven-
tion strategies in HPV-associated anogenital disease. 
Future prospects
Effective antitumor immune mechanisms can be limited simply by the absence of 
proinflammatory local environment or more sophisticated by immunoregulatory 
components such as regulatory T-cells and type 2 cytokines like IL-10 and TGFβ. 
Immunotherapeutic combination strategies in which these negative local aspects are 
counteracted are currently tested in mouse tumor models and in the clinic (read 
above). Another mechanism by which tumor cells can escape the immune system is 
by defects in MHC class I antigen presentation. Loss of HLA class I expression and 
mutations in TAP genes are frequently observed in cervical cancer and high-grade 
VIN47,93-95. Recently, a category of CTLs was described that may be able to prevent the 
escape of tumor cells with defects in MHC class I antigen processing96. These CD8+ 
T-cells are directed against a repertoire of peptides (T-cell epitopes associated with 
impaired peptide processing, TEIPPs) that are presented at the surface of process-
ing-deficient cells. Addition of these CD8+ peptide-epitopes to current vaccines may 
prevent the escape of TAP down-regulated tumor cells.
Based on the results of the studies described in this thesis, it is not likely that vaccina-
tion alone will be sufficient for the effective eradication of established (pre)malignant 
HPV-induced lesions. Therapies should a) aim at the depletion of regulatory T-cells, 
b) induce local inflammation, for example by topical application of immune modi-
fiers, local destructive therapies, or a combination of chemotherapy and radiation, 
and c) induce both CD4+ and CD8+ T-cells specific for HPV16 and maybe even the 
induction of TEIPP-specific CD8+ T-cells, to have the best chance in establishing 
clinical efficacy at early and late stages of anogenital disease. 
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Samenvatting

Humaan papillomavirus (HPV) en ziekten van de vrouwelijke geslachtsorganen
Baarmoederhalskanker is wereldwijd de op een na meest voorkomende vorm van 
kanker onder vrouwen. In Nederland worden jaarlijks ongeveer 700 nieuwe geval-
len vastgesteld en overlijden tussen de 250 en 300 vrouwen aan de gevolgen van 
deze ziekte. Het bevolkingsonderzoek, waarbij van alle vrouwen tussen de 30 en 60 
jaar eens in de 5 jaar een uitstrijkje wordt gemaakt, is gericht op de opsporing van 
voorstadia van baarmoederhalskanker, ook wel cervicale intraepitheliale neoplasie of 
CIN genaamd. Recent is duidelijk geworden dat in vrijwel alle gevallen van baarmo-
ederhalskanker en CIN, maar ook bijvoorbeeld voorstadia van kanker van de schaam-
lippen, vagina of de anus, het humane papillomavirus (HPV) wordt aangetroffen. 
Humane papillomavirussen kunnen worden onderverdeeld in laagrisico en hoogrisico 
typen. De eerstgenoemde veroorzaken bijvoorbeeld genitale wratten. De hoog-risico 
typen zijn in staat om (voorstadia van) kanker te veroorzaken wanneer zij langdurig 
in het lichaam verblijven. Het belangrijkste voorbeeld uit deze groep is HPV type 16 
(HPV16). In ongeveer 60% van de gevallen van baarmoederhalskanker wordt dit type 
aangetroffen. De ongecontroleerde groei van cellen, kenmerkend voor (voorstadia 
van) kanker, wordt veroorzaakt door binding van bepaalde eiwitten van HPV aan 
structuren van geinfecteerde cellen. De E6 en E7 eiwitten van HPV zijn hiervan de 
belangrijkste voorbeelden. Het zogenaamde L1 eiwit van HPV is het belangrijkste 
onderdeel van het kapsel of omhulsel van het virus. In tegenstelling tot de E6 en E7 
eiwitten, die in alle gevallen van kanker gevonden worden, komt het L1 eiwit voor-
namelijk tot uiting in geinfecteerde cellen en in vroege voorstadia van kanker, en 
juist niet meer in de latere stadia van infectie en afwijkingen. 
HPV is een zeer veel voorkomend virus dat via sexueel contact van mens op mens 
kan worden overgebracht. Naar schatting komt ongeveer 80% van alle mensen eens 
in zijn of haar leven in contact met HPV. De overgrote meerderheid van deze mensen 
is in staat om het virus op te ruimen uit het lichaam. Het is aannemelijk dat het 
immuunsysteem een belangrijke rol hierin speelt omdat bekend is dat mensen met 
een verminderde afweer, zoals bijvoorbeeld patiënten met HIV, vaker HPV infec-
ties hebben die ook vaak ernstiger verlopen dan mensen met een goed werkend 
immuunsysteem. 
Het immuunsysteem
Het immuunsysteem kan worden onderverdeeld in het zogenaamde aangeboren 
immuunsysteem en het verworven immuunsyteem. Voorbeelden van het aangeboren 
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immuunsysteem zijn bijvoorbeeld de huid en slijmvliezen die als eerste verdedig-
ing dienen tegen ongewenste indringers zoals bacteriën en virussen. Het verworven 
immuunsysteem heeft als belangrijkste kenmerk dat het specifiek is, dat wil zeggen 
dat het zeer sterk kan reageren tegen bepaalde lichaamsvreemde indringers, en dat 
het in staat is om geheugen op te bouwen, zodat een volgend contact met dezelfde 
indringer sneller en effectiever zal leiden tot het opruimen ervan. Het verworven 
immuunsysteem bestaat uit 2 componenten: het humorale immuunsysteem en het 
cellulaire immuunsysteem. Het humorale immuunsysteem bestaat uit zogenaamde 
B-cellen die antilichamen kunnen produceren. Voor virusinfecties geldt dat deze anti-
lichamen gericht zijn tegen het virale kapsel of omhulsel, dus in het geval van HPV 
infecties tegen het L1 eiwit. Antilichamen dienen ervoor om te verhinderen dat een 
bepaalde indringer een cel binnentreedt, met andere woorden: zij voorkomen het 
optreden van een bepaalde infectie. Wanneer een virus zich eenmaal in een gastheer-
cel heeft genesteld kunnen antilichamen er niet meer bij omdat zij niet in staat zijn 
om cellen binnen te komen. Het cellulaire immuunsysteem bestaat uit zogenaamde T-
cellen of T-lymfocyten en richt zich met name op intracellulaire infecties, waaronder 
HPV infecties vallen, maar ook op tumorcellen. Er zijn verschillende soorten T-cellen 
te onderscheiden: T-helper cellen of CD4+ T-cellen, cytotoxische T-cellen of CD8+ 
T-cellen, en ook de recent beschreven regulatoire T-cellen. T-helper cellen spelen een 
centrale rol in de afweer tegen virusinfecties en bepaalde vormen van kanker, omdat 
zij andere cellen van het immuunsysteem kunnen aansturen en activeren. Zo zijn zij 
van cruciaal belang voor het aansturen van B-cellen, maar ook voor de activatie van 
cytotoxische T-cellen, die virus-geinfecteerde cellen en tumorcellen kunnen doden. 
Regulatoire T-cellen zijn in staat om andere T-cellen te onderdrukken en worden 
daarom gezien als remmers van een effectieve afweer. T-cellen maken verschillende 
stoffen, cytokines genaamd, die van belang zijn voor het reguleren van afweerpro-
cessen. Type 1 cytokines, waarvan interferon-gamma (IFNγ) het belangrijkste voor-
beeld is, zijn belangrijk voor de activatie van de cellulaire afweer. Type 2 cytokines, 
zoals interleukine-4 (IL-4), IL-5 en IL-10 zijn belangrijk voor de humorale afweer. 
Daarnaast kan IL-10 ook remmend werken op de immuunrespons. 
De studies in dit proefschrift hebben voornamelijk betrekking op de cellulaire Th-cel 
immuniteit tegen HPV16 omdat deze de spil lijkt van een effectieve afweer respons 
tegen infecties die het virus veroorzaakt en gerelateerde ziekten van de vrouwelijke 
geslachtsorganen.
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De cellulaire immuunrespons tegen HPV16 in gezonde mensen en in mensen met 
HPV-geassocieerde ziekte; dit proefschrift
Zoals hierboven reeds genoemd, is de overgrote meerderheid van de bevolking eens 
in zijn of haar leven in contact geweest met HPV en weten wij dat slechts een klein 
percentage hiervan afwijkingen ontwikkelt die door het virus worden veroorzaakt. Is 
er iets mis met de T-cel afweer tegen HPV in vrouwen met HPV-geassocieerde aan-
doeningen, en zo ja wat? Om deze vraag te kunnen beantwoorden onderzochten wij 
T-cellen uit het bloed van gezonde mensen en vergeleken deze met die van vrouwen 
met CIN en baarmoederhalskanker. Wij vonden dat bloed van gezonde mensen in 
bijna alle gevallen T-helper cellen bevatte gericht tegen vroege eiwitten van HPV16, 
en dat deze T-helper cellen zowel type 1 als type 2 cytokines produceerden. In bloed 
van patiënten met baarmoederhalskanker werden T-helper cellen gericht tegen 
HPV16 maar in de helft van de gevallen aangetroffen, en deze T-cellen maakten 
veel minder type 1 en 2 cytokines. Deze resultaten suggereren sterk dat mensen met 
baarmoederhalskanker niet goed in staat zijn om T-helper cellen gericht tegen HPV 
(HPV-specifieke Th-cellen) te maken, en dat T-helper cellen gericht tegen de vroege 
eiwitten van HPV een belangrijke rol spelen in het onder controle houden van HPV 
infecties in gezonde mensen. In tegenstelling tot Th-cellen gericht tegen de vroege 
eiwitten van HPV werden in het bloed van mensen met CIN of baarmoederhalskanker 
even vaak Th-cellen gericht tegen het L1 eiwit van HPV gevonden als in het bloed 
van gezonde personen. Dit betekent dat Th-cel afweer tegen het L1 eiwit waarschijn-
lijk geen belangrijke rol speelt in de bescherming tegen het ontstaan van HPV-geas-
socieerde aandoeningen. 
Vaccinatie is een manier om afweer op te bouwen tegen een bepaalde ziektever-
wekker. Het rijksvaccinatieprogramma is gericht op de bescherming van kinderen 
tegen gevaarlijke infectieziektes. Ook tegen HPV zijn er verschillende soorten vaccins 
ontwikkeld. In tegenstelling tot de zogenaamde preventieve HPV vaccins, gericht op 
de produktie van antilichamen tegen het kapseleiwit L1 en het voorkomen een infectie 
met HPV, zijn therapeutische HPV vaccins gericht op het verkrijgen van HPV-speci-
fieke T-cellen die van belang zijn voor de afweer tegen reeds geinfecteerde cellen en 
tumorcellen. Wij vonden dat een vaccin dat de E6 en E7 eiwitten van HPV bevatte 
zeer effectief was in de inductie van HPV-specifieke Th-cellen in een groep vrouwen 
met afwijkingen van de baarmoedermond, vagina en schaamlippen. Hoewel in som-
mige gevallen de afwijkingen na vaccinatie kleiner werden, was er geen duidelijk 
verband tussen het voorkomen van HPV-specifieke T-cellen in het bloed en uitkomst 
na behandeling in deze groep vrouwen. In een andere groep patiënten met voorstadia 
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van kanker van de schaamlippen vonden wij dat vrouwen met in het bloed aanwezige 
HPV-specifieke Th-cellen reageerden met het kleiner worden van de afwijkingen na 
behandeling met een ontstekingsbevorderende crème op de aangedane plekken. Uit 
deze twee studies kan worden geconcludeerd dat het voorkomen van HPV-specifieke 
Th-cellen in het bloed van belang lijkt voor het opruimen van aandoeningen die door 
HPV zijn veroorzaakt, maar dat het circuleren van zulke T-cellen alleen waarschijnlijk 
niet voldoende is. De afweerreacties ter plaatse van de afwijkingen lijken van groot 
belang voor de uiteindelijke uitkomst na behandeling. Het is mogelijk dat HPV-speci-
fieke T-cellen hun werk niet kunnen doen ter plaatse van de afwijking in mensen met 
HPV geassocieerde aandoeningen. Mogelijke oorzaken hiervoor zijn het ontbreken 
van T-cellen tegen HPV of het onvermogen van deze T-cellen om vanuit het bloed de 
afwijking binnen te komen, bijvoorbeeld door het ontbreken van stoffen die T-cellen 
kunnen aantrekken, zoals ontstekingsbevorderende cytokines. Ook is het mogelijk dat 
regulatoire T-cellen de werking van de HPV-specifieke T-cellen teniet doen.
Om de plaatselijke afweerreacties te bestuderen hebben wij gekeken naar het 
voorkomen van de verschillende T-cel types in stukjes tumorweefsel van een groep 
vrouwen met baarmoederhalskanker. Er waren meer T-cellen aanwezig in tumor-
weefsel van patiënten dan in baarmoederhalsweefsel van een groep gezonde vrou-
wen. Verder vonden wij dat niet alleen het aantal T-cellen, maar juist de verhouding 
tussen de verschillende T-cel types in de tumor verband hield met een prognostisch 
betere variant van baarmoederhalskanker. Dit was al eerder aangetoond voor andere 
vormen van kanker in mensen, zoals darm- en eierstokkanker. 
Samenvattend spelen HPV-specifieke T-helper cellen waarschijnlijk een belangrijke 
rol in de bescherming tegen ziekten van de vrouwelijke geslachtsorganen die door 
HPV worden veroorzaakt. Als mensen van nature niet in staat zijn om deze T-cellen 
te maken, is het mogelijk om ze door middel van vaccinatie te verkrijgen. Vaccinatie 
alleen is waarschijnlijk onvoldoende. Combinatietherapieën, gericht op het enerzijds 
induceren van HPV-specifieke T-cellen door vaccinatie, en anderzijds op het creëren 
van een gunstige plaatselijke situatie, bijvoorbeeld door toediening van ontstekings-
bevorderende stoffen, zijn mogelijk zeer effectief in de behandeling van aandoenin-
gen die door HPV worden veroorzaakt. 
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Abbreviations
AGIN anogenital intraepithelial neoplasia
APC antigen-presenting cell
CBA cytometric bead array
CIN cervical intraepithelial neoplasia
CTL cytotoxic T lymphocyte
ELISA enzyme-linked immunosorbant assay
ELISPOT enzyme-linked immunospot
FIGO Fédération Internationale des Gynaecologistes et Obstetristes
HPV human papillomavirus
IFNγ interferon-gamma
IL-2 interleukin-2
MRM memory response mix
PBMC peripheral blood mononuclear cells
Th cell T-helper cell
Treg regulatory T-cell
VIN vulvar intraepithelial neoplasia
VLP virus-like particles
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